vortioxetine profile

Vortioxetine: A piperazine derivative that acts as a serotonin reuptake inhibitor, as a 5-HT3 receptor antagonist, and 5-HT1A receptor agonist. It is used for the treatment of anxiety and depression. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

vortioxetine : An N-arylpiperazine in which the aryl group is specified as 2-[(2,4-dimethylphenyl)sulfanyl]phenyl. Used (as its hydrobromide salt) for treatment of major depressive disorder. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

ID Source	ID
PubMed CID	9966051
CHEMBL ID	2104993
CHEBI ID	76016
SCHEMBL ID	236115
MeSH ID	M0586839

Synonym
1-[2-(2,4-dimethylphenyl)sulfanylphenyl]piperazine
vortioxetine (usan)
D10184
508233-74-7
piperazine, 1-[2-[(2,4-dimethylphenyl)thio]phenyl]-
lu aa21004
3o2k1s3wqv ,
unii-3o2k1s3wqv
1-(2-((2,4-dimethylphenyl)sulfanyl)phenyl}piperazine
vortioxetine [usan:inn]
vortioxetine
piperazine, 1-(2-((2,4-dimethylphenyl)thio)phenyl)-
hsdb 8250
AKOS016008748
bdbm50400902
FT-0686961
vortioxetine [usan]
vortioxetine [inn]
vortioxetine [who-dd]
vortioxetine [mi]
vortioxetine [vandf]
chebi:76016 ,
CHEMBL2104993
lu-aa21004
luaa21004
S5506
vortioxetinum
vortioxetina
1-{2-[(2,4-dimethylphenyl)sulfanyl]phenyl}piperazine
gtpl7351
SCHEMBL236115
HY-15414
CS-1471
1-(2-(2,4-dimethylphenylsulfanyl)phenyl)piperazine
1-[2-(2,4-dimethylphenylsulfanyl)-phenyl]piperazine
1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine
1-[2-(2,4-dimethyl-phenylsulfanyl)-phenyl]-piperazine
YQNWZWMKLDQSAC-UHFFFAOYSA-N
vortioxetine, lu aa21004
GG-0052
1-(2-((2,4-dimethylphenyl)thio)phenyl)piperazine
AC-27648
DB09068
CCG-229998
lu aa 21004
piperazine, 1-[2-[(2,4-dimethylphenyl)thio]phenyl]-; 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine; lu aa 21004; vortioxetine
vortioxetine (lu aa21004)
BCP05996
lu aa 21004 pound>>luaa21004 pound>> lu-aa21004 pound>> lu aa21004 pound>> aa21004
Q3563148
508233-74-7 (free base)
vortioxetine free base
SB16506
AR-270/43507985
HMS3886M08
AMY38899
DTXSID80965062
NCGC00386237-08
A853366
EN300-746942
n06ax26
ps37 - vortioxetine

Excerpt	Reference	Relevance
"Vortioxetine is a multimodal-acting antidepressant that provides improvements on cognitive function aside from antidepressants and anxiolytic effects. "	( Vortioxetine in major depressive disorder: from mechanisms of action to clinical studies. An updated review. Crespo, JM; De Diego-Adeliño, J; Gutiérrez-Rojas, L; Iborra, P; Mora, F; Neyra, A; Salonia, SF, 2022)	3.61
"Vortioxetine is a novel multimodal antidepressant for the treatment of major depressive disorders and is widely used in clinical practice. "	( Vortioxetine-Induced Amenorrhea: A Case Report. Işik, M; Kurhan, F; Özdemir, PG; Ülkevan, T, )	3.02
"Vortioxetine (VOR) is a new antidepressant drug used to treat major depressive disorder. "	( Development of the Validated Stability-Indicating Method for the Determination of Vortioxetine in Bulk and Pharmaceutical Formulation by HPLC-DAD, Stress Degradation Kinetics Studies and Detection of Degradation Products by LC-ESI-QTOF-MS. Buszewski, B; Janiszewska, D; Petruczynik, A; Szultka-Młyńska, M; Wróblewski, K, 2022)	2.39
"Vortioxetine is a new antidepressant with multipharmacologic actions that elevate the concentration of serotonin and modulate multiple neurotransmitter receptors in the brain."	( Effect of Vortioxetine on Cognitive Impairment in Patients With Major Depressive Disorder: A Systematic Review and Meta-analysis of Randomized Controlled Trials. Chang, TS; Chen, C; Huang, IC; Sung, JY, 2022)	1.85
"Vortioxetine is a serotoninergic multi-target antidepressant, approved to treat major depressive disorder, and carries out its behavioral, pharmacological, and physiological effects through the blocking of serotonin 5-HT"	( Vortioxetine treatment decreases cocaine-induced locomotor sensitization in rats. Barbosa-Méndez, S; Perez-Sánchez, G; Salazar-Juárez, A, 2022)	3.61
"Vortioxetine is a new antidepressant drug with multimodal action, which gives it a unique profile."	( Role of vortioxetine in the treatment of neuropathic pain. Alcántara Montero, A; Pacheco de Vasconcelos, SR, 2022)	1.88
"Vortioxetine is an antidepressant recently licensed in USA and EU for the treatment of major depressive disorder. "	( Development and validation of a LC-MS/MS method for analysis of vortioxetine in postmortem specimens. First data from an authentic case. Barbera, N; Carnazza, G; Zuccarello, P, 2023)	2.59
"Vortioxetine is a new multimodal antidepressant with 5-HT1A agonism, 5-HT1B partial agonism, 5-HT3, 5-HT7, and 5-HT1D antagonism, and serotonin reuptake inhibition."	( Vortioxetine improved negative and cognitive symptoms of schizophrenia in subchronic MK-801 model in rats. Bozkurt, NM; Unal, G, 2023)	3.07
"Vortioxetine is an antidepressant recently licensed in the US and EU for the treatment of major depressive disorder. "	( Lethal vortioxetine poisoning? A forensic investigation. Arcifa, V; Barbera, N; Carnazza, G; Cosentino, S; Giorlandino, A; Zuccarello, P, 2023)	2.81
"Vortioxetine is a monoaminergic drug with a novel multimodal mechanism of action. "	( A 6-Month Open-Label Study of Vortioxetine among Cancer Patients with Major Depressive Disorder (MDD). Abdul Taib, NIA; Abousheishaa, AA; Awaluddin, AB; Ismail, F; Loo, TH; Low, SY; Mohamad Kamal, NAB; Ng, CG; Nik Jaafar, NR; Thong, KS; Yacob, SB; Zainal, NZ; Zamaniah Wi, W, 2023)	2.64
"Vortioxetine is a novel, multimodal antidepressant with unique targets, including the inhibition of the serotonin transporter (SET), of serotonin 5-HT"	( Vortioxetine Subchronically Activates Serotonergic Transmission via Desensitization of Serotonin 5-HT Fukuyama, K; Okada, M; Okubo, R, 2019)	3.4
"Vortioxetine is a multimodal antidepressant, which has been proposed as a suitable treatment option for cognitive symptoms in depression."	( Vortioxetine on Cognition in Schizophrenia: A Pilot Study. Bruno, A; Cedro, C; Mento, C; Muscatello, MRA; Pandolfo, G; Santoro, V; Scala, L; Spina, E; Troili, GM; Zoccali, RA, )	2.3
"Vortioxetine is a novel antidepressant whose safety, tolerability, and therapeutic action have been supported by several studies. "	( Effectiveness, tolerability, and dropout rates of vortioxetine in comorbid depression: A naturalistic study. Benatti, B; Bosi, MF; Colombo, A; De Carlo, V; Dell'Osso, B; Grancini, B; Viganò, CA; Vismara, M, 2020)	2.25
"Vortioxetine is an antidepressant with a novel mechanism of action."	( Tolerability and efficacy of vortioxetine versus SSRIs in elderly with major depression. Study protocol of the VESPA study: a pragmatic, multicentre, open-label, parallel-group, superiority, randomized trial. Aguglia, A; Aguglia, E; Alessi, MC; Amaddeo, F; Amore, M; Barbato, A; Barbui, C; Bartoli, F; Biondi, M; Bortolaso, P; Callegari, C; Carrà, G; Caruso, R; Cavallotti, S; Crocamo, C; D'Agostino, A; D'Avanzo, B; De Fazio, P; Di Natale, C; Gastaldon, C; Giusti, L; Grassi, L; Martinotti, G; Monti, I; Nosé, M; Ostuzzi, G; Papola, D; Purgato, M; Rodolico, A; Roncone, R; Ruggeri, M; Tarsitani, L; Tettamanti, M; Turrini, G; Zanini, E, 2020)	1.57
"Vortioxetine is a potent antagonist of the 5-hydroxytryptamine receptor and serotonin transporter and has been reported to function as an antidepressant in the treatment of major depressive disorder. "	( Vortioxetine induces apoptosis and autophagy of gastric cancer AGS cells via the PI3K/AKT pathway. Lv, GB; Sun, W; Wang, HK; Wang, TT; Zhao, LF; Zhu, HL, 2020)	3.44
"Vortioxetine (VOR) is a multimodal antidepressant drug with pro-cognitive actions in animal models and MDD patients."	( Sub-chronic vortioxetine (but not escitalopram) normalizes brain rhythm alterations and memory deficits induced by serotonin depletion in rats. Artigas, F; Celada, P; Riga, MS; Sanchez, C, 2020)	1.66
"Vortioxetine is a novel antidepressant drug for the treatment of major depressive disorders."	( Vortioxetine increases absence-like seizures in WAG/Rij rats but decreases penicillin- and pentylenetetrazole-induced seizures in Wistar rats. Aygun, H; Ayyildiz, M, 2021)	2.79
"Vortioxetine (Vot) is an effective antidepressant with unique mechanisms exerting multi-target effects. "	( Vortioxetine Derivatives with Amino Acid as Promoiety: Synthesis, Activity, Stability and Preliminary Pharmacokinetic Study. Bi, X; Li, J; Li, X; Li, Y; Mo, X; Zhou, H; Zhu, X, 2021)	3.51
"Vortioxetine is an antidepressant primarily metabolized by the polymorphic enzyme cytochrome P450 (CYP) 2D6. "	( Validation of a Population Pharmacokinetic Model of Vortioxetine Using Therapeutic Drug Monitoring Data. Areberg, J; Frederiksen, T; Molden, E; Smith, RL; Wollmann, BM, 2021)	2.31
"Vortioxetine (VTX) is a multimodal antidepressant agent that balances 5-HT receptors and represses the serotonin transporter."	( Vortioxetine mitigates neuronal damage by restricting PERK/eIF2α/ATF4/CHOP signaling pathway in rats subjected to focal cerebral ischemia-reperfusion. Ahmed, NA; Emam, AM; Saad, MA; Zaki, HF, 2021)	2.79
"Vortioxetine is a novel multimodal antidepressant that has improved cognitive function including executive function in depressed patients in randomised placebo-controlled clinical trials."	( Vortioxetine reduces BOLD signal during performance of the N-back working memory task: a randomised neuroimaging trial in remitted depressed patients and healthy controls. Browning, M; Buchbjerg, J; Christensen, SR; Conen, S; Dawson, GR; Deakin, JF; Goodwin, G; Harmer, CJ; Hawkins, P; Larsen, KG; Morris, R; Olsen, CK; Smallman, R; Smith, J, 2018)	2.64
"Vortioxetine appears to be a valid option for patients with MDD who have not been effectively treated with first-line pharmacotherapies."	( Comparative evaluation of vortioxetine as a switch therapy in patients with major depressive disorder. Brignone, M; Danchenko, N; Diamand, F; Florea, I; Jacobsen, PL; Thase, ME; Vieta, E, 2017)	1.48
"Vortioxetine is a novel multimodal antidepressant that possesses pro-cognitive properties and differentiates from other conventional antidepressants on various cognitive and plasticity measures."	( Neuroplasticity pathways and protein-interaction networks are modulated by vortioxetine in rodents. Abdourahman, A; du Jardin, KG; Elfving, B; Li, Y; Nygaard, SH; Pehrson, AL; Sánchez, C; Tamm, JA; Waller, JA; Wernersson, R, 2017)	1.41
"Vortioxetine is a novel antidepressant with a unique profile, as it acts as a multimodal serotoninergic agent."	( Vortioxetine: A new alternative for the treatment of major depressive disorder. Grande, I; Salagre, E; Sanchez-Moreno, J; Solé, B; Vieta, E, )	2.3
"Vortioxetine is an approved antidepressant that has also demonstrated positive effects on anxiety symptoms in subjects with generalized anxiety disorder (GAD). "	( Efficacy of vortioxetine in working patients with generalized anxiety disorder. Christensen, MC; Florea, I; Loft, H; McIntyre, RS, 2019)	2.34
"Vortioxetine is a multimodal drug that blocks serotonin (5-HT) reuptake and directly modulates 5-HT receptors. "	( Partial inhibition of catecholamine activity and enhanced responsiveness to NMDA after sustained administration of vortioxetine. Blier, P; Ebrahimzadeh, M; El Mansari, M, 2018)	2.13
"Vortioxetine is a multimodal antidepressant that has been developed for the treatment of major depressive and anxiety disorders. "	( Vortioxetine Treatment for Anxiety Disorder: A Meta-Analysis Study. Ng, CG; Seng, LH; Yee, A, 2018)	3.37
"Vortioxetine is a novel antidepressant with multimodal activity currently approved for the treatment of major depressive disorder. "	( Vortioxetine: Clinical Pharmacokinetics and Drug Interactions. Areberg, J; Chen, G; Højer, AM; Nomikos, G, 2018)	3.37
"Vortioxetine is a relatively new, multi-functional agent."	( VORTIOXETINE - THE NEW ANTIDEPRESSANT AGENT WITH PROCOGNITIVE PROPERTIES. Dziwota, E; Olajossy, M, 2016)	2.6
"Vortioxetine is an antidepressant agent with multimodal activity that is approved for the treatment of major depressive disorder at doses of 5 to 20 mg once daily. "	( Effects of Intrinsic Factors on the Clinical Pharmacokinetics of Vortioxetine. Affinito, J; Chen, G; Jacobson, W; Nomikos, GG; Wang, S; Xie, J; Zhao, Z, 2018)	2.16
"Vortioxetine is a new multimodal antidepressant approved by the Food and Drug Administration for the treatment of Major Depressive Disorder and recently introduced in Europe. "	( Vortioxetine overdose in a suicidal attempt: A case report. Botti, ER; Clerici, M; Mazza, MG; Rossetti, A, 2018)	3.37
"Vortioxetine is a novel antidepressant capable of improving depressive and cognitive symptoms associated with major depressive disorder (MDD). "	( Effects of vortioxetine and fluoxetine on the level of Brain Derived Neurotrophic Factors (BDNF) in the hippocampus of chronic unpredictable mild stress-induced depressive rats. Ho, CS; Ho, RC; Lu, Y; McIntyre, RS; Wang, W, 2018)	2.31
"Vortioxetine is a multimodal antidepressant that potently antagonizes 5-HT3 serotonin receptors, inhibits the high-affinity serotonin transporter, activates 5-HT1A and 5-HT1B receptors, and antagonizes 5-HT1D and 5-HT7 receptors. "	( Multimodal antidepressant vortioxetine causes analgesia in a mouse model of chronic neuropathic pain. Alemà, GS; Casolini, P; Dal Moro, F; Lattanzi, R; Maftei, D; Nicoletti, F; Zuena, AR, )	1.87
"Vortioxetine is a multimodal antidepressant drug with combined effects on SERT as an inhibitor, 5-HT1A as agonist and 5-HT3A as an antagonist. "	( QSAR Analysis of Multimodal Antidepressants Vortioxetine Analogs Using Physicochemical Descriptors and MLR Modeling. Parthasarathy, S; Rajathei, DM; Selvaraj, S, 2019)	2.22
"Vortioxetine is a novel antidepressant drug approved for the treatment of major depressive disorder (MDD) in adults. "	( Vortioxetine: a novel antidepressant for the treatment of major depressive disorder. Gonda, X; Sharma, SR; Tarazi, FI, 2019)	3.4
"Vortioxetine is a novel multimodal antidepressant approved in 2013 by the Food and Drug Administration and the European Medicines Agency for the treatment of major depressive disorder (MDD). "	( Chronic vortioxetine treatment improves the responsiveness to an acute stress acting through the ventral hippocampus in a glucocorticoid-dependent way. Brivio, P; Calabrese, F; Corsini, G; Riva, MA, 2019)	2.39
"Vortioxetine is a recently developed pharmacological agent with effects on the serotonergic but also other neurochemical systems, which has yet to be evaluated in this context."	( A double-blind, placebo-controlled study of vortioxetine in the treatment of binge-eating disorder. Cavic, E; Chamberlain, SR; Grant, JE; Redden, SA; Valle, S, 2019)	1.5
"Vortioxetine is a multimodal antidepressant agent that modulates 5-HT receptors and inhibits the serotonin transporter. "	( The effect of vortioxetine on penicillin-induced epileptiform activity in rats. Beyazçiçek, E; Çetinkaya, A; Ögün, MN, 2019)	2.32
"Vortioxetine (Lu AA21004) is a new potential substance for the treatment of anxiety and mood disorders. "	( 5-HTT and 5-HT(1A) receptor occupancy of the novel substance vortioxetine (Lu AA21004). A PET study in control subjects. Halldin, C; Lundberg, J; Stenkrona, P, 2013)	2.07
"Vortioxetine (Lu AA21004) is an investigational novel antidepressant with multimodal activity that functions as a 5-HT3, 5-HT7 and 5-HT(1D) receptor antagonist, 5-HT(1B) receptor partial agonist, 5-HT(1A) receptor agonist and inhibitor of the 5-HT transporter in vitro. "	( Antidepressant and anxiolytic potential of the multimodal antidepressant vortioxetine (Lu AA21004) assessed by behavioural and neurogenesis outcomes in mice. David, DJ; Ebert, B; Gardier, AM; Guiard, BP; Guilloux, JP; Hen, R; Mendez-David, I; Miller, S; Orvoën, S; Pehrson, A; Repérant, C; Sanchez, C, 2013)	2.06
"Vortioxetine is a multi-modal antidepressant that functions as a human 5-HT3A and 5-HT7 receptor antagonist, 5-HT1B receptor partial agonist, 5-HT1A receptor agonist, and inhibitor of the serotonin transporter. "	( Vortioxetine for major depressive disorder: a systematic review of the efficacy and safety profile for this newly approved antidepressant - what is the number needed to treat, number needed to harm and likelihood to be helped or harmed? Citrome, L, 2014)	3.29
"Vortioxetine is an orally administered small molecule developed by Lundbeck A/S for the once-daily treatment of major depressive disorder (MDD) and generalized anxiety disorder (GAD). "	( Vortioxetine: first global approval. Deeks, ED; Gibb, A, 2014)	3.29
"Vortioxetine is a recently approved multimodal antidepressant with anxiolytic properties in preclinical studies."	( A randomized, double-blind, fixed-dose study comparing the efficacy and tolerability of vortioxetine 2.5 and 10 mg in acute treatment of adults with generalized anxiety disorder. Chen, Y; Jacobsen, PL; Mahableshwarkar, AR; Serenko, M, 2014)	2.07
"Vortioxetine is a novel multimodal antidepressant agent, which inhibits the 5-HT transporter protein, acts as a 5-HT3 antagonist, 5-HT1A receptor agonist, 5-HT7 receptor antagonist, and a partial agonist of the 5-HT1B receptor. "	( Vortioxetine for the treatment of depression. Murphy, JA; Pearce, EF, 2014)	3.29
"Vortioxetine is an effective agent for the treatment of MDD, but it does not have any clear advantages over other available treatment options."	( Vortioxetine for the treatment of depression. Murphy, JA; Pearce, EF, 2014)	3.29
"Vortioxetine (Lu AA21004) is a new antidepressant that combines a number of neurotransmitter reuptake and receptor effects that have been thought to predict efficacy as a treatment for depressive and anxiety disorders."	( Pharmacokinetic evaluation of vortioxetine for the treatment of major depressive disorder. Dubovsky, SL, 2014)	1.41
"Vortioxetine is a new multi-modal drug against major depressive disorder with high affinity for a range of different serotonergic targets in the CNS. "	( (11)C-labeling and preliminary evaluation of vortioxetine as a PET radioligand. Andersen, VL; Hansen, HD; Herth, MM; Knudsen, GM; Kristensen, JL, 2014)	2.1
"Vortioxetine is a 5-HT3 , 5-HT7 , and 5-HT1D receptor antagonist, 5-HT1B partial agonist, 5-HT1A agonist, and 5-HT transporter inhibitor."	( Multimodal antidepressant vortioxetine increases frontal cortical oscillations unlike escitalopram and duloxetine--a quantitative EEG study in rats. Leiser, SC; Pehrson, AL; Robichaud, PJ; Sanchez, C, 2014)	1.42
"Vortioxetine is an antidepressant with multimodal activity which has shown efficacy in major depressive disorder (MDD) patients in six of ten short-term, randomized, placebo-controlled trials (completed end 2012)."	( Relative efficacy and tolerability of vortioxetine versus selected antidepressants by indirect comparisons of similar clinical studies. Brignone, M; Ereshefsky, L; Francois, C; Lançon, C; Llorca, PM; Rive, B; Salah, S, 2014)	2.12
"Vortioxetine is a novel multimodal compound that has recently been approved by the FDA for the treatment of major depressive disorder (MDD). "	( Vortioxetine in the treatment of adult patients with major depressive disorder: a meta-analysis of randomized double-blind controlled trials. Barker, A; Berhan, A, 2014)	3.29
"Vortioxetine is an agonist of 5-HT1A, a partial agonist of 5-HT1B and an antagonist of 5-HT1D, 5-HT3 and 5-HT7 serotoninergic receptors."	( The efficacy of vortioxetine for the treatment of major depressive disorder. Dhir, A; Sarvaiya, J, 2014)	1.47
"Vortioxetine is a multimodal antidepressant that inhibits 5-HT1D, 5-HT3, 5-HT7 receptor activity, 5-HT reuptake, and enhances the activity of 5-HT1A and 5-HT1B receptors."	( Involvement of 5-HT₇ receptors in vortioxetine's modulation of circadian rhythms and episodic memory in rodents. Dkhissi-Benyahya, O; Haddjeri, N; Sánchez, C; Westrich, L, 2015)	1.42
"Vortioxetine is a multimodal acting antidepressant that functions as a 5-HT3 and 5-HT7 and 5-HT1D receptor antagonist, 5-HT1B receptor partial agonist, 5-HT1A receptor agonist and inhibitor of the 5-HT transporter."	( Effect of the multimodal acting antidepressant vortioxetine on rat hippocampal plasticity and recognition memory. Bétry, C; Etiévant, A; Haddjeri, N; Pehrson, A; Sánchez, C, 2015)	1.4
"Vortioxetine is a new treatment for MDD, and its adverse event profile is similar to that of other SSRIs."	( The US Food and Drug Administration's perspective on the new antidepressant vortioxetine. Dow, A; Fossom, L; Jackson, AJ; Kordzakhia, G; Mathis, MV; Patel, H; Sellers, JW; Temple, RJ; Unger, EF; Yang, P; Zhang, J; Zhu, H, 2015)	2.09
"Vortioxetine is an antidepressant with multimodal activity approved for the treatment of major depressive disorder. "	( Lack of effect of multiple doses of vortioxetine on the pharmacokinetics and pharmacodynamics of aspirin and warfarin. Chen, G; Serenko, M; Zhang, W, 2015)	2.13
"Vortioxetine is a novel multimodal antidepressant that is a 5-HT1B receptor partial agonist, a 5-HT1A receptor agonist, an inhibitor of the serotonin (5-HT) transporter, and a 5-HT1D, 5-HT3, and 5-HT7 receptor antagonist in vitro. "	( Effects of acute and sustained administration of vortioxetine on the serotonin system in the hippocampus: electrophysiological studies in the rat brain. Blier, P; El Mansari, M; Lecours, M, 2015)	2.11
"Vortioxetine is a novel antidepressant with a unique mechanism of action: it acts through the serotonine reuptake inhibition, but works also as 5HT(1A) agonist, as well as partial agonist of the 5HT(1B) receptor and antagonist of the 5HT(1D), 5HT(3) and 5HT(7) receptors."	( [Cognitive dysfunctions in depression - underestimated symptom or new dimension?]. Czernikiewicz, A; Dudek, D; Jarema, M, )	0.85
"Vortioxetine is an antidepressant that targets multiple pharmacologic modes of action at sites--or nodes--where serotonergic neurons connect to various brain circuits. "	( Modes and nodes explain the mechanism of action of vortioxetine, a multimodal agent (MMA): enhancing serotonin release by combining serotonin (5HT) transporter inhibition with actions at 5HT receptors (5HT1A, 5HT1B, 5HT1D, 5HT7 receptors). Stahl, SM, 2015)	2.11
"Vortioxetine is a serotonin reuptake inhibitor with additional serotonergic receptor effects of uncertain significance; hence, its classification as 'multimodal'. "	( Vortioxetine: A multimodal antidepressant or another selective serotonin reuptake inhibitor? Culhane, C; Hope, J; Keks, NA, 2015)	3.3
"Vortioxetine is a pharmacodynamically novel antidepressant that exerts effects on various neurotransmitters including serotonin, noradrenaline, dopamine, glutamate, histamine and acetylcholine. "	( Vortioxetine : a review of efficacy, safety and tolerability with a focus on cognitive symptoms in major depressive disorder. Al-Sukhni, M; Maruschak, NA; McIntyre, RS, 2015)	3.3
"Vortioxetine (Lu AA21004) is an antidepressant with a mechanism of action thought to be related to a combination of 2 pharmacologic actions: direct modulation of several receptors and inhibition of the serotonin transporter."	( A randomized, double-blind, placebo-controlled study of the efficacy and safety of vortioxetine 10 mg and 20 mg in adults with major depressive disorder. Chan, S; Jacobsen, PL; Mahableshwarkar, AR; Serenko, M; Trivedi, MH, 2015)	2.08
"Vortioxetine is an antidepressant with multiple pharmacologic modes of action at targets where serotonin neurons connect with other neurons. "	( Modes and nodes explain the mechanism of action of vortioxetine, a multimodal agent (MMA): modifying serotonin's downstream effects on glutamate and GABA (gamma amino butyric acid) release. Stahl, SM, 2015)	2.11
"Vortioxetine is an antidepressant with multiple pharmacologic modes of action that enhance release of dopamine, norepinephrine, acetylcholine, and histamine. "	( Modes and nodes explain the mechanism of action of vortioxetine, a multimodal agent (MMA): actions at serotonin receptors may enhance downstream release of four pro-cognitive neurotransmitters. Stahl, SM, 2015)	2.11
"Vortioxetine is an antidepressant with multiple pharmacologic modes of action at targets where serotonin neurons connect with other neurons. "	( Modes and nodes explain the mechanism of action of vortioxetine, a multimodal agent (MMA): blocking 5HT3 receptors enhances release of serotonin, norepinephrine, and acetylcholine. Stahl, SM, 2015)	2.11
"Vortioxetine is a new antidepressant, which mechanism of action is multimodal, targeting the 5-HT1A, 5-HT1B, 5-HT1D, 5-HT3, 5-HT7 receptors and the serotonin transporter (5-HTT). "	( [Vortioxetine: a new antidepressant to treat depressive episodes]. Colle, R; Corruble, E, 2016)	2.79
"Vortioxetine is a novel antidepressant that has been developed in a joint partnership between H. "	( Quantitative determination of the antidepressant vortioxetine and its major human metabolite in plasma. Jørgensen, M; Kall, MA; Rohde, M, 2015)	2.11
"Vortioxetine is a well tolerated treatment, showing statistically lower withdrawal rates due to AEs compared with other antidepressants."	( Efficacy and tolerability of switching therapy to vortioxetine versus other antidepressants in patients with major depressive disorder. Brignone, M; Diamand, F; Painchault, C; Takyar, S, 2016)	1.41
"Vortioxetine is a structurally novel medication that has recently been approved for treatment of major depressive disorder (MDD). "	( Vortioxetine: a New Treatment for Major Depressive Disorder. Connolly, KR; Thase, ME, 2016)	3.32
"Vortioxetine is a novel multimodal antidepressant that acts as a serotonin (5-HT)3, 5-HT7, and 5-HT1D receptor antagonist; 5-HT1B receptor partial agonist; 5-HT1A receptor agonist; and 5-HT transporter inhibitor in vitro. "	( Histamine may contribute to vortioxetine's procognitive effects; possibly through an orexigenic mechanism. Budac, DP; Li, Y; Pehrson, AL; Sánchez, C; Smagin, GN; Song, D; Waller, JA, 2016)	2.17
"Vortioxetine (VRX) is a multimodal antidepressant with a unique mechanism of action, by acting as 5-HT3A, 5-HT1D and 5-HT7 receptor antagonist, partial agonist at the 5-HT1A and 5-HT1B receptors and inhibitor at the 5-HT transporter."	( New advances in the treatment of generalized anxiety disorder: the multimodal antidepressant vortioxetine. Buonaguro, EF; de Bartolomeis, A; De Berardis, D; Di Giannantonio, M; Fiengo, A; Fornaro, M; Iasevoli, F; Martinotti, G; Mazza, M; Orsolini, L; Perna, G; Tomasetti, C; Valchera, A; Vecchiotti, R; Vellante, F, 2016)	1.38
"Vortioxetine is a multimodal-acting antidepressant that exert its therapeutic activity through serotonin (5-hydroxytryptamine; 5-HT) reuptake inhibition and modulation of several 5-HT receptors."	( A single dose of vortioxetine, but not ketamine or fluoxetine, increases plasticity-related gene expression in the rat frontal cortex. du Jardin, KG; Elfving, B; Müller, HK; Sanchez, C; Wegener, G, 2016)	1.5
"Vortioxetine is a multimodal-acting antidepressant that is hypothesized to exert its therapeutic activity through 5-HT reuptake inhibition and modulation of several 5-HT receptors."	( Differential interaction with the serotonin system by S-ketamine, vortioxetine, and fluoxetine in a genetic rat model of depression. du Jardin, KG; Elfving, B; Liebenberg, N; Müller, HK; Sanchez, C; Wegener, G, 2016)	1.39
"Vortioxetine is a recently introduced antidepressant with a multimodal mechanism of action."	( A prospective, longitudinal study of platelet serotonin and plasma brain-derived neurotrophic factor concentrations in major depression: effects of vortioxetine treatment. Kusevic, Z; Maravic, A; Mihaljevic Peles, A; Nikolac Perkovic, M; Pivac, N; Sagud, M; Svob Strac, D; Vuksan-Cusa, B; Zivkovic, M, 2016)	1.36
"Vortioxetine is a multimodal antidepressant that may improve some aspects of cognitive function in patients with MDD, including attention, processing speed, executive function, and memory."	( Task- and Treatment Length-Dependent Effects of Vortioxetine on Scopolamine-Induced Cognitive Dysfunction and Hippocampal Extracellular Acetylcholine in Rats. Budac, D; Cajina, M; Haddjeri, N; Hillhouse, TM; Mørk, A; Pehrson, AL; Porter, JH; Rovera, R; Sanchez, C; Smagin, G; Song, D, 2016)	1.41
"Vortioxetine (VRX) is a multimodal antidepressant that acts as serotonin (5HT) transporter inhibitor as well as 5HT3A and 5HT7 receptors antagonist, 5HT1A and 5HT1B receptors partial agonist. "	( Current and Future Perspectives on the Major Depressive Disorder: Focus on the New Multimodal Antidepressant Vortioxetine. Buonaguro, EF; Carano, A; De Berardis, D; De Giannantonio, M; Di Bartolomeis, A; Di Nicola, M; Fiengo, ALC; Fornaro, M; Iasevoli, F; Martinotti, G; Matarazzo, I; Orsolini, L; Perna, G; Tomasetti, C; Valchera, A; Vecchiotti, R; Vellante, F, 2017)	2.11
"Vortioxetine is a multi-modal antidepressant that functions both as serotonin transporter (SERT) inhibitor and as 5-HT3, 5-HT7 and 5-HT1D receptors antagonist, 5-HT1A receptor agonist and 5-HT1B receptor partial agonist."	( [Vortioxetine in the treatment of major depression]. de Bartolomeis, A; Fagiolini, A; Maina, G, )	1.76
"Vortioxetine is a multimodal antidepressant, with anxiolytic properties observed in preclinical studies. "	( Vortioxetine (Lu AA21004) in generalized anxiety disorder: results of an 8-week, multinational, randomized, double-blind, placebo-controlled clinical trial. Bidzan, L; Jacobsen, P; Mahableshwarkar, AR; Sheehan, DV; Yan, M, 2012)	3.26
"Vortioxetine (Lu AA21004) is a multi-modal antidepressant in clinical development for the treatment of major depressive disorder (MDD). "	( A randomized, double-blind, placebo-controlled 6-wk trial of the efficacy and tolerability of 5 mg vortioxetine in adults with major depressive disorder. Chen, Y; Jacobsen, PL; Jain, R; Mahableshwarkar, AR; Thase, ME, 2013)	2.05
"Vortioxetine (Lu AA21004) is an investigational antidepressant. "	( A randomized, double-blind trial of 2.5 mg and 5 mg vortioxetine (Lu AA21004) versus placebo for 8 weeks in adults with major depressive disorder. Chen, Y; Jacobsen, PL; Mahableshwarkar, AR, 2013)	2.08

Excerpt	Reference	Relevance
"Vortioxetine has a positive effect on cognitive function in patients with major depressive disorder (MDD). "	( Improved cognitive function in patients with major depressive disorder after treatment with vortioxetine: A EEG study. Baik, SY; Kim, H; Kim, YW; Lee, SH, 2022)	2.38
"Vortioxetine has a safe profile."	( Vortioxetine-Induced Amenorrhea: A Case Report. Işik, M; Kurhan, F; Özdemir, PG; Ülkevan, T, )	2.3
"Vortioxetine has a unique "multi-modal" mechanism of action."	( Vortioxetine for the treatment of major depression. Dhir, A, 2013)	2.55
"Vortioxetine has a beneficial pharmacological profile for reducing anxiety and depression. "	( Vortioxetine, a multimodal antidepressant for generalized anxiety disorder: a systematic review and meta-analysis. Han, C; Lee, SJ; Masand, PS; Pae, CU; Patkar, AA; Serretti, A; Wang, SM, 2015)	3.3
"Vortioxetine has been found to be one of the most effective and best tolerated options for major depressive disorder (MDD) in head-to-head trials."	( Vortioxetine in major depressive disorder: from mechanisms of action to clinical studies. An updated review. Crespo, JM; De Diego-Adeliño, J; Gutiérrez-Rojas, L; Iborra, P; Mora, F; Neyra, A; Salonia, SF, 2022)	2.89
"Vortioxetine has been reported to exhibit a variety of neurobiological functions and neuroprotective effects. "	( Vortioxetine administration attenuates cognitive and synaptic deficits in 5×FAD mice. Huang, GD; Jiang, LX; Su, F; Wang, H; Yu, X; Zhang, C, 2020)	3.44
"Vortioxetine has been effective in various animal models of depression and anxiety and clinical studies have shown the antidepressant and antianxiety properties of vortioxetine in a dose range of 5-20 mg/day."	( Vortioxetine for the treatment of major depression. Dhir, A, 2013)	2.55
"Vortioxetine has been shown to improve cognitive performance in several preclinical rat models and in patients with major depressive disorder."	( Vortioxetine disinhibits pyramidal cell function and enhances synaptic plasticity in the rat hippocampus. Dale, E; Leiser, SC; Lu, D; Plath, N; Sanchez, C; Xiao, Y; Yang, CR; Zhang, H, 2014)	2.57
"Vortioxetine has been registered by regulatory authorities for the treatment of major depressive disorder."	( Vortioxetine: A multimodal antidepressant or another selective serotonin reuptake inhibitor? Culhane, C; Hope, J; Keks, NA, 2015)	2.58

Excerpt	Reference	Relevance
"Vortioxetine had a lower risk of low adherence compared to duloxetine, paroxetine, and venlafaxine and a higher risk compared to citalopram, escitalopram, and sertraline."	( Adherence to, and Persistence of, Antidepressant Therapy in Patients with Major Depressive Disorder: Results from a Population-based Study in Italy. Cipelli, R; Dell'Osso, B; Di Nicola, M; Martinotti, G; Peduto, I; Pugliese, AC; Signorelli, MS; Ventriglio, A, 2023)	1.63
"Vortioxetine did not cause cognitive or psychomotor impairment."	( A randomized trial on the acute and steady-state effects of a new antidepressant, vortioxetine (Lu AA21004), on actual driving and cognition. Højer, AM; Ramaekers, JG; Street, D; Theunissen, EL; van Oers, A; Vermeeren, A, 2013)	1.34
"Vortioxetine displays an antidepressant and anxiolytic profile following repeated administration associated with increased neurogenesis at several stages."	( Antidepressant and anxiolytic potential of the multimodal antidepressant vortioxetine (Lu AA21004) assessed by behavioural and neurogenesis outcomes in mice. David, DJ; Ebert, B; Gardier, AM; Guiard, BP; Guilloux, JP; Hen, R; Mendez-David, I; Miller, S; Orvoën, S; Pehrson, A; Repérant, C; Sanchez, C, 2013)	1.34

Excerpt	Reference	Relevance
"Vortioxetine treatment improved cognitive function and induced changes in EEG (decreased theta power and increased beta power) in patients with MDD. "	( Improved cognitive function in patients with major depressive disorder after treatment with vortioxetine: A EEG study. Baik, SY; Kim, H; Kim, YW; Lee, SH, 2022)	2.38
"Vortioxetine treatment significantly attenuated IGF-1 levels and improved all psychopathological, neuropsychological parameters."	( Serum insulin-like growth factor-1 as a potential marker for MDD diagnosis, its clinical characteristics, and treatment efficacy validation: data from an open-label vortioxetine study. Levada, OA; Pinchuk, IY; Troyan, AS, 2020)	1.47
"Vortioxetine treatment was superior in simple attention efficiency."	( Distinct association of plasma BDNF concentration and cognitive function in depressed patients treated with vortioxetine or escitalopram. Dvojkovic, A; Jaksic, N; Kusevic, Z; Mihaljevic-Peles, A; Nikolac Perkovic, M; Pivac, N; Sagud, M; Vuksan-Cusa, B; Zivkovic, M, 2021)	1.56
"Vortioxetine treatment was associated with significant improvement in cognitive function and a favorable safety profile in community-dwelling older adults with MCI."	( Vortioxetine improves cognition in mild cognitive impairment. Tan, C; Tan, SN, 2021)	2.79
"Vortioxetine treatment was safe and well tolerated in both studies."	( Randomized, 8-week, double-blind, placebo-controlled trial of vortioxetine in Japanese adults with major depressive disorder, followed by a 52-week open-label extension trial. Inoue, T; Kitagawa, T; Nishimura, A; Sasai, K, 2018)	1.44
"Both vortioxetine and placebo treatment were associated with significant reductions in binge-eating frequency. "	( A double-blind, placebo-controlled study of vortioxetine in the treatment of binge-eating disorder. Cavic, E; Chamberlain, SR; Grant, JE; Redden, SA; Valle, S, 2019)	1.29
"Vortioxetine treatment was well tolerated; common adverse events (incidence ≥ 5%) were nausea, headache, diarrhea, dry mouth and dizziness."	( Efficacy and safety of vortioxetine (Lu AA21004), 15 and 20 mg/day: a randomized, double-blind, placebo-controlled, duloxetine-referenced study in the acute treatment of adult patients with major depressive disorder. Boulenger, JP; Loft, H; Olsen, CK, 2014)	1.43
"Vortioxetine 2.5 and 10 mg treatment did not significantly improve generalized anxiety disorder symptoms versus placebo. "	( A randomized, double-blind, fixed-dose study comparing the efficacy and tolerability of vortioxetine 2.5 and 10 mg in acute treatment of adults with generalized anxiety disorder. Chen, Y; Jacobsen, PL; Mahableshwarkar, AR; Serenko, M, 2014)	2.07
"Vortioxetine is a new treatment for MDD, and its adverse event profile is similar to that of other SSRIs."	( The US Food and Drug Administration's perspective on the new antidepressant vortioxetine. Dow, A; Fossom, L; Jackson, AJ; Kordzakhia, G; Mathis, MV; Patel, H; Sellers, JW; Temple, RJ; Unger, EF; Yang, P; Zhang, J; Zhu, H, 2015)	2.09
"Vortioxetine treatment was also associated with significantly higher rates of response and remission and with significant improvements in other depression-related scores versus placebo."	( A meta-analysis of randomized, placebo-controlled trials of vortioxetine for the treatment of major depressive disorder in adults. Dragheim, M; Loft, H; Mahableshwarkar, AR; Thase, ME; Vieta, E, 2016)	1.4
"Vortioxetine treatment significantly (p < 0.0001; ω = 0.80) decreased platelet 5-HT concentration and significantly (p = 0.004; ω = 0.80) increased plasma BDNF concentration in depressed patients compared to their baseline values."	( A prospective, longitudinal study of platelet serotonin and plasma brain-derived neurotrophic factor concentrations in major depression: effects of vortioxetine treatment. Kusevic, Z; Maravic, A; Mihaljevic Peles, A; Nikolac Perkovic, M; Pivac, N; Sagud, M; Svob Strac, D; Vuksan-Cusa, B; Zivkovic, M, 2016)	1.36
"Treatment with vortioxetine for 52 weeks was well tolerated, with no new safety signals identified."	( Safety, tolerability, and efficacy of vortioxetine (Lu AA21004) in major depressive disorder: results of an open-label, flexible-dose, 52-week extension study. Alam, MY; Chen, Y; Jacobsen, PL; Mahableshwarkar, AR; Serenko, M, 2014)	1.01
"Rats treated with vortioxetine 1h before training spent more time exploring the novel object in the novel object recognition test."	( Vortioxetine (Lu AA21004), a novel multimodal antidepressant, enhances memory in rats. Gulinello, M; Li, Y; Miller, S; Montezinho, LP; Mørk, A; Plath, N; Sanchez, C; Trippodi-Murphy, C, 2013)	2.16

Excerpt	Reference	Relevance
" NNH for discontinuation because of an adverse event (AE) was 36 (95% CI 24-70)."	( Vortioxetine for major depressive disorder: a systematic review of the efficacy and safety profile for this newly approved antidepressant - what is the number needed to treat, number needed to harm and likelihood to be helped or harmed? Citrome, L, 2014)	1.85
" Among the 834 evaluable study participants, treatment-emergent adverse events were reported in 70."	( Safety, tolerability, and efficacy of vortioxetine (Lu AA21004) in major depressive disorder: results of an open-label, flexible-dose, 52-week extension study. Alam, MY; Chen, Y; Jacobsen, PL; Mahableshwarkar, AR; Serenko, M, 2014)	0.67
" Vortioxetine treatment was well tolerated; common adverse events (incidence ≥ 5%) were nausea, headache, diarrhea, dry mouth and dizziness."	( Efficacy and safety of vortioxetine (Lu AA21004), 15 and 20 mg/day: a randomized, double-blind, placebo-controlled, duloxetine-referenced study in the acute treatment of adult patients with major depressive disorder. Boulenger, JP; Loft, H; Olsen, CK, 2014)	1.62
" (2) The common adverse effects included nausea, dizziness, headache, dry mouth, and diarrhea."	( The efficacy and safety of 5 mg/d Vortioxetine compared to placebo for major depressive disorder: A meta-analysis. Chen, Y; Fu, J, 2015)	0.7
" Current pharmaceutical treatment options are limited in their success by modest effects and adverse events that often lead to discontinuation."	( A review of the clinical efficacy, safety and tolerability of the antidepressants vilazodone, levomilnacipran and vortioxetine. Deardorff, WJ; Grossberg, GT, 2014)	0.61
" The most common adverse events were nausea and vomiting which increased in frequency with higher doses."	( The safety and efficacy of vortioxetine for acute treatment of major depressive disorder: a systematic review and meta-analysis. Hartung, DM; Haxby, DG; Herink, MC; Meeker, AS, 2015)	0.71
" Safety and tolerability were assessed on the basis of treatment-emergent adverse events (TEAEs), vital signs, laboratory values, physical examination, and the Columbia-Suicide Severity Rating Scale."	( Safety and tolerability of vortioxetine (15 and 20 mg) in patients with major depressive disorder: results of an open-label, flexible-dose, 52-week extension study. Chan, S; Chrones, L; Harper, L; Jacobsen, PL; Mahableshwarkar, AR, 2015)	0.71
" Treatment was well tolerated, with the most frequently reported adverse events consisting of nausea, headache, diarrhea, and dizziness."	( A randomized, double-blind, placebo-controlled study of the efficacy and safety of vortioxetine 10 mg and 20 mg in adults with major depressive disorder. Chan, S; Jacobsen, PL; Mahableshwarkar, AR; Serenko, M; Trivedi, MH, 2015)	0.64
" Adverse events were recorded during the study, suicidal ideation and behavior were assessed using the Columbia-Suicide Severity Rating Scale (C-SSRS), and sexual dysfunction was assessed using the Arizona Sexual Experience (ASEX) scale."	( A randomized, double-blind, placebo-controlled study of the efficacy and safety of 2 doses of vortioxetine in adults with major depressive disorder. Chen, Y; Jacobsen, PL; Mahableshwarkar, AR; Serenko, M; Trivedi, MH, 2015)	0.64
" Discontinuation due to adverse events occurred in 7 subjects (4."	( A randomized, double-blind, placebo-controlled study of the efficacy and safety of 2 doses of vortioxetine in adults with major depressive disorder. Chen, Y; Jacobsen, PL; Mahableshwarkar, AR; Serenko, M; Trivedi, MH, 2015)	0.64
" Tolerability was based on the nature, incidence and severity of treatment-emergent adverse events (TEAEs) during acute (6/8) week treatment in 11 randomized, double-blind placebo-controlled short-term studies in major depressive disorder: six with an active reference."	( The safety and tolerability of vortioxetine: Analysis of data from randomized placebo-controlled trials and open-label extension studies. Baldwin, DS; Chrones, L; Florea, I; Nielsen, R; Nomikos, GG; Palo, W; Reines, E, 2016)	0.72
" Adverse events (AEs), vital signs, ECG values, liver enzymes, and body weight were pooled from the same studies."	( Efficacy, safety, and tolerability of vortioxetine for the treatment of major depressive disorder in patients aged 55 years or older. Affinito, J; Nomikos, GG; Palo, W; Tomori, D; Zhong, W, 2017)	0.73
" Most adverse events were mild in severity and consistent with those seen in adults."	( Pharmacokinetics and Safety of Vortioxetine in Pediatric Patients. Areberg, J; Auby, P; Chen, G; DelBello, M; Findling, RL; Huss, M; Lemming, OM; McNamara, N; Poulsen, LH; Robb, AS; Sarkis, E; Scheffer, R, 2017)	0.74
" Adverse events were summarized."	( Randomized, double-blind, placebo-controlled 8-week trial of the efficacy, safety, and tolerability of 5, 10, and 20 mg/day vortioxetine in adults with major depressive disorder. Aritomi, Y; Kitagawa, T; Mahableshwarkar, AR; Nishimura, A; Sasai, K, 2018)	0.69
" Vortioxetine was safe and well tolerated."	( Randomized, double-blind, placebo-controlled 8-week trial of the efficacy, safety, and tolerability of 5, 10, and 20 mg/day vortioxetine in adults with major depressive disorder. Aritomi, Y; Kitagawa, T; Mahableshwarkar, AR; Nishimura, A; Sasai, K, 2018)	1.6
" The primary end points included pharmacokinetic parameters of vortioxetine and incidence of adverse events (AEs)."	( Pharmacokinetics, Safety, and Tolerability of Vortioxetine Following Single- and Multiple-Dose Administration in Healthy Japanese Adults. Aritomi, Y; Matsuno, K; Nakamura, K; Nishimura, A, 2018)	0.98
" It facilitates early adverse drug reaction detection which enables health professionals to identify adverse events that may not have been identified in pre-marketing clinical trials."	( Novel adverse events of vortioxetine: A disproportionality analysis in USFDA adverse event reporting system database. Beulah, E; Maheswari, E; Singh, H; Subeesh, V, 2017)	0.76
"The present study suggests that vortioxetine may result in these adverse events."	( Novel adverse events of vortioxetine: A disproportionality analysis in USFDA adverse event reporting system database. Beulah, E; Maheswari, E; Singh, H; Subeesh, V, 2017)	1.05
" Although rates of overall adverse events and discontinuation due to adverse events were similar, RCTs reported several differences in specific adverse events."	( Efficacy and safety of levomilnacipran, vilazodone and vortioxetine compared with other second-generation antidepressants for major depressive disorder in adults: A systematic review and network meta-analysis. Gartlehner, G; Klerings, I; Schultes, MT; Teufer, B; Titscher, V; Wagner, G, 2018)	0.73
" Moreover, there was no statistically significant difference regarding the remission rates, discontinuation for any reason rates, discontinuation due to adverse events rates, Short-Form 36 Health Survey scores or Sheehan Disability Scale scores between administration of multiple doses (2."	( Vortioxetine treatment for generalised anxiety disorder: a meta-analysis of anxiety, quality of life and safety outcomes. Chen, H; Gao, W; Huang, G; Qin, B; Yang, M; Yang, Q; Zhao, M, 2019)	1.96
"Although our results suggest that vortioxetine did not improve the GAD symptoms, QoL and functional status impairment of patients with GAD, it was safe and well tolerated."	( Vortioxetine treatment for generalised anxiety disorder: a meta-analysis of anxiety, quality of life and safety outcomes. Chen, H; Gao, W; Huang, G; Qin, B; Yang, M; Yang, Q; Zhao, M, 2019)	2.24
"The aim of this study was to explore the adverse event reporting pattern of vortioxetine through a cluster analysis."	( Post-Marketing Safety Profile of Vortioxetine Using a Cluster Analysis and a Disproportionality Analysis of Global Adverse Event Reports. Chandler, R; Ekhart, C; Meldau, EL; Norén, GN; Taavola, H; van Hunsel, F; van Puijenbroek, E, 2022)	1.23
"Individual case safety reports for vortioxetine in VigiBase up to 1 November, 2019 were subjected to consensus clustering, to identify and describe natural groupings of reports based on their reported adverse events."	( Post-Marketing Safety Profile of Vortioxetine Using a Cluster Analysis and a Disproportionality Analysis of Global Adverse Event Reports. Chandler, R; Ekhart, C; Meldau, EL; Norén, GN; Taavola, H; van Hunsel, F; van Puijenbroek, E, 2022)	1.28
" The two largest clusters included 48% of the vortioxetine reports and appeared to represent gastrointestinal adverse events and hypersensitivity adverse events."	( Post-Marketing Safety Profile of Vortioxetine Using a Cluster Analysis and a Disproportionality Analysis of Global Adverse Event Reports. Chandler, R; Ekhart, C; Meldau, EL; Norén, GN; Taavola, H; van Hunsel, F; van Puijenbroek, E, 2022)	1.26
"A pattern of co-reported adverse events that is consistent with labelled adverse events for vortioxetine and the safety profile for selective serotonin reuptake inhibitors in general was revealed."	( Post-Marketing Safety Profile of Vortioxetine Using a Cluster Analysis and a Disproportionality Analysis of Global Adverse Event Reports. Chandler, R; Ekhart, C; Meldau, EL; Norén, GN; Taavola, H; van Hunsel, F; van Puijenbroek, E, 2022)	1.22
" We believe that these results highlight the adverse effects of vortioxetine on non-target organisms and that further investigations will be required to provide a higher confidence."	( Toxicity of waterborne vortioxetine, a new antidepressant, in non-target aquatic organisms: From wonder to concern drugs? Hong, X; Zha, J; Zhang, L, 2022)	1.27
" The rate and pattern of adverse events were similar across the sub-groups with comorbidities and was consistent with that expected for vortioxetine treatment."	( Efficacy and safety of vortioxetine in treatment of patients with major depressive disorder and common co-morbid physical illness. Baldwin, DS; Necking, O; Reines, EH; Ren, H; Schmidt, SN, 2022)	1.23
" Vortioxetine was generally safe and well tolerated and without unexpected adverse events in these subpopulations, most of whom are taking multiple concomitant medications."	( Efficacy and safety of vortioxetine in treatment of patients with major depressive disorder and common co-morbid physical illness. Baldwin, DS; Necking, O; Reines, EH; Ren, H; Schmidt, SN, 2022)	1.94
"Vortioxetine is effective, well tolerated, and safe for treating MDD in clinical practice, with significant improvements observed in depressive severity, cognitive function, and functioning."	( Effectiveness and Safety of Vortioxetine for the Treatment of Major Depressive Disorder in the Real World: A Systematic Review and Meta-Analysis. Chen, S; Hao, Y; He, L; Li, J; Li, M; Li, Z; Liu, S; Liu, T; Liu, Y; Peng, P; Wang, Q; Wang, X; Wang, Y; Wu, Q; Xu, H; Yang, Q, 2023)	2.65

Excerpt	Reference	Relevance
" Standard pharmacokinetic parameters were estimated with non-compartmental analysis."	( The clinical pharmacokinetics of Lu AA21004 and its major metabolite in healthy young volunteers. Areberg, J; Højer, AM; Søgaard, B, 2012)	0.38
" Clinical studies in healthy subjects were performed to evaluate potential pharmacokinetic interactions between vortioxetine (Lu AA21004) and co-administered agents, including fluconazole (cytochrome P450 [CYP] 2C9, CYP2C19 and CYP3A inhibitor), ketoconazole (CYP3A and P-glycoprotein inhibitor), rifampicin (CYP inducer), bupropion (CYP2D6 inhibitor and CYP2B6 substrate), ethinyl estradiol/levonorgestrel (CYP3A substrates) and omeprazole (CYP2C19 substrate and inhibitor)."	( Pharmacokinetic drug interactions involving vortioxetine (Lu AA21004), a multimodal antidepressant. Buchbjerg, JK; Chen, G; Højer, AM; Lee, R; Serenko, M; Zhao, Z, 2013)	0.86
", area under the plasma concentration-time curve [AUC] and maximum plasma concentration [C max]) was used to assess pharmacokinetic interactions."	( Pharmacokinetic drug interactions involving vortioxetine (Lu AA21004), a multimodal antidepressant. Buchbjerg, JK; Chen, G; Højer, AM; Lee, R; Serenko, M; Zhao, Z, 2013)	0.65
" The average elimination half-life was 65."	( Population pharmacokinetic meta-analysis of vortioxetine in healthy individuals. Areberg, J; Chen, G; Naik, H; Petersen, KB, 2014)	0.66
" Vortioxetine had no effect on the steady-state pharmacokinetic parameters of aspirin or its metabolite salicylic acid, and no statistically significant effect on the inhibition of arachidonic acid-, adenosine-5'-diphosphate-, or collagen-induced platelet aggregation at any time points."	( Lack of effect of multiple doses of vortioxetine on the pharmacokinetics and pharmacodynamics of aspirin and warfarin. Chen, G; Serenko, M; Zhang, W, 2015)	1.6
" The method has been successfully applied to a pharmacokinetic study of vortioxetine in rats for the first time, which provides the basis for the further development and application of vortioxetine."	( An UPLC-MS/MS method for the quantitation of vortioxetine in rat plasma: Application to a pharmacokinetic study. Gu, EM; Hu, G; Huang, C; Lan, T; Liang, B; Yuan, L; Zhou, H, 2015)	0.91
" Polysomnography and blood sampling for pharmacokinetic analysis were performed on the pre-dose night and nights 1 and 3 of dosing in each period."	( Differentiated effects of the multimodal antidepressant vortioxetine on sleep architecture: Part 1, a pharmacokinetic/pharmacodynamic comparison with paroxetine in healthy men. Areberg, J; Buchberg, J; Højer, AM; Nutt, DJ; Wilson, S, 2015)	0.66
" This analysis aimed to develop pharmacokinetic (PK) and PK/Efficacy models to evaluate the exposure-response relationship for vortioxetine in patients with MDD."	( A Population Pharmacokinetic-Pharmacodynamic Meta-Analysis of Vortioxetine in Patients with Major Depressive Disorder. Areberg, J; Chan, S; Chen, G; Loft, H; Mahableshwarkar, AR; Naik, H; Vakilynejad, M, 2016)	0.88
"These studies evaluated whether there are pharmacokinetic and/or pharmacodynamic interactions between vortioxetine and ethanol, diazepam, or lithium."	( Lack of Effect of Vortioxetine on the Pharmacokinetics and Pharmacodynamics of Ethanol, Diazepam, and Lithium. Affinito, J; Chen, G; Nomikos, GG; Zhao, Z, 2016)	0.98
" These two studies evaluated the effect of coadministration on standardized psychomotor parameters and on selected pharmacokinetic parameters of each drug."	( Lack of Effect of Vortioxetine on the Pharmacokinetics and Pharmacodynamics of Ethanol, Diazepam, and Lithium. Affinito, J; Chen, G; Nomikos, GG; Zhao, Z, 2016)	0.77
"Concomitant administration of these agents with vortioxetine was generally well tolerated, with no clinically relevant drug-drug pharmacokinetic or pharmacodynamic interactions identified."	( Lack of Effect of Vortioxetine on the Pharmacokinetics and Pharmacodynamics of Ethanol, Diazepam, and Lithium. Affinito, J; Chen, G; Nomikos, GG; Zhao, Z, 2016)	1.02
" The analytical method was successfully applied to a pharmacokinetic interaction study of vortioxetine and carvedilol after oral administration vortioxetine and carvedilol in rats."	( Simultaneous quantification of vortioxetine, carvedilol and its active metabolite 4-hydroxyphenyl carvedilol in rat plasma by UPLC-MS/MS: Application to their pharmacokinetic interaction study. Huang, Y; Li, T; Pan, Y; Shao, MM; Xu, ZS; Zheng, S, 2016)	0.94
" The primary end points included pharmacokinetic parameters of vortioxetine and incidence of adverse events (AEs)."	( Pharmacokinetics, Safety, and Tolerability of Vortioxetine Following Single- and Multiple-Dose Administration in Healthy Japanese Adults. Aritomi, Y; Matsuno, K; Nakamura, K; Nishimura, A, 2018)	0.98
" The pharmacokinetics of vortioxetine are linear and dose proportional, with a mean terminal half-life of approximately 66 h and steady-state plasma concentrations generally achieved within 2 weeks of dosing."	( Vortioxetine: Clinical Pharmacokinetics and Drug Interactions. Areberg, J; Chen, G; Højer, AM; Nomikos, G, 2018)	2.23
" A series of single- and multiple-dose pharmacokinetic studies were performed to evaluate the impact of intrinsic (ie, subject-related) factors, such as age, sex, race, and renal and hepatic function, on the pharmacokinetics of vortioxetine."	( Effects of Intrinsic Factors on the Clinical Pharmacokinetics of Vortioxetine. Affinito, J; Chen, G; Jacobson, W; Nomikos, GG; Wang, S; Xie, J; Zhao, Z, 2018)	0.9
" In addition, the method was successfully applied to a plasma pharmacokinetic study of JJH201501 tablets in healthy volunteers which was part of the phase I trial."	( Simultaneous determination of deuterated vortioxetine and its major metabolite in human plasma by UPLC-MS/MS and application to a pharmacokinetic study in healthy volunteers. Chen, X; Li, N; Lu, Y; Ren, G; Yi, Y; Zhao, D; Zheng, M, 2020)	0.82
" The aim of this study was to quantify the in vivo CYP2D6 activity of different CYP2D6 alleles and genotypes through population pharmacokinetic (PopPK) modeling of vortioxetine and Lu AA34443."	( Quantification of In Vivo Metabolic Activity of CYP2D6 Genotypes and Alleles Through Population Pharmacokinetic Analysis of Vortioxetine. Areberg, J; Bjerregaard Stage, T; Brøsen, K; Frederiksen, T; Schmidt, E, 2021)	1.02
" A population pharmacokinetic (popPK) model of vortioxetine and its CYP2D6-dependent metabolite was recently published."	( Validation of a Population Pharmacokinetic Model of Vortioxetine Using Therapeutic Drug Monitoring Data. Areberg, J; Frederiksen, T; Molden, E; Smith, RL; Wollmann, BM, 2021)	1.13

Excerpt	Reference	Relevance
"The identification and quantification of potential drug-drug interactions is important for avoiding or minimizing the interaction-induced adverse events associated with specific drug combinations."	( Pharmacokinetic drug interactions involving vortioxetine (Lu AA21004), a multimodal antidepressant. Buchbjerg, JK; Chen, G; Højer, AM; Lee, R; Serenko, M; Zhao, Z, 2013)	0.65
" Like other antidepressants enhancing serotonergic activity, vortioxetine is associated with a potential risk of serotonin syndrome when used in combination with other serotonergic agents."	( Drug interactions with vortioxetine, a new multimodal antidepressant. Santoro, V; Spina, E, )	0.68

Excerpt	Reference	Relevance
" The absolute bioavailability was 75%."	( The clinical pharmacokinetics of Lu AA21004 and its major metabolite in healthy young volunteers. Areberg, J; Højer, AM; Søgaard, B, 2012)	0.38
" The pharmacokinetics of vortioxetine was best characterised by a two-compartment model with first-order absorption, lag-time and linear elimination, with interindividual error terms for absorption rate constant, oral clearance and central volume of distribution."	( Population pharmacokinetic meta-analysis of vortioxetine in healthy individuals. Areberg, J; Chen, G; Naik, H; Petersen, KB, 2014)	0.97
" The mean absolute oral bioavailability of vortioxetine is 75%."	( Vortioxetine: Clinical Pharmacokinetics and Drug Interactions. Areberg, J; Chen, G; Højer, AM; Nomikos, G, 2018)	2.19
" The results of our study provide conclusive in-vivo evidence that in mice vortioxetine's brain bioavailability is P-gp dependent, expanding previous findings on this topic."	( abcb1ab p-glycoprotein is involved in the uptake of the novel antidepressant vortioxetine into the brain of mice. Namendorf, C; Namendorf, T; Spieler, D; Uhr, M, 2019)	0.97

Excerpt	Relevance	Reference
" The metabolite was found in urine and plasma from humans and animals dosed with 1-[2-(2,4-dimethyl-phenylsulfanyl)-phenyl]-piperazine hydrobromide (Lu AA21004, 1), as a novel multimodal antidepressant under development for treatment of depression."	( Biosynthesis and identification of an N-oxide/N-glucuronide metabolite and first synthesis of an N-O-glucuronide metabolite of Lu AA21004. Dalgaard, L; Juhl, M; Pedersen, H; Uldam, HK, 2011)	0.37
" The exposure of Lu AA21004 showed a linear relationship with dose in the dose ranges studied (up to 75-mg single dosing and 60-mg multiple dosing)."	( The clinical pharmacokinetics of Lu AA21004 and its major metabolite in healthy young volunteers. Areberg, J; Højer, AM; Søgaard, B, 2012)	0.38
" Acute dosing of vortioxetine inhibited neuronal firing activity more potently than fluoxetine."	( The rapid recovery of 5-HT cell firing induced by the antidepressant vortioxetine involves 5-HT(3) receptor antagonism. Bétry, C; Ebert, B; Etiévant, A; Haddjeri, N; Pehrson, AL; Sánchez, C, 2013)	0.96
" In this study 11 control subjects were examined with PET and [¹¹C]MADAM at baseline, after a single dose and after 9 days of dosing with Lu AA21004 (2."	( 5-HTT and 5-HT(1A) receptor occupancy of the novel substance vortioxetine (Lu AA21004). A PET study in control subjects. Halldin, C; Lundberg, J; Stenkrona, P, 2013)	0.63
" Acute and repeated dosing of vortioxetine produced more pronounced anxiolytic- and antidepressant-like activities than fluoxetine."	( Antidepressant and anxiolytic potential of the multimodal antidepressant vortioxetine (Lu AA21004) assessed by behavioural and neurogenesis outcomes in mice. David, DJ; Ebert, B; Gardier, AM; Guiard, BP; Guilloux, JP; Hen, R; Mendez-David, I; Miller, S; Orvoën, S; Pehrson, A; Repérant, C; Sanchez, C, 2013)	0.91
" Rats were acutely dosed with vortioxetine, ondansetron (5-HT3 receptor antagonist) or flesinoxan (5-HT1A receptor agonist)."	( Vortioxetine dose-dependently reverses 5-HT depletion-induced deficits in spatial working and object recognition memory: a potential role for 5-HT1A receptor agonism and 5-HT3 receptor antagonism. du Jardin, KG; Jensen, JB; Pehrson, AL; Sanchez, C, 2014)	2.13
" Rates of treatment-emergent sexual dysfunction (TESD) in the vortioxetine dosing groups were similar to placebo."	( A randomised, double-blind, placebo-controlled, duloxetine-referenced study of the efficacy and tolerability of vortioxetine in the acute treatment of adults with generalised anxiety disorder. Chen, Y; Jacobsen, PL; Mahableshwarkar, AR; Simon, JS, 2014)	0.85
" The applicant has agreed to conduct a US maintenance dose-response study covering the US-approved dose range."	( The US Food and Drug Administration's perspective on the new antidepressant vortioxetine. Dow, A; Fossom, L; Jackson, AJ; Kordzakhia, G; Mathis, MV; Patel, H; Sellers, JW; Temple, RJ; Unger, EF; Yang, P; Zhang, J; Zhu, H, 2015)	0.65
"We compared the effect of vortioxetine, paroxetine and placebo after three days of dosing on sleep architecture."	( Differentiated effects of the multimodal antidepressant vortioxetine on sleep architecture: Part 1, a pharmacokinetic/pharmacodynamic comparison with paroxetine in healthy men. Areberg, J; Buchberg, J; Højer, AM; Nutt, DJ; Wilson, S, 2015)	0.96
" On the other hand, dosage adjustments may be required when vortioxetine is coadministered with strong CYP2D6 inhibitors or broad-spectrum CYP inducers."	( Drug interactions with vortioxetine, a new multimodal antidepressant. Santoro, V; Spina, E, )	0.68
" Rats were dosed for 1 and 4 weeks with vortioxetine and fluoxetine at doses relevant for antidepressant activity."	( Vortioxetine promotes early changes in dendritic morphology compared to fluoxetine in rat hippocampus. Chen, F; du Jardin, KG; Nyengaard, JR; Sanchez, C; Waller, JA; Wegener, G, 2016)	2.14
" These data suggest that vortioxetine has some effects on memory that could be mediated through cholinergic neurotransmission, however these effects are modest and only seen under acute dosing conditions."	( Task- and Treatment Length-Dependent Effects of Vortioxetine on Scopolamine-Induced Cognitive Dysfunction and Hippocampal Extracellular Acetylcholine in Rats. Budac, D; Cajina, M; Haddjeri, N; Hillhouse, TM; Mørk, A; Pehrson, AL; Porter, JH; Rovera, R; Sanchez, C; Smagin, G; Song, D, 2016)	0.99
"The primary objectives of this study were to evaluate the pharmacokinetics (PK) and tolerability of single and multiple doses of vortioxetine in children and adolescents with a depressive or anxiety disorder and to provide supportive information for appropriate dosing regimens for pediatric clinical trials."	( Pharmacokinetics and Safety of Vortioxetine in Pediatric Patients. Areberg, J; Auby, P; Chen, G; DelBello, M; Findling, RL; Huss, M; Lemming, OM; McNamara, N; Poulsen, LH; Robb, AS; Sarkis, E; Scheffer, R, 2017)	0.95
"This OLE confirms the findings from the lead-in study, which concluded that a dosing strategy of 5-20 mg/day is safe, well tolerated, and suitable for future clinical studies of vortioxetine in pediatric patients."	( A 6-Month Open-Label Extension Study of Vortioxetine in Pediatric Patients with Depressive or Anxiety Disorders. Auby, P; Chen, G; DelBello, MP; Findling, RL; Huss, M; Lemming, OM; McNamara, NK; Poulsen, LH; Robb, AS; Sarkis, EH; Scheffer, RE, 2018)	0.94
" In addition, increasing the dosage improved the efficacy of vortioxetine but worsened the tolerability."	( Efficacy and tolerability of different doses of three new antidepressants for treating major depressive disorder: A PRISMA-compliant meta-analysis. An, X; Fan, Y; Guo, L; He, H; Lyu, J; Ma, X; Wang, W; Zheng, J, 2018)	0.72
"6 years) on stable clozapine treatment, assessed by neuropsychological (Wisconsin Card Sorting Test, Verbal Fluency, and Stroop task) and psychodiagnostic instruments (Positive and Negative Syndrome Scale [PANSS] and Calgary Depression Scale for Schizophrenia), received vortioxetine at the single daily dose of 10 mg/d until week 12; the dose was increased at 20 mg/d afterward, and this dosage was maintained unchanged until week 24."	( Vortioxetine on Cognition in Schizophrenia: A Pilot Study. Bruno, A; Cedro, C; Mento, C; Muscatello, MRA; Pandolfo, G; Santoro, V; Scala, L; Spina, E; Troili, GM; Zoccali, RA, )	1.75
" The mean vortioxetine daily dosage was 12."	( Effectiveness, tolerability, and dropout rates of vortioxetine in comorbid depression: A naturalistic study. Benatti, B; Bosi, MF; Colombo, A; De Carlo, V; Dell'Osso, B; Grancini, B; Viganò, CA; Vismara, M, 2020)	1.21
"We conducted a 12-week placebo-controlled, randomized clinical trial of vortioxetine (flexibly dosed from 10 to 20 mg/d) versus placebo in adults with PTSD."	( Efficacy of Vortioxetine Monotherapy for Posttraumatic Stress Disorder: A Randomized, Placebo-Controlled Trial. Barone, K; Dunlop, BW; Harvey, PD; Mletzko-Crowe, T; Nemeroff, CB; Newport, DJ; Rakofsky, JJ, )	0.74
" After experiencing a major Covid-19-related personal trauma, patients showed clinical worsening which required dosage adjustment (20 mg/day vortioxetine; 600 mg/day trazodone, and 200 mg/day sertraline) and, for some of them, hospitalisation."	( Differential Response to Three Antidepressants in Patients with Major Depressive Episode Who Suffered Covid-19-Related Trauma. Amici, E; De Filippis, S; Di Giovanni, A; Giovanetti, V; Kotzalidis, GD; Lombardozzi, G; Matrone, M; Perrini, F; Trovini, G, 2022)	0.92
" Vortioxetine starting dosage was 10 mg/day, with forced up-titration to 20 mg/day after 1 week."	( Effectiveness of vortioxetine in patients with major depressive disorder comorbid with generalized anxiety disorder: Results of the RECONNECT study. Christensen, MC; Grande, I; Schmidt, S, 2022)	1.97
" Findings support increasing vortioxetine dosage to 20 mg/day early in the course of therapy, and show that this may be achieved without compromising tolerability."	( Effectiveness of vortioxetine in patients with major depressive disorder comorbid with generalized anxiety disorder: Results of the RECONNECT study. Christensen, MC; Grande, I; Schmidt, S, 2022)	1.35
" This study assessed the real-world effectiveness of vortioxetine in patients with MDD, with particular focus on functioning; dose-response was also assessed."	( Real-world effectiveness of vortioxetine in outpatients with major depressive disorder: functioning and dose effects. Balta, G; Ettrup, A; Galanopoulos, A; Karavelas, E; Kontis, D; Markopoulou, M; Panagiotidis, P; Papalexi, E; Vlachos, T, 2022)	1.26
" Analyses were stratified according to vortioxetine dosage at 3 months: 5-10 mg/day versus 15-20 mg/day."	( Real-world effectiveness of vortioxetine in outpatients with major depressive disorder: functioning and dose effects. Balta, G; Ettrup, A; Galanopoulos, A; Karavelas, E; Kontis, D; Markopoulou, M; Panagiotidis, P; Papalexi, E; Vlachos, T, 2022)	1.28
" Vortioxetine has demonstrated efficacy in treating anxiety symptoms in patients with MDD; however, efficacy and tolerability have not been assessed across the entire approved dosage range."	( Vortioxetine in patients with major depressive disorder and high levels of anxiety symptoms: An updated analysis of efficacy and tolerability. Adair, M; Christensen, MC; Fagiolini, A; Florea, I; Loft, H, 2023)	3.26
"The pooled analysis of fixed-dose studies demonstrated a clear dose-response relationship for vortioxetine 5-20 mg/day for improvements in MADRS, HAM-A, and SDS total scores."	( Vortioxetine in patients with major depressive disorder and high levels of anxiety symptoms: An updated analysis of efficacy and tolerability. Adair, M; Christensen, MC; Fagiolini, A; Florea, I; Loft, H, 2023)	2.57
"Biorelevant dissolution tests of oral solid dosage forms open the gate to valid in vitro-in vivo predictions (IVIVP)."	( Application of a novel PhysioCell apparatus for biopredictive dissolution tests of oral immediate release formulations - A case study workflow for in vitro-in vivo predictions. Danielak, D; Dobosz, J; Garbacz, G; Hrem, O; Kątny, M; Paszkowska, J; Pieczuro, J; Puk, E; Renn-Hojan, M; Romanova, S; Romański, M; Roznerska, D; Schraube, M; Staniszewska, M; Szczepański, J, 2023)	0.91
"Patients (n = 82) aged 55-85 years with a primary diagnosis of MDD (onset before age 55 years) and comorbid early-stage dementia (diagnosed ≥6 months before screening and after onset of MDD; Mini-Mental State Examination-2 total score, 20-24) received vortioxetine for 12 weeks (initiated at 5 mg/day and up-titrated to 10 mg/day at day 8, with flexible dosing thereafter [5-20 mg/day])."	( Effectiveness of vortioxetine in patients with major depressive disorder and early-stage dementia: The MEMORY study. Christensen, MC; Grande, I; Schmidt, SN, 2023)	1.43

Role	Description
antidepressant	Antidepressants are mood-stimulating drugs used primarily in the treatment of affective disorders and related conditions.
anxiolytic drug	Anxiolytic drugs are agents that alleviate anxiety, tension, and anxiety disorders, promote sedation, and have a calming effect without affecting clarity of consciousness or neurologic conditions.
serotonergic agonist	An agent that has an affinity for serotonin receptors and is able to mimic the effects of serotonin by stimulating the physiologic activity at the cell receptors. Serotonin agonists are used as antidepressants, anxiolytics, and in the treatment of migraine disorders.
serotonergic antagonist	Drugs that bind to but do not activate serotonin receptors, thereby blocking the actions of serotonin or serotonergic agonists.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Class	Description
N-arylpiperazine
aryl sulfide	Any organic sulfide in which the sulfur is attached to at least one aromatic group.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein	Taxonomy	Measurement	Average (µ)	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
PPM1D protein	Homo sapiens (human)	Potency	26.2123	0.0052	9.4661	32.9993	AID1347411
Interferon beta	Homo sapiens (human)	Potency	26.2123	0.0033	9.1582	39.8107	AID1347411
Spike glycoprotein	Severe acute respiratory syndrome-related coronavirus	Potency	39.8107	0.0096	10.5250	35.4813	AID1479145
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
5-hydroxytryptamine receptor 1A	Homo sapiens (human)	Ki	0.0106	0.0001	0.5326	10.0000	AID1368107; AID1403536; AID1610335; AID1611371; AID1916456
Sodium-dependent serotonin transporter	Homo sapiens (human)	Ki	0.0016	0.0000	0.7048	8.1930	AID1916458
Sodium-dependent serotonin transporter	Rattus norvegicus (Norway rat)	IC50 (µMol)	0.0029	0.0003	0.8197	8.4900	AID1610339; AID1611373
5-hydroxytryptamine receptor 7	Homo sapiens (human)	Ki	0.0246	0.0003	0.3806	10.0000	AID1368108; AID1403538; AID1610337; AID1611372; AID1916461
Alpha-1A adrenergic receptor	Homo sapiens (human)	Ki	0.0260	0.0000	0.2726	10.0000	AID1403538
5-hydroxytryptamine receptor 3A	Homo sapiens (human)	Ki	0.0037	0.0000	0.7411	9.9000	AID1916457
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Process	via Protein(s)	Taxonomy
cell surface receptor signaling pathway via JAK-STAT	Interferon beta	Homo sapiens (human)
response to exogenous dsRNA	Interferon beta	Homo sapiens (human)
B cell activation involved in immune response	Interferon beta	Homo sapiens (human)
cell surface receptor signaling pathway	Interferon beta	Homo sapiens (human)
cell surface receptor signaling pathway via JAK-STAT	Interferon beta	Homo sapiens (human)
response to virus	Interferon beta	Homo sapiens (human)
positive regulation of autophagy	Interferon beta	Homo sapiens (human)
cytokine-mediated signaling pathway	Interferon beta	Homo sapiens (human)
natural killer cell activation	Interferon beta	Homo sapiens (human)
positive regulation of peptidyl-serine phosphorylation of STAT protein	Interferon beta	Homo sapiens (human)
cellular response to interferon-beta	Interferon beta	Homo sapiens (human)
B cell proliferation	Interferon beta	Homo sapiens (human)
negative regulation of viral genome replication	Interferon beta	Homo sapiens (human)
innate immune response	Interferon beta	Homo sapiens (human)
positive regulation of innate immune response	Interferon beta	Homo sapiens (human)
regulation of MHC class I biosynthetic process	Interferon beta	Homo sapiens (human)
negative regulation of T cell differentiation	Interferon beta	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	Interferon beta	Homo sapiens (human)
defense response to virus	Interferon beta	Homo sapiens (human)
type I interferon-mediated signaling pathway	Interferon beta	Homo sapiens (human)
neuron cellular homeostasis	Interferon beta	Homo sapiens (human)
cellular response to exogenous dsRNA	Interferon beta	Homo sapiens (human)
cellular response to virus	Interferon beta	Homo sapiens (human)
negative regulation of Lewy body formation	Interferon beta	Homo sapiens (human)
negative regulation of T-helper 2 cell cytokine production	Interferon beta	Homo sapiens (human)
positive regulation of apoptotic signaling pathway	Interferon beta	Homo sapiens (human)
response to exogenous dsRNA	Interferon beta	Homo sapiens (human)
B cell differentiation	Interferon beta	Homo sapiens (human)
natural killer cell activation involved in immune response	Interferon beta	Homo sapiens (human)
adaptive immune response	Interferon beta	Homo sapiens (human)
T cell activation involved in immune response	Interferon beta	Homo sapiens (human)
humoral immune response	Interferon beta	Homo sapiens (human)
behavioral fear response	5-hydroxytryptamine receptor 1A	Homo sapiens (human)
G protein-coupled receptor signaling pathway	5-hydroxytryptamine receptor 1A	Homo sapiens (human)
adenylate cyclase-inhibiting serotonin receptor signaling pathway	5-hydroxytryptamine receptor 1A	Homo sapiens (human)
serotonin receptor signaling pathway	5-hydroxytryptamine receptor 1A	Homo sapiens (human)
gamma-aminobutyric acid signaling pathway	5-hydroxytryptamine receptor 1A	Homo sapiens (human)
positive regulation of cell population proliferation	5-hydroxytryptamine receptor 1A	Homo sapiens (human)
regulation of serotonin secretion	5-hydroxytryptamine receptor 1A	Homo sapiens (human)
regulation of vasoconstriction	5-hydroxytryptamine receptor 1A	Homo sapiens (human)
exploration behavior	5-hydroxytryptamine receptor 1A	Homo sapiens (human)
regulation of dopamine metabolic process	5-hydroxytryptamine receptor 1A	Homo sapiens (human)
serotonin metabolic process	5-hydroxytryptamine receptor 1A	Homo sapiens (human)
regulation of hormone secretion	5-hydroxytryptamine receptor 1A	Homo sapiens (human)
regulation of behavior	5-hydroxytryptamine receptor 1A	Homo sapiens (human)
chemical synaptic transmission	5-hydroxytryptamine receptor 1A	Homo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger	5-hydroxytryptamine receptor 1A	Homo sapiens (human)
monoamine transport	Sodium-dependent serotonin transporter	Homo sapiens (human)
response to hypoxia	Sodium-dependent serotonin transporter	Homo sapiens (human)
neurotransmitter transport	Sodium-dependent serotonin transporter	Homo sapiens (human)
response to nutrient	Sodium-dependent serotonin transporter	Homo sapiens (human)
memory	Sodium-dependent serotonin transporter	Homo sapiens (human)
circadian rhythm	Sodium-dependent serotonin transporter	Homo sapiens (human)
response to xenobiotic stimulus	Sodium-dependent serotonin transporter	Homo sapiens (human)
response to toxic substance	Sodium-dependent serotonin transporter	Homo sapiens (human)
positive regulation of gene expression	Sodium-dependent serotonin transporter	Homo sapiens (human)
positive regulation of serotonin secretion	Sodium-dependent serotonin transporter	Homo sapiens (human)
negative regulation of cerebellar granule cell precursor proliferation	Sodium-dependent serotonin transporter	Homo sapiens (human)
negative regulation of synaptic transmission, dopaminergic	Sodium-dependent serotonin transporter	Homo sapiens (human)
response to estradiol	Sodium-dependent serotonin transporter	Homo sapiens (human)
social behavior	Sodium-dependent serotonin transporter	Homo sapiens (human)
vasoconstriction	Sodium-dependent serotonin transporter	Homo sapiens (human)
sperm ejaculation	Sodium-dependent serotonin transporter	Homo sapiens (human)
negative regulation of neuron differentiation	Sodium-dependent serotonin transporter	Homo sapiens (human)
positive regulation of cell cycle	Sodium-dependent serotonin transporter	Homo sapiens (human)
negative regulation of organ growth	Sodium-dependent serotonin transporter	Homo sapiens (human)
behavioral response to cocaine	Sodium-dependent serotonin transporter	Homo sapiens (human)
enteric nervous system development	Sodium-dependent serotonin transporter	Homo sapiens (human)
brain morphogenesis	Sodium-dependent serotonin transporter	Homo sapiens (human)
serotonin uptake	Sodium-dependent serotonin transporter	Homo sapiens (human)
membrane depolarization	Sodium-dependent serotonin transporter	Homo sapiens (human)
platelet aggregation	Sodium-dependent serotonin transporter	Homo sapiens (human)
cellular response to retinoic acid	Sodium-dependent serotonin transporter	Homo sapiens (human)
cellular response to cGMP	Sodium-dependent serotonin transporter	Homo sapiens (human)
regulation of thalamus size	Sodium-dependent serotonin transporter	Homo sapiens (human)
conditioned place preference	Sodium-dependent serotonin transporter	Homo sapiens (human)
sodium ion transmembrane transport	Sodium-dependent serotonin transporter	Homo sapiens (human)
amino acid transport	Sodium-dependent serotonin transporter	Homo sapiens (human)
smooth muscle contraction	5-hydroxytryptamine receptor 7	Homo sapiens (human)
circadian rhythm	5-hydroxytryptamine receptor 7	Homo sapiens (human)
blood circulation	5-hydroxytryptamine receptor 7	Homo sapiens (human)
vasoconstriction	5-hydroxytryptamine receptor 7	Homo sapiens (human)
G protein-coupled serotonin receptor signaling pathway	5-hydroxytryptamine receptor 7	Homo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger	5-hydroxytryptamine receptor 7	Homo sapiens (human)
chemical synaptic transmission	5-hydroxytryptamine receptor 7	Homo sapiens (human)
MAPK cascade	Alpha-1A adrenergic receptor	Homo sapiens (human)
negative regulation of heart rate involved in baroreceptor response to increased systemic arterial blood pressure	Alpha-1A adrenergic receptor	Homo sapiens (human)
norepinephrine-epinephrine vasoconstriction involved in regulation of systemic arterial blood pressure	Alpha-1A adrenergic receptor	Homo sapiens (human)
positive regulation of heart rate by epinephrine-norepinephrine	Alpha-1A adrenergic receptor	Homo sapiens (human)
positive regulation of the force of heart contraction by epinephrine-norepinephrine	Alpha-1A adrenergic receptor	Homo sapiens (human)
apoptotic process	Alpha-1A adrenergic receptor	Homo sapiens (human)
smooth muscle contraction	Alpha-1A adrenergic receptor	Homo sapiens (human)
signal transduction	Alpha-1A adrenergic receptor	Homo sapiens (human)
G protein-coupled receptor signaling pathway	Alpha-1A adrenergic receptor	Homo sapiens (human)
activation of phospholipase C activity	Alpha-1A adrenergic receptor	Homo sapiens (human)
positive regulation of cytosolic calcium ion concentration	Alpha-1A adrenergic receptor	Homo sapiens (human)
adult heart development	Alpha-1A adrenergic receptor	Homo sapiens (human)
negative regulation of cell population proliferation	Alpha-1A adrenergic receptor	Homo sapiens (human)
response to xenobiotic stimulus	Alpha-1A adrenergic receptor	Homo sapiens (human)
response to hormone	Alpha-1A adrenergic receptor	Homo sapiens (human)
negative regulation of autophagy	Alpha-1A adrenergic receptor	Homo sapiens (human)
positive regulation of cardiac muscle hypertrophy	Alpha-1A adrenergic receptor	Homo sapiens (human)
positive regulation of synaptic transmission, GABAergic	Alpha-1A adrenergic receptor	Homo sapiens (human)
intracellular signal transduction	Alpha-1A adrenergic receptor	Homo sapiens (human)
positive regulation of MAPK cascade	Alpha-1A adrenergic receptor	Homo sapiens (human)
positive regulation of action potential	Alpha-1A adrenergic receptor	Homo sapiens (human)
positive regulation of vasoconstriction	Alpha-1A adrenergic receptor	Homo sapiens (human)
positive regulation of smooth muscle contraction	Alpha-1A adrenergic receptor	Homo sapiens (human)
calcium ion transport into cytosol	Alpha-1A adrenergic receptor	Homo sapiens (human)
positive regulation of cardiac muscle contraction	Alpha-1A adrenergic receptor	Homo sapiens (human)
cell growth involved in cardiac muscle cell development	Alpha-1A adrenergic receptor	Homo sapiens (human)
positive regulation of ERK1 and ERK2 cascade	Alpha-1A adrenergic receptor	Homo sapiens (human)
positive regulation of protein kinase C signaling	Alpha-1A adrenergic receptor	Homo sapiens (human)
pilomotor reflex	Alpha-1A adrenergic receptor	Homo sapiens (human)
neuron-glial cell signaling	Alpha-1A adrenergic receptor	Homo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathway	Alpha-1A adrenergic receptor	Homo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathway	Alpha-1A adrenergic receptor	Homo sapiens (human)
cell-cell signaling	Alpha-1A adrenergic receptor	Homo sapiens (human)
serotonin receptor signaling pathway	5-hydroxytryptamine receptor 3A	Homo sapiens (human)
monoatomic ion transmembrane transport	5-hydroxytryptamine receptor 3A	Homo sapiens (human)
excitatory postsynaptic potential	5-hydroxytryptamine receptor 3A	Homo sapiens (human)
inorganic cation transmembrane transport	5-hydroxytryptamine receptor 3A	Homo sapiens (human)
regulation of presynaptic membrane potential	5-hydroxytryptamine receptor 3A	Homo sapiens (human)
chemical synaptic transmission	5-hydroxytryptamine receptor 3A	Homo sapiens (human)
regulation of membrane potential	5-hydroxytryptamine receptor 3A	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
cytokine activity	Interferon beta	Homo sapiens (human)
cytokine receptor binding	Interferon beta	Homo sapiens (human)
type I interferon receptor binding	Interferon beta	Homo sapiens (human)
protein binding	Interferon beta	Homo sapiens (human)
chloramphenicol O-acetyltransferase activity	Interferon beta	Homo sapiens (human)
G protein-coupled serotonin receptor activity	5-hydroxytryptamine receptor 1A	Homo sapiens (human)
protein binding	5-hydroxytryptamine receptor 1A	Homo sapiens (human)
receptor-receptor interaction	5-hydroxytryptamine receptor 1A	Homo sapiens (human)
neurotransmitter receptor activity	5-hydroxytryptamine receptor 1A	Homo sapiens (human)
serotonin binding	5-hydroxytryptamine receptor 1A	Homo sapiens (human)
integrin binding	Sodium-dependent serotonin transporter	Homo sapiens (human)
monoatomic cation channel activity	Sodium-dependent serotonin transporter	Homo sapiens (human)
neurotransmitter transmembrane transporter activity	Sodium-dependent serotonin transporter	Homo sapiens (human)
serotonin:sodium:chloride symporter activity	Sodium-dependent serotonin transporter	Homo sapiens (human)
protein binding	Sodium-dependent serotonin transporter	Homo sapiens (human)
monoamine transmembrane transporter activity	Sodium-dependent serotonin transporter	Homo sapiens (human)
antiporter activity	Sodium-dependent serotonin transporter	Homo sapiens (human)
syntaxin-1 binding	Sodium-dependent serotonin transporter	Homo sapiens (human)
cocaine binding	Sodium-dependent serotonin transporter	Homo sapiens (human)
sodium ion binding	Sodium-dependent serotonin transporter	Homo sapiens (human)
identical protein binding	Sodium-dependent serotonin transporter	Homo sapiens (human)
nitric-oxide synthase binding	Sodium-dependent serotonin transporter	Homo sapiens (human)
actin filament binding	Sodium-dependent serotonin transporter	Homo sapiens (human)
serotonin binding	Sodium-dependent serotonin transporter	Homo sapiens (human)
protein binding	5-hydroxytryptamine receptor 7	Homo sapiens (human)
G protein-coupled serotonin receptor activity	5-hydroxytryptamine receptor 7	Homo sapiens (human)
neurotransmitter receptor activity	5-hydroxytryptamine receptor 7	Homo sapiens (human)
alpha1-adrenergic receptor activity	Alpha-1A adrenergic receptor	Homo sapiens (human)
protein binding	Alpha-1A adrenergic receptor	Homo sapiens (human)
protein heterodimerization activity	Alpha-1A adrenergic receptor	Homo sapiens (human)
protein binding	5-hydroxytryptamine receptor 3A	Homo sapiens (human)
serotonin-gated monoatomic cation channel activity	5-hydroxytryptamine receptor 3A	Homo sapiens (human)
identical protein binding	5-hydroxytryptamine receptor 3A	Homo sapiens (human)
serotonin binding	5-hydroxytryptamine receptor 3A	Homo sapiens (human)
ligand-gated monoatomic ion channel activity involved in regulation of presynaptic membrane potential	5-hydroxytryptamine receptor 3A	Homo sapiens (human)
transmitter-gated monoatomic ion channel activity involved in regulation of postsynaptic membrane potential	5-hydroxytryptamine receptor 3A	Homo sapiens (human)
excitatory extracellular ligand-gated monoatomic ion channel activity	5-hydroxytryptamine receptor 3A	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
extracellular space	Interferon beta	Homo sapiens (human)
extracellular region	Interferon beta	Homo sapiens (human)
plasma membrane	5-hydroxytryptamine receptor 1A	Homo sapiens (human)
synapse	5-hydroxytryptamine receptor 1A	Homo sapiens (human)
plasma membrane	5-hydroxytryptamine receptor 1A	Homo sapiens (human)
dendrite	5-hydroxytryptamine receptor 1A	Homo sapiens (human)
plasma membrane	Sodium-dependent serotonin transporter	Homo sapiens (human)
focal adhesion	Sodium-dependent serotonin transporter	Homo sapiens (human)
endosome membrane	Sodium-dependent serotonin transporter	Homo sapiens (human)
endomembrane system	Sodium-dependent serotonin transporter	Homo sapiens (human)
presynaptic membrane	Sodium-dependent serotonin transporter	Homo sapiens (human)
membrane raft	Sodium-dependent serotonin transporter	Homo sapiens (human)
synapse	Sodium-dependent serotonin transporter	Homo sapiens (human)
postsynaptic membrane	Sodium-dependent serotonin transporter	Homo sapiens (human)
serotonergic synapse	Sodium-dependent serotonin transporter	Homo sapiens (human)
synapse	Sodium-dependent serotonin transporter	Homo sapiens (human)
plasma membrane	Sodium-dependent serotonin transporter	Homo sapiens (human)
neuron projection	Sodium-dependent serotonin transporter	Homo sapiens (human)
plasma membrane	5-hydroxytryptamine receptor 7	Homo sapiens (human)
trans-Golgi network membrane	5-hydroxytryptamine receptor 7	Homo sapiens (human)
synapse	5-hydroxytryptamine receptor 7	Homo sapiens (human)
dendrite	5-hydroxytryptamine receptor 7	Homo sapiens (human)
plasma membrane	5-hydroxytryptamine receptor 7	Homo sapiens (human)
nucleus	Alpha-1A adrenergic receptor	Homo sapiens (human)
nucleoplasm	Alpha-1A adrenergic receptor	Homo sapiens (human)
cytoplasm	Alpha-1A adrenergic receptor	Homo sapiens (human)
cytosol	Alpha-1A adrenergic receptor	Homo sapiens (human)
plasma membrane	Alpha-1A adrenergic receptor	Homo sapiens (human)
caveola	Alpha-1A adrenergic receptor	Homo sapiens (human)
nuclear membrane	Alpha-1A adrenergic receptor	Homo sapiens (human)
intracellular membrane-bounded organelle	Alpha-1A adrenergic receptor	Homo sapiens (human)
plasma membrane	Alpha-1A adrenergic receptor	Homo sapiens (human)
plasma membrane	5-hydroxytryptamine receptor 3A	Homo sapiens (human)
cleavage furrow	5-hydroxytryptamine receptor 3A	Homo sapiens (human)
postsynaptic membrane	5-hydroxytryptamine receptor 3A	Homo sapiens (human)
serotonin-activated cation-selective channel complex	5-hydroxytryptamine receptor 3A	Homo sapiens (human)
synapse	5-hydroxytryptamine receptor 3A	Homo sapiens (human)
plasma membrane	5-hydroxytryptamine receptor 3A	Homo sapiens (human)
transmembrane transporter complex	5-hydroxytryptamine receptor 3A	Homo sapiens (human)
neuron projection	5-hydroxytryptamine receptor 3A	Homo sapiens (human)
virion membrane	Spike glycoprotein	Severe acute respiratory syndrome-related coronavirus
[Information is prepared from geneontology information from the June-17-2024 release]

Assay ID	Title	Year	Journal	Article
AID1610339	Inhibition of rat synaptosomes 5HT transporter assessed as reduction in [3H]serotonin reuptake incubated for 15 mins by scintillation counting method
AID1368109	Half-life in rat liver microsomes at 1 uM in presence of NADPH regenerating system by LC-MS/MS analysis
AID1611380	Antidepressant activity in mouse assessed as decrease in immobility time at 40 mg/kg, po administrated for daily for 7 days measured 1 hr post last dose by forced swim test relative to control
AID1611377	Clearance in human liver microsomes at 1 uM in presence of NADPH generating system measured for 10 to 90 mins by LC-MS/MS analysis
AID1611368	Displacement of [3H]-8-OH-DPAT from 5HT1A receptor (unknown origin) expressed in HEK293 cells membranes at 1 uM incubated for 60 mins by scintillation counting method relative to control
AID1611370	Inhibition of rat synaptosomes 5HT transporter assessed as reduction in [3H]serotonin reuptake at 1 uM incubated for 15 mins by scintillation counting method relative to control
AID1611372	Displacement of [3H]-LSD from 5HT7 receptor (unknown origin) expressed in CHO cell membranes incubated for 120 mins by scintillation counting method
AID1368107	Displacement of [3H]8-OH-DPAT from recombinant human 5-HT1A receptor expressed in HEK293 cell membranes measured after 60 mins by scintillation counting method
AID1368108	Displacement of [3H]-LSD from recombinant human 5-HT7 receptor expressed in CHO cell membranes measured after 60 mins by scintillation counting method
AID1610341	Half life in rat liver microsomes at 1 uM in presence of NADPH generating system measured for 10 to 90 mins by LC-MS/MS analysis
AID1610349	Antidepressant activity in ICR mouse assessed as decrease in immobility time at 40 mg/kg, po administrated for daily for 7 days measured 1 hr post last dose by forced swim test relative to control
AID1368110	Clearance in rat liver microsomes at 1 uM measured after 90 mins in presence of NADPH regenerating system by LC-MS/MS analysis
AID1610343	Half life in human liver microsomes at 1 uM in presence of NADPH generating system measured for 10 to 90 mins by LC-MS/MS analysis
AID1611383	Antidepressant activity in mouse assessed as decrease in immobility time at 30 mg/kg, po administrated for daily for 7 days measured 1 hr post last dose by tail suspension test relative to control
AID1368106	Inhibition of SERT in rat brain synaptosomes assessed as reduction in [3H]-5-HT uptake measured after 15 mins by scintillation counting method
AID1611375	Clearance in rat liver microsomes at 1 uM in presence of NADPH generating system measured for 10 to 90 mins by LC-MS/MS analysis
AID1368111	Antidepressant-like activity in mouse assessed as reduction in immobility time at 20 mg/kg, po administered once daily for 7 days measured last 4 mins of 6 mins test by forced swim test relative to control
AID1610335	Displacement of [3H]-8-OH-DPAT from 5HT1A receptor (unknown origin) expressed in HEK293 cells membranes incubated for 60 mins by scintillation counting method
AID1611376	Half life in human liver microsomes at 1 uM in presence of NADPH generating system measured for 10 to 90 mins by LC-MS/MS analysis
AID1610337	Displacement of [3H]-LSD from 5HT7 receptor (unknown origin) expressed in CHO cell membranes incubated for 120 mins by scintillation counting method
AID1403541	Antidepressant-like activity in mouse assessed as reduction in immobility time at 40 mg/kg/day, po once daily for 7 days measured for last 4 mins of 6 mins test at 1 hr post last dose by forced swim test relative to control
AID1403538	Displacement of [3H]LSD from recombinant human 5-HT7 receptor expressed in CHO cell membranes after 120 mins by TopCount scintillation counting method
AID1610344	Clearance in human liver microsomes at 1 uM in presence of NADPH generating system measured for 10 to 90 mins by LC-MS/MS analysis
AID1916456	Binding affinity to human 5-HT1A assessed as inhibition constant	2021	Bioorganic & medicinal chemistry letters, 10-01, Volume: 49	Chemical update on the potential for serotonin 5-HT
AID1611369	Displacement of [3H]-LSD from 5HT7 receptor (unknown origin) expressed in CHO cell membranes at 1 uM incubated for 120 mins by scintillation counting method relative to control
AID1403540	Clearance in rat liver microsomes at 1 uM in presence of NADPH by LC-MS/MS analysis
AID1611374	Half life in rat liver microsomes at 1 uM in presence of NADPH generating system measured for 10 to 90 mins by LC-MS/MS analysis
AID1403534	Inhibition of [3H]serotonin reuptake in rat brain synaptosomes SERT after 15 mins by TopCount scintillation counting method
AID1610342	Clearance in rat liver microsomes at 1 uM in presence of NADPH generating system measured for 10 to 90 mins by LC-MS/MS analysis
AID1916458	Binding affinity to human SERT assessed as inhibition constant	2021	Bioorganic & medicinal chemistry letters, 10-01, Volume: 49	Chemical update on the potential for serotonin 5-HT
AID1403536	Displacement of [3H]8-OH-DPAT from recombinant human 5-HT1A receptor expressed in HEK293 cell membranes after 60 mins by TopCount scintillation counting method
AID1917795	Antidepressant activity in ICR mouse assessed as reduction in immobility time at 40 mg/kg, po for 7 days by forced swimming test	2022	Bioorganic & medicinal chemistry letters, 11-15, Volume: 76	Synthesis and antidepressant activity of novel 1-(1-benzoylpiperidin-4-yl) methanamine derivatives selectively targeting SSRI/5-HT
AID1403539	Half life in rat liver microsomes at 1 uM in presence of NADPH by LC-MS/MS analysis
AID1916457	Binding affinity to human 5-HT3R assessed as inhibition constant	2021	Bioorganic & medicinal chemistry letters, 10-01, Volume: 49	Chemical update on the potential for serotonin 5-HT
AID1916461	Binding affinity to human 5-HT7R assessed as inhibition constant	2021	Bioorganic & medicinal chemistry letters, 10-01, Volume: 49	Chemical update on the potential for serotonin 5-HT
AID1611373	Inhibition of rat synaptosomes 5HT transporter assessed as reduction in [3H]serotonin reuptake incubated for 15 mins by scintillation counting method
AID1611371	Displacement of [3H]-8-OH-DPAT from 5HT1A receptor (unknown origin) expressed in HEK293 cells membranes incubated for 60 mins by scintillation counting method
AID1345170	Human 5-HT6 receptor (5-Hydroxytryptamine receptors)	2011	Journal of medicinal chemistry, May-12, Volume: 54, Issue:9	Discovery of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine (Lu AA21004): a novel multimodal compound for the treatment of major depressive disorder.
AID1346943	Human SERT (Monoamine transporter subfamily)	2011	Journal of medicinal chemistry, May-12, Volume: 54, Issue:9	Discovery of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine (Lu AA21004): a novel multimodal compound for the treatment of major depressive disorder.
AID1345615	Human 5-HT1A receptor (5-Hydroxytryptamine receptors)	2011	Journal of medicinal chemistry, May-12, Volume: 54, Issue:9	Discovery of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine (Lu AA21004): a novel multimodal compound for the treatment of major depressive disorder.
AID1345291	Human 5-HT7 receptor (5-Hydroxytryptamine receptors)	2011	Journal of medicinal chemistry, May-12, Volume: 54, Issue:9	Discovery of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine (Lu AA21004): a novel multimodal compound for the treatment of major depressive disorder.
AID1346481	Rat 5-HT1D receptor (5-Hydroxytryptamine receptors)	2004	Journal of medicinal chemistry, Sep-09, Volume: 47, Issue:19	Synthesis and structure--activity relationship in a class of indolebutylpiperazines as dual 5-HT(1A) receptor agonists and serotonin reuptake inhibitors.
AID1259419	Human 5-HT2A receptor (5-Hydroxytryptamine receptors)	2011	Journal of medicinal chemistry, May-12, Volume: 54, Issue:9	Discovery of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine (Lu AA21004): a novel multimodal compound for the treatment of major depressive disorder.
AID1345068	Human 5-HT5A receptor (5-Hydroxytryptamine receptors)	2011	Journal of medicinal chemistry, May-12, Volume: 54, Issue:9	Discovery of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine (Lu AA21004): a novel multimodal compound for the treatment of major depressive disorder.
AID1346264	Human 5-HT1B receptor (5-Hydroxytryptamine receptors)	2011	Journal of medicinal chemistry, May-12, Volume: 54, Issue:9	Discovery of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine (Lu AA21004): a novel multimodal compound for the treatment of major depressive disorder.
AID1347411	qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary	2020	ACS chemical biology, 07-17, Volume: 15, Issue:7	High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (0.25)	29.6817
2010's	244 (61.77)	24.3611
2020's	150 (37.97)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	103 (24.76%)	5.53%
Reviews	86 (20.67%)	6.00%
Case Studies	20 (4.81%)	4.05%
Observational	10 (2.40%)	0.25%
Other	197 (47.36%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (103)

Trial Overview

Trial	Phase	Enrollment	Study Type	Start Date	Status
A Phase 3, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Duloxetine-Referenced, Fixed-Dose Study Comparing the Efficacy and Safety of 2 Doses (15 and 20 mg) of Lu AA21004 in Acute Treatment of Adults With Major Depressive Disorder [NCT01153009]	Phase 3	614 participants (Actual)	Interventional	2010-06-30	Completed
Relationship Among Changes in Brain Network Activation, Changes in Core Depressive and Cognitive Symptoms and Safety and Tolerability in Adults With Major Depressive Disorder Treated With Open-Label, Flexible-Dose Vortioxetine [NCT02749721]	Phase 4	31 participants (Actual)	Interventional	2016-12-31	Completed
An Open-Label Clinical Trial Evaluating Sensitivity to Change in Cognition Using the THINC-it Following Treatment With Vortioxetine in Major Depressive Disorder [NCT03053362]	Phase 2/Phase 3	158 participants (Actual)	Interventional	2017-05-24	Completed
An Open-Label, Single-Arm, Multicenter, Prospective, Phase 4, Interventional, Flexible Dose Study to Evaluate the Effectiveness of Vortioxetine on Goal Achievement After a Change in Antidepressant Medication for the Treatment of Subjects With Major Depres [NCT02972632]	Phase 4	123 participants (Actual)	Interventional	2016-12-22	Completed
A 10-Week, Open-Label, Flexible Dose Adaptive Study Evaluating the Efficacy of Vortioxetine in Subjects With Panic Disorder [NCT02395510]	Phase 4	27 participants (Actual)	Interventional	2015-05-31	Completed
Interventional, Open-Label, Single Cohort, Canadian Study to Describe the Relationship Between Cognitive Symptoms and Work Productivity in Working Adults Treated With Vortioxetine for Major Depressive Disorder (MDD) [NCT02332954]	Phase 4	226 participants (Actual)	Interventional	2015-02-28	Completed
Interventional, Randomised, Double-blind, Placebo-controlled, Active Comparator, Four-way Crossover Electroencephalography Study Investigating the Effects of Vortioxetine (Lu AA21004) in Healthy Male Subjects [NCT02072278]	Phase 1	32 participants (Actual)	Interventional	2014-02-28	Completed
A Randomized, Double-Blind, Parallel Group, Placebo- and Active-Controlled, Phase 4 Study Evaluating the Effect of Vortioxetine 10 and 20 mg/Day vs Paroxetine 20 mg/Day on Sexual Functioning in Healthy Subjects [NCT02932904]	Phase 4	361 participants (Actual)	Interventional	2016-11-21	Completed
Single Dose Oral Bioequivalence Study of Vortioxetine Hemihydrobromide Orally Disintegrating Tablets 20 mg and 'Trintellix' (Vortioxetine) Tablets 20 mg in Healthy Adult Human Subjects Under Fasting Conditions [NCT05417087]	Phase 1	48 participants (Actual)	Interventional	2022-06-27	Completed
Single Dose Oral Food Effect Bioavailability Study of Vortioxetine Hemihydrobromide Orally Disintegrating Tablets 20 mg in Healthy Adult Human Subjects Under Fasting and Fed Conditions [NCT05416957]	Phase 1	24 participants (Actual)	Interventional	2022-09-18	Completed
Single Dose Study to Evaluate Dose-proportionality of Vortioxetine Hemihydrobromide Orally Disintegrating Tablets (5 mg, 10 mg and 20 mg) in Healthy Adult Human Subjects Under Fasting Conditions [NCT05416762]	Phase 1	30 participants (Actual)	Interventional	2022-09-19	Completed
A Double-blind, Randomised, Placebo-controlled, Multicentre, Relapse-prevention Study With Two Doses of [Vortioxetine] Lu AA21004 in Patients With Major Depressive Disorder [NCT00596817]	Phase 3	639 participants (Actual)	Interventional	2007-12-31	Completed
Cognitive Effects of Adjuvant Vortioxetine in Early Schizophrenia [NCT04895488]	Phase 2/Phase 3	37 participants (Anticipated)	Interventional	2021-11-15	Not yet recruiting
Post-marketing Database Survey: A Cohort Study of Comparison the Risk of Haemorrhage (Serious Intracranial Haemorrhage Such as Cerebral Haemorrhage and Subarachnoid Haemorrhage) Between Vortioxetine Tablets and SSRIs In Patients With Depression Using JMDC [NCT05932407]		115,000 participants (Anticipated)	Observational	2024-06-01	Not yet recruiting
Substance Misuse To Psychiatric Disorders for Cannabis (SToP-C)--an Early Assertive Pharmacotherapy Intervention Pilot Study [NCT03485274]	Phase 2/Phase 3	37 participants (Actual)	Interventional	2018-07-25	Completed
Interventional, Open-label Study of Flexible Doses of Vortioxetine on Depressive Symptoms in Patients With Major Depressive Disorder and Early Dementia [NCT04294654]	Phase 4	82 participants (Actual)	Interventional	2020-02-28	Completed
Real-life Effectiveness of Vortioxetine in Patients With Major Depressive Disorder: Non-interventional, Multi-national, Prospective Cohort Study to Assess Real-life Effectiveness of Vortioxetine [NCT03555136]		992 participants (Actual)	Observational	2017-11-17	Completed
Interventional, Randomised, Double-blind, Placebo-controlled, Active Reference (Fluoxetine), Fixed-dose Study of Vortioxetine in Paediatric Patients Aged 12 to 17 Years, With Major Depressive Disorder (MDD) [NCT02709746]	Phase 3	784 participants (Actual)	Interventional	2016-05-31	Completed
Vortioxetine as a Novel Anti-depressant With Improvement in Cognitive Abilities - a Randomized Controlled Parallel Assigned Study [NCT05104918]	Phase 3	500 participants (Anticipated)	Interventional	2022-02-28	Not yet recruiting
Interventional, Randomised, Double-blind 4-way Crossover Study Comparing the Gastro-intestinal Tolerability and Absorption Profile of Vortioxetine After Administration of Modified-release Formulations and Immediate-release Formulation in Healthy Women [NCT02112903]	Phase 1	40 participants (Actual)	Interventional	2014-04-30	Completed
Adjunctive Vortioxetine in Schizophrenia [NCT02357797]	Phase 4	88 participants (Anticipated)	Interventional	2016-02-29	Active, not recruiting
Interventional, Open-label, Sequential-period Study Investigating the Pharmacokinetic Properties and Safety and Tolerability of Sublingual Formulations of Vortioxetine in Healthy Subjects [NCT03884491]	Phase 1	16 participants (Actual)	Interventional	2019-03-18	Completed
A Randomized, Double-blind, Placebo- and Active- Controlled, Multicenter Study of Rapastinel as Monotherapy in Major Depressive Disorder [NCT03855865]	Phase 3	0 participants (Actual)	Interventional	2019-07-01	Withdrawn(stopped due to Business decision to stop the program.)
Interventional, Randomized, Double-blind, Placebo-controlled Study of the Efficacy and Safety of Initial Administration of 25 mg Vortioxetine Intravenously With 10 mg/Day Vortioxetine Orally in Patients With Major Depressive Disorder [NCT03766867]	Phase 2	80 participants (Actual)	Interventional	2018-12-03	Completed
Long-term, Open-label, Flexible-dose, Extension Study of Vortioxetine in Child and Adolescent Patients With Major Depressive Disorder (MDD) From 7 to 18 Years of Age [NCT02871297]	Phase 3	662 participants (Actual)	Interventional	2016-08-17	Terminated(stopped due to The study was terminated based on new efficacy data from another study.)
Interventional, Open-label, Flexible-dose Study of Vortioxetine on Emotional Functioning in Patients With Major Depressive Disorder With Inadequate Response to SSRI/SNRI Treatment [NCT03835715]	Phase 4	150 participants (Actual)	Interventional	2019-02-05	Completed
A Long-Term, Open-Label, Flexible-Dose, Extension Study Evaluating the Safety and Tolerability of Lu AA21004 in Subjects With Major Depressive Disorder [NCT00707980]	Phase 3	836 participants (Actual)	Interventional	2008-06-30	Completed
Interventional, Open-label Effectiveness Study of Flexible Doses of Vortioxetine on Depressive Symptoms in Patients With Major Depressive Disorder Comorbid With Generalized Anxiety Disorder [NCT04220996]	Phase 4	100 participants (Actual)	Interventional	2019-12-27	Completed
Vortioxetine for Cancer Patients With Depression: An Observational Study [NCT04253678]		140 participants (Anticipated)	Observational	2019-12-12	Recruiting
An Interventional, Randomised, Double-blind, Parallel-group, Placebo-controlled Study on the Efficacy of Vortioxetine on Cognitive Dysfunction in Patients With Partial or Full Remission of Major Depressive Disorder [NCT02279953]	Phase 3	151 participants (Actual)	Interventional	2014-10-31	Completed
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase III Study to Assess the Efficacy and Safety of Lu AA21004 in Patients With Major Depressive Disorder [NCT01355081]	Phase 3	366 participants (Actual)	Interventional	2011-05-31	Completed
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase III Study to Evaluate the Efficacy and Safety of Once Daily Oral Lu AA21004 in Patients With Major Depressive Disorder [NCT02389816]	Phase 3	493 participants (Actual)	Interventional	2015-04-10	Completed
A Randomised, Double-blind, Parallel-group, Placebo-controlled, Duloxetine-referenced, Fixed-dose Study Evaluating the Efficacy and Safety of Three Dosages of [Vortioxetine] Lu AA21004, in Acute Treatment of Major Depressive Disorder [NCT00635219]	Phase 3	766 participants (Actual)	Interventional	2008-02-29	Completed
[NCT02294305]	Phase 4	40 participants (Anticipated)	Interventional	2014-12-31	Active, not recruiting
A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Fixed-Dose Study Comparing the Efficacy and Safety of a Single Dose of Lu AA21004 in Acute Treatment of Adults With Generalized Anxiety Disorder [NCT00744627]	Phase 3	301 participants (Actual)	Interventional	2008-09-30	Completed
Vortioxetine for the Treatment of Major Depression and Neuropsychiatric Co-morbidities After Traumatic Brain Injury (TBI) [NCT02845349]	Phase 3	0 participants (Actual)	Interventional	2016-10-31	Withdrawn(stopped due to Funding withdrawn.)
Vortioxetine Versus Sertraline in Control Metabolic, Distress and Depression in Mexican Patients With Type 2 Diabetes [NCT03978286]	Phase 4	21 participants (Actual)	Interventional	2016-06-30	Completed
Double-blind, Randomised, Placebo-controlled Study Comparing the Efficacy and Safety of Two Fixed Dosages of a Novel Antidepressant Compound to That of Placebo in Patients With Major Depressive Disorder [NCT00839423]	Phase 2	426 participants (Actual)	Interventional	2006-08-31	Completed
An Open-label, Long-Term Extension Study to Assess the Safety and Efficacy of Lu AA21004 in Patients With Major Depressive Disorder (Extension to Lu AA21004/CCT-003 Study) [NCT01395147]	Phase 3	119 participants (Actual)	Interventional	2011-07-31	Completed
A Randomized, Double-blind, Parallel-group, Placebo-controlled, Fixed-dose Study Comparing the Efficacy and Safety of Lu AA21004 Versus Placebo in Acute Treatment of Adults With Major Depressive Disorder [NCT00672958]	Phase 3	600 participants (Actual)	Interventional	2008-04-30	Completed
A Long-term, Open-label Study Evaluating the Safety and Tolerability of [Vortioxetine] Lu AA21004 in Patients With Major Depressive Disorder [NCT00761306]	Phase 2	74 participants (Actual)	Interventional	2007-06-30	Completed
A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Fixed-Dose Study Comparing the Efficacy and Safety of 2 Doses of Lu AA21004 in Acute Treatment of Adults With Generalized Anxiety Disorder [NCT00731120]	Phase 3	457 participants (Actual)	Interventional	2008-06-30	Completed
A Phase 3, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Fixed-Dose Study Comparing the Efficacy and Safety of 2 Doses (10 and 15 mg) of Lu AA21004 in Acute Treatment of Adults With Major Depressive Disorder [NCT01179516]	Phase 3	469 participants (Actual)	Interventional	2010-08-31	Completed
A Phase 3, Long-Term, Open-Label, Flexible-Dose, Extension Study Evaluating the Safety and Tolerability of Lu AA21004 (15 and 20 mg) in Subjects With Major Depressive Disorder [NCT01152996]	Phase 3	1,075 participants (Actual)	Interventional	2010-09-30	Completed
A Randomised, Double-blind, Parallel-group, Placebo-controlled, Duloxetine-referenced, Fixed-dose Study Evaluating the Efficacy and Safety of Lu AA21004 (15 and 20 mg/Day) in the Acute Treatment of Adult Patients With Major Depressive Disorder [NCT01140906]	Phase 3	607 participants (Actual)	Interventional	2010-05-31	Completed
A Phase 1, Single-Center, Randomized, Single-Blind, Placebo-Controlled, Multiple-Dose Study to Assess the Effects of Oral Administration of Lu AA21004 20 mg on the Concentrations of Selected Neurotransmitters in Healthy Male Subjects [NCT01299805]	Phase 1	17 participants (Actual)	Interventional	2011-03-31	Completed
Vortioxetine for the Treatment of Hoarding Disorder- an Open Label Study [NCT04035850]	Phase 3	30 participants (Anticipated)	Interventional	2019-08-01	Not yet recruiting
A Long-term, Open-label, Flexible-dose, Extension Study Evaluating the Safety and Tolerability of [Vortioxetine] Lu AA21004 in Patients With Major Depressive Disorder [NCT00694304]	Phase 3	535 participants (Actual)	Interventional	2008-05-31	Completed
A Phase 3, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Fixed-Dose Study Comparing the Efficacy and Safety of 2 Doses (10 and 20 mg) of Lu AA21004 in Acute Treatment of Adults With Major Depressive Disorder [NCT01163266]	Phase 3	462 participants (Actual)	Interventional	2010-07-31	Completed
A Double-blind, Randomised, Placebo-controlled, Multicentre, Relapse-prevention Study With Lu AA21004 in Patients With Generalized Anxiety Disorder [NCT00788034]	Phase 3	459 participants (Actual)	Interventional	2008-10-31	Completed
A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Active-Referenced, Fixed-Dose Study Comparing the Efficacy and Safety of 2 Doses of Lu AA21004 in Acute Treatment of Adults With Major Depressive Disorder [NCT00672620]	Phase 3	611 participants (Actual)	Interventional	2008-04-30	Completed
A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Fixed-Dose Study Comparing the Efficacy and Safety of Single Dose of Lu AA21004 in Acute Treatment of Adults With Generalized Anxiety Disorder [NCT00734071]	Phase 3	304 participants (Actual)	Interventional	2008-06-30	Completed
Randomised, Double-blind, Parallel-group, Placebo-controlled, Duloxetine-referenced, Fixed Dose Study Comparing the Efficacy and Safety of [Vortioxetine] Lu AA21004 in Acute Treatment of Major Depressive Disorder in Elderly Patients [NCT00811252]	Phase 3	453 participants (Actual)	Interventional	2009-01-31	Completed
A Randomized, Double-blind, Parallel-Group, Placebo-Controlled, Fixed-Dose Study Comparing the Efficacy and Safety of 3 Doses of Lu AA21004 in Acute Treatment of Adults With Major Depressive Disorder [NCT00735709]	Phase 3	560 participants (Actual)	Interventional	2008-08-31	Completed
A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Active-Referenced, Fixed-Dose Study Comparing the Efficacy and Safety of 3 Doses of Lu AA21004 in Acute Treatment of Adults With Generalized Anxiety Disorder [NCT00730691]	Phase 3	781 participants (Actual)	Interventional	2008-06-30	Completed
Comparative Responses to 15 Different Antidepressants in Major Depressive Disorder - Results From a Long-term Nation-wide Population-based Study Emulating a Randomized Trial [NCT05952713]		73,336 participants (Actual)	Observational	2022-10-01	Completed
An Interventional, Randomised, Double-blind, Parallel-group, Placebo-controlled, Active-referenced (Paroxetine), Fixed-dose Study on the Efficacy of Vortioxetine on Cognitive Dysfunction in Working Patients With Major Depressive Disorder [NCT02279966]	Phase 3	152 participants (Actual)	Interventional	2014-10-31	Completed
An Interventional, Randomised, Double-blind, Parallel-group, Active-comparator, Flexible-dose Study on the Efficacy of Vortioxetine Versus Escitalopram on Cognitive Dysfunction in Patients With Inadequate Response to Current Antidepressant Treatment of Ma [NCT02272517]	Phase 3	101 participants (Actual)	Interventional	2014-12-31	Completed
Vortioxetine Monotherapy for Major Depressive Disorder in Type 2 Diabetes: Role of Inflammation, Kynurenine Pathway, and Structural and Functional Brain Connectivity as Biomarkers [NCT03580967]	Phase 4	0 participants (Actual)	Interventional	2019-07-01	Withdrawn(stopped due to COVID-19 Pandemic interfered with Pt recruitment)
A Double-blind, Placebo-controlled, Randomized Study of Vortioxetine Treatment on Major Depression, Cognition, and Systemic Inflammatory Biomarkers Associated With Depression and Cancer Progression in Women With Breast Cancer. [NCT02637466]	Phase 4	0 participants (Actual)	Interventional	2016-07-31	Withdrawn(stopped due to Funding not received)
Combining Data Sources to Identify Effect Moderation for Personalized Mental Health [NCT05267873]		14,146 participants (Anticipated)	Observational	2015-01-01	Active, not recruiting
Randomized, Double-Blinded, Placebo-Controlled Study Evaluating Vortioxetine for Cognitive Deficits in Persons With Post-COVID-19 Condition [NCT05047952]	Phase 2	200 participants (Actual)	Interventional	2021-09-16	Completed
Interventional, Randomised, Double-blind, Parallel-group Study of the Efficacy and Safety of Initial Administration of 17 mg Vortioxetine Intravenously With 10 mg/Day Vortioxetine Orally in Patients With Major Depressive Disorder [NCT02919501]	Phase 2	55 participants (Actual)	Interventional	2016-09-27	Completed
Vortioxetine add-on Treatment Improves the Symptoms in Patients With Bipolar Depression [NCT03598868]	Phase 2	100 participants (Anticipated)	Interventional	2018-08-08	Recruiting
A Long-term, Open-label, Flexible-dose, Extension Study Evaluating the Safety and Tolerability of [Vortioxetine] Lu AA21004 (15 and 20 mg/Day) in Patients With Major Depressive Disorder [NCT01323478]	Phase 3	71 participants (Actual)	Interventional	2011-04-30	Completed
Comparative Evaluation of Vortioxetine Versus Other Antidepressants With Pregabalin Augmentation in Treatment-resistant Burning Mouth Syndrome: a Prospective Longitudinal Clinical Trial With Treatment Response Prediction [NCT06025474]	Phase 3	203 participants (Anticipated)	Interventional	2023-01-01	Recruiting
A Double-Blind, Placebo-Controlled Study of Vortioxetine in the Treatment of Binge Eating Disorder [NCT02528409]	Phase 2	80 participants (Actual)	Interventional	2016-06-30	Completed
A Multinational, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study to Assess the Efficacy and Safety of Lu AA21004 in Patients With Major Depressive Disorder [NCT01255787]	Phase 2/Phase 3	600 participants (Actual)	Interventional	2010-11-30	Completed
Open-label, Flexible-dose Study of Vortioxetine in Patients With Major Depressive Disorder in India [NCT04288895]	Phase 4	400 participants (Actual)	Interventional	2020-02-20	Completed
Interventional, Randomised, Double-blind, Parallel-group, Placebo-controlled, Exploratory Study Investigating the Effects of [Vortioxetine] Lu AA21004 on Cognition and BOLD fMRI Signals in Subjects Remitted From Depression and Controls [NCT01607125]	Phase 1	96 participants (Actual)	Interventional	2012-07-31	Completed
Randomised, Double-blind, Parallel-group, Placebo-controlled, Fixed Dose Study on the Efficacy of [Vortioxetine] Lu AA21004 on Cognitive Dysfunction in Adult Patients With Major Depressive Disorder (MDD) [NCT01422213]	Phase 3	598 participants (Actual)	Interventional	2011-12-31	Completed
An Open-label Study Evaluating the Pharmacokinetics and Tolerability of [Vortioxetine] Lu AA21004 in Connection With Multiple Oral Dosing of [Vortioxetine] Lu AA21004 in Child and Adolescent Patients With a DSM-IV Diagnosis of Depressive or Anxiety Disord [NCT01491035]	Phase 2	48 participants (Actual)	Interventional	2012-04-30	Completed
A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Active-Referenced, Flexible Dose Study on the Efficacy of Lu AA21004 on Cognitive Dysfunction in Adult Subjects With Major Depressive Disorder (MDD) [NCT01564862]	Phase 2	602 participants (Actual)	Interventional	2012-04-30	Completed
A Randomized, Double-Blind, Placebo-Controlled, Phase 4, Relapse Prevention Study Evaluating the Efficacy and Safety of Vortioxetine (5, 10 and 20 mg) in Adults With Major Depressive Disorder [NCT02371980]	Phase 4	1,106 participants (Actual)	Interventional	2015-02-10	Completed
A Randomised, Double-blind, Parallel-group, Active Controlled Study Evaluating the Efficacy of Vortioxetine Versus Desvenlafaxine in Adult Patients Suffering From Major Depressive Disorder With Partial Response to SSRI Treatment [NCT04448431]	Phase 4	605 participants (Actual)	Interventional	2020-06-18	Completed
Effect of Vortioxetine on Cognitive Symptoms in Patients With [NCT04456777]	Early Phase 1	120 participants (Anticipated)	Interventional	2020-07-01	Recruiting
Efficacy of Mindfulness-based Relapse Prevention With or Without Vortioxetine on the Prevention of Relapse in Chronic Methamphetamine Users [NCT03830827]	Phase 4	220 participants (Anticipated)	Interventional	2020-09-01	Not yet recruiting
Prediction of the Therapeutic Response in Depression Based on an Early Neuro-computational Modeling Assessment of Motivation [NCT05866575]		136 participants (Anticipated)	Interventional	2023-06-01	Not yet recruiting
Interventional, Randomised, Double-blind, Placebo-controlled, Fixed-dose Study of Vortioxetine in Adults With Attention Deficit Hyperactivity Disorder (ADHD) [NCT02327013]	Phase 2	227 participants (Actual)	Interventional	2014-12-31	Completed
Comparison of Antidepressants in the Real-World: Retrospective Cohort Study Using Big Data [NCT04446039]		405,349 participants (Actual)	Observational	2022-07-04	Completed
Using 18F-FPEB PET to Identify mGLUR5 Availability in Affective Disorders [NCT05840861]		59 participants (Anticipated)	Observational	2020-11-05	Recruiting
Sequenced Treatment Alternatives to Relieve Adolescent Depression (STAR-AD) a Multicentre Open-label Randomized Controlled Trial Protocol [NCT05814640]	Phase 1/Phase 2	520 participants (Anticipated)	Interventional	2023-02-20	Recruiting
Pattern Separation, Brain Derived Neurotrophic Factors, and Mechanisms of Vortioxetine [NCT02969876]	Phase 4	2 participants (Actual)	Interventional	2017-08-24	Terminated(stopped due to Site was unable to reach Sponsor recruitment goals.)
A Randomized, Open-Label, 2×2 Crossover Phase 1 Study to Evaluate the Bioequivalence of Single Oral Dose of Lu AA21004 20 mg Tablet and 2× Lu AA21004 10 mg Tablets in Healthy Adult Subjects [NCT03437564]	Phase 1	28 participants (Actual)	Interventional	2018-02-16	Completed
A Randomised, Open-label, Single-centre, Single- and Multiple-dose Interventional Study Investigating the Pharmacokinetic Properties of Vortioxetine in Healthy Young Chinese Men and Women [NCT02386488]	Phase 1	64 participants (Actual)	Interventional	2015-03-31	Completed
Assessing Tolerability and Efficacy of Vortioxetine Versus SSRIs in Elderly Patients With Depression: a Pragmatic, Multicenter, Open-label, Parallel-group, Superiority, Randomized Trial [NCT03779789]	Phase 4	362 participants (Actual)	Interventional	2019-02-01	Completed
A Randomised, Double-blind, Parallel-group, Active-controlled, Flexible Dose Study Evaluating the Effects of [Vortioxetine] Lu AA21004 Versus Agomelatine in Adult Patients Suffering From Major Depressive Disorder With Inadequate Response to Antidepressant [NCT01488071]	Phase 3	495 participants (Actual)	Interventional	2012-01-31	Completed
Remediation of Age-related Cognitive Decline: Vortioxetine and Cognitive Training [NCT03272711]	Phase 4	129 participants (Actual)	Interventional	2016-08-31	Completed
A Multicenter, Randomized, Double-blind, Controlled Clinical Trial of Votioxetine in the Treatment of Depression After Radiotherapy for Head and Neck Cancer [NCT04818099]	Phase 3	208 participants (Anticipated)	Interventional	2020-10-10	Recruiting
Clinical Efficacy and Safety of Vortioxetine Combined With Mood Stabilizer in the Treatment of Bipolar Disorder Type II Depression [NCT05481957]	Phase 4	131 participants (Actual)	Interventional	2022-03-01	Completed
Interventional, Randomized, Double-blind, Placebo-controlled, Active-reference (Fluoxetine), Fixed-dose Study of Vortioxetine in Paediatric Patients Aged 7 to 11 Years, With Major Depressive Disorder (MDD) [NCT02709655]	Phase 3	683 participants (Actual)	Interventional	2016-05-18	Completed
Cognitive Dysfunction in Patients With Major Depressive Disorder, Clinical Peculiarities, Biological Markers, and Treatment Efficacy [NCT03187093]	Phase 4	150 participants (Anticipated)	Interventional	2016-10-31	Recruiting
Tolerability, Safety and Efficacy of Vortioxetine for Treatment od Depression in Parkinson's Disease: a 16 Week Open Label Study [NCT04301492]	Phase 4	20 participants (Anticipated)	Interventional	2019-11-20	Recruiting
Randomised, Double-blind, Parallel-group, Active-comparator (Venlafaxine Extended Release), Fixed-dose Study of [Vortioxetine] Lu AA21004 in Major Depressive Disorder in Asian Countries [NCT01571453]	Phase 3	437 participants (Actual)	Interventional	2012-05-31	Completed
A Double-blind, Randomized, Placebo-controlled, Multicentre, Relapse-prevention Study of Vortioxetine in Paediatric Patients Aged 7 to 11 Years With Major Depressive Disorder [NCT05014919]	Phase 3	35 participants (Actual)	Interventional	2021-08-10	Terminated(stopped due to The study was terminated based on new efficacy data from another study.)
A Phase 1, Open-Label, Parallel-Group Study to Evaluate the Pharmacokinetics, Safety and Tolerability of a Single Oral Dose of 5 mg Vortioxetine in Subjects With Normal Hepatic Function or Severe Hepatic Impairment [NCT02170220]	Phase 1	12 participants (Actual)	Interventional	2014-07-31	Completed
A Single-centre, Open-label, Single-dose Interventional Study Investigating the Pharmacokinetic Properties of Lu AA21004 in Healthy Young Chinese Men and Women [NCT01676571]	Phase 1	16 participants (Actual)	Interventional	2012-10-31	Completed
Evaluation of the Efficacy of Vortioxetine for Posttraumatic Stress Disorder [NCT02637895]	Phase 4	41 participants (Actual)	Interventional	2016-12-31	Completed
A Randomized, Double-Blind, Parallel-Group, Active-Controlled, Flexible-Dose Study Evaluating the Effect of Lu AA21004 vs Escitalopram on Sexual Functioning in Adults With Well-Treated Major Depressive Disorder Experiencing Selective Serotonin Reuptake In [NCT01364649]	Phase 3	447 participants (Actual)	Interventional	2011-06-30	Completed
Vortioxetine for Menopausal Depression and Associated Symptoms [NCT02234362]	Phase 4	47 participants (Actual)	Interventional	2015-06-12	Completed
A Randomized, Double-Blind, Placebo-Controlled Trial of Vortioxetine for Depressive Mood and Alcohol Use in Adults With Major Depressive Disorder and Alcohol Use Disorder [NCT04498897]	Phase 2	128 participants (Anticipated)	Interventional	2019-01-25	Recruiting
Long-term, Open-label, Flexible-dose, Continuation Extension Study With Vortioxetine in Child and Adolescent Patients With Major Depressive Disorder (MDD) From 7 to 17 Years of Age [NCT03108625]	Phase 3	94 participants (Actual)	Interventional	2017-03-01	Completed
An 8-week, Open-Label Clinical Trial of the Efficacy and Safety of Vortioxetine in Patients With Major Depressive Disorder and Coronary Artery Disease [NCT02454426]	Early Phase 1	0 participants (Actual)	Interventional	2016-04-30	Withdrawn(stopped due to PI left institution)
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Trial	Outcome
NCT00596817 (9) [back to overview]	Change From Double-blind Baseline in HAM-A Total Score After 24 Weeks of Double-blind Treatment
NCT00596817 (9) [back to overview]	Relapse Within First 24 Weeks of the Double-blind Period Based on a MADRS Total Score >=22 or an Unsatisfactory Treatment Effect (Lack of Efficacy) as Judged by the Investigator
NCT00596817 (9) [back to overview]	Relapse During the Entire Double-blind Period Based on a MADRS Total Score >=22 or an Unsatisfactory Treatment Effect (Lack of Efficacy) as Judged by the Investigator
NCT00596817 (9) [back to overview]	Proportion of Responders at Week 24 of the Double-blind Period (Response Defined as a >=50% Reduction in MADRS Total Score From Open-label Baseline)
NCT00596817 (9) [back to overview]	Change From Double-blind Baseline in HAM-D-17 Total Score After 24 Weeks of Double-blind Treatment
NCT00596817 (9) [back to overview]	Change From Double-blind Baseline in MADRS Total Score After 24 Weeks of Double-blind Treatment
NCT00596817 (9) [back to overview]	Change From Double-blind Baseline in SDS Total Score at Week 24 of the Double-blind Period
NCT00596817 (9) [back to overview]	Proportion of Remitters at Week 24 of the Double-blind Period (Remission Defined as a MADRS Total Score <=10)
NCT00596817 (9) [back to overview]	Change From Double-blind Baseline in CGI-S Score After 24 Weeks of Double-blind Treatment
NCT00635219 (10) [back to overview]	Change in Clinical Status Using CGI-I Score at Week 8
NCT00635219 (10) [back to overview]	Change From Baseline in ASEX Total Score After 8 Weeks of Treatment
NCT00635219 (10) [back to overview]	Change From Baseline in CGI-S Score After 8 Weeks of Treatment
NCT00635219 (10) [back to overview]	Change From Baseline in HAM-A Total Score After 8 Weeks of Treatment
NCT00635219 (10) [back to overview]	Change From Baseline in MADRS Total Score After 8 Weeks of Treatment
NCT00635219 (10) [back to overview]	Change From Baseline in HAM-D-24 Total Score After 8 Weeks of Treatment
NCT00635219 (10) [back to overview]	Change From Baseline in HAM-D-24 Total Score After 8 Weeks of Treatment in Patients With Baseline HAM-A Total Score >=20
NCT00635219 (10) [back to overview]	Proportion of Responders at Week 8 (Response Defined as a >=50% Decrease in the MADRS Total Score From Baseline)
NCT00635219 (10) [back to overview]	Proportion of Remitters at Week 8 (Remission Defined as a MADRS Total Score <=10)
NCT00635219 (10) [back to overview]	Change From Baseline in SDS Total Score After 8 Weeks of Treatment
NCT00672620 (12) [back to overview]	Clinical Global Impression Scale-Global Improvement Scale
NCT00672620 (12) [back to overview]	Healthcare Resource Utilization as Assessed by the Health Economic Assessment Questionnaire
NCT00672620 (12) [back to overview]	Percentage of Responders in HAM-D 24 Total Score by Study Visit
NCT00672620 (12) [back to overview]	Change From Baseline in the Hamilton Anxiety Scale (HAM-A) Total Score
NCT00672620 (12) [back to overview]	Change From Baseline in Sheehan Disability Scale (SDS) Total Score at Week 8
NCT00672620 (12) [back to overview]	Change From Baseline in the 24-item Hamilton Depression Scale Total Score at Week 8
NCT00672620 (12) [back to overview]	Percentage of Participants in MADRS Remission at Week 8
NCT00672620 (12) [back to overview]	Percentage of Participants With a Sustained Response in HAM-D24
NCT00672620 (12) [back to overview]	Change From Baseline in Montgomery-Åsberg Depression Rating Scale - Self-assessment (MADRS-S)
NCT00672620 (12) [back to overview]	Change From Baseline in the 24-item Hamilton Depression Scale Total Score at Other Weeks Assessed
NCT00672620 (12) [back to overview]	Change From Baseline in the Clinical Global Impression Scale-Severity of Illness Scale
NCT00672620 (12) [back to overview]	Change From Baseline in the Montgomery Åsberg Depression Rating Scale (MADRS) Total Score
NCT00672958 (13) [back to overview]	Percentage of Responders in HAM-D24 Total Score by Study Visit
NCT00672958 (13) [back to overview]	Health Care Resource Utilization as Assessed by the Health Economic Assessment Questionnaire
NCT00672958 (13) [back to overview]	Clinical Global Impression Scale-Global Improvement Scale
NCT00672958 (13) [back to overview]	Change From Baseline in the 24-item Hamilton Depression Scale Total Score at Other Weeks Assessed
NCT00672958 (13) [back to overview]	Change From Baseline in Montgomery-Åsberg Depression Rating Scale - Self-assessment (MADRS-S)
NCT00672958 (13) [back to overview]	Change From Baseline in Montgomery Åsberg Depression Rating Scale (MADRS) Total Score
NCT00672958 (13) [back to overview]	Change From Baseline in Hamilton Anxiety Scale (HAM-A)
NCT00672958 (13) [back to overview]	Change From Baseline in Clinical Global Impression Scale-Severity of Illness
NCT00672958 (13) [back to overview]	Change From Baseline in 36-item Short-form Health Survey (SF-36) at Week 6
NCT00672958 (13) [back to overview]	Change From Baseline in Sheehan Disability Scale (SDS) Total Score at Week 6
NCT00672958 (13) [back to overview]	Percentage of Participants With a Sustained Response in HAM-D24
NCT00672958 (13) [back to overview]	Percentage of Participants in MADRS Remission at Week 6
NCT00672958 (13) [back to overview]	Change From Baseline in the 24-item Hamilton Depression Scale Total Score at Week 6
NCT00694304 (10) [back to overview]	Change From Baseline in CGI-S Score After 52 Weeks of Treatment
NCT00694304 (10) [back to overview]	Change From Baseline in HAM-A Total Score After 52 Weeks of Treatment
NCT00694304 (10) [back to overview]	Change From Baseline in HAM-D-24 Total Score After 52 Weeks of Treatment
NCT00694304 (10) [back to overview]	Change From Baseline in MADRS Total Score After 52 Weeks of Treatment
NCT00694304 (10) [back to overview]	Change From Baseline in SDS Total Score After 52 Weeks of Treatment
NCT00694304 (10) [back to overview]	Percentage of Patients Who Withdrew Due to Intolerance to Treatment
NCT00694304 (10) [back to overview]	Proportion of Patients With a MADRS Total Score >=22 After 52 Weeks of Treatment
NCT00694304 (10) [back to overview]	Proportion of Remitters at Week 52 (Remission Defined as a MADRS Total Score <=10)
NCT00694304 (10) [back to overview]	Number of Patients With Adverse Events (AEs)
NCT00694304 (10) [back to overview]	Proportion of Responders at Week 52 (Response Defined as a >=50% Decrease in MADRS Total Score)
NCT00707980 (12) [back to overview]	Health Care Resource Utilization Assessed by the Health Economic Assessment Questionnaire
NCT00707980 (12) [back to overview]	Number of Participants With Potentially Clinically Significant Electrocardiogram (ECG) Findings
NCT00707980 (12) [back to overview]	Number of Participants With Potentially Clinically Significant Laboratory Evaluation Findings
NCT00707980 (12) [back to overview]	Number of Participants With Potentially Clinically Significant Vital Sign Findings
NCT00707980 (12) [back to overview]	Physical Examination Findings
NCT00707980 (12) [back to overview]	Change From Baseline in Hamilton Depression Scale-24 Item (HAM-D24) Total Score
NCT00707980 (12) [back to overview]	Change From Baseline to the Final Visit in the Sheehan Disability Scale
NCT00707980 (12) [back to overview]	Number of Participants With Adverse Events (AEs)
NCT00707980 (12) [back to overview]	Change From Baseline in the Clinical Global Impression of Severity of Illness Scale
NCT00707980 (12) [back to overview]	Change From Baseline in the Hamilton Anxiety Scale (HAM-A) Total Score
NCT00707980 (12) [back to overview]	Change From Baseline in the Montgomery Åsberg Depression Rating Scale (MADRS) Total Score
NCT00707980 (12) [back to overview]	Change From Baseline to the Final Visit in 36-item Short-form Health Survey (SF-36)
NCT00730691 (16) [back to overview]	Mean Clinical Global Impression Scale-Global Improvement (CGI-I) at Other Weeks Assessed
NCT00730691 (16) [back to overview]	Health Care Resource Utilization Assessed by the Health Economic Assessment Questionnaire
NCT00730691 (16) [back to overview]	Change From Baseline in the Hamilton Anxiety Scale (HAM-A) Total Score at Other Weeks Assessed in Participants With Baseline HAM-A ≥25
NCT00730691 (16) [back to overview]	Change From Baseline in Sheehan Disability Scale (SDS) at Other Weeks Assessed
NCT00730691 (16) [back to overview]	Change From Baseline in Hospital Anxiety and Depression (HAD) - Depression Subscale at All Weeks Assessed
NCT00730691 (16) [back to overview]	Change From Baseline in Hospital Anxiety and Depression (HAD) - Anxiety Subscale at Other Weeks Assessed
NCT00730691 (16) [back to overview]	Change From Baseline in Hamilton Anxiety Scale (HAM-A) Total Score at Other Weeks Assessed
NCT00730691 (16) [back to overview]	Change From Baseline in Clinical Global Impression Scale-Severity of Illness (CGI-S)
NCT00730691 (16) [back to overview]	Percentage of Responders in HAM-A Total Score at Week 8
NCT00730691 (16) [back to overview]	Mean Clinical Global Impression Scale-Global Improvement (CGI-I) at Week 8
NCT00730691 (16) [back to overview]	Change From Baseline in the Hamilton Anxiety Scale (HAM-A) Total Score at Week 8 in Participants With Baseline HAM-A ≥25
NCT00730691 (16) [back to overview]	Change From Baseline in the Hamilton Anxiety (HAM-A) Scale Total Score at Week 8
NCT00730691 (16) [back to overview]	Change From Baseline in Sheehan Disability Scale (SDS) at Week 8
NCT00730691 (16) [back to overview]	Change From Baseline in Hospital Anxiety and Depression (HAD) - Anxiety Subscale at Week 8
NCT00730691 (16) [back to overview]	Percentage of Responders in HAM-A Total Score at Other Weeks Assessed
NCT00730691 (16) [back to overview]	Percentage of Participants in HAM-A Remission at Each Week Assessed
NCT00731120 (10) [back to overview]	Clinical Global Impression Scale-Global Improvement (CGI-I) at Each Week Assessed
NCT00731120 (10) [back to overview]	Change From Baseline in Sheehan Disability Scale (SDS) at Week 8
NCT00731120 (10) [back to overview]	Change From Baseline in the Hamilton Anxiety Scale (HAM-A) Total Score
NCT00731120 (10) [back to overview]	Percentage of Participants in HAM-A Remission at Week 8
NCT00731120 (10) [back to overview]	Percentage of Responders in HAM-A Total Score at Week 8
NCT00731120 (10) [back to overview]	Change From Baseline in 36-item Short-form Health Survey (SF-36)
NCT00731120 (10) [back to overview]	Change From Baseline in Clinical Global Impression Scale-Severity of Illness (CGI-S)
NCT00731120 (10) [back to overview]	Change From Baseline in Hamilton Anxiety Scale (HAM-A) Total Score at Other Weeks Assessed
NCT00731120 (10) [back to overview]	Change From Baseline in Hospital Anxiety and Depression (HAD) Scales
NCT00731120 (10) [back to overview]	Health Care Resource Utilization Assessed by the Health Economic Assessment Questionnaire
NCT00734071 (25) [back to overview]	Change From Baseline in 36-Item Short-Form Health Survey (SF-36) Social Functioning Subscore at Week 8
NCT00734071 (25) [back to overview]	Change From Baseline in Sheehan Disability Scale (SDS) Total Score at Week 8
NCT00734071 (25) [back to overview]	Change From Baseline in the Hamilton Anxiety Scale (HAM-A) Total Score at Week 8
NCT00734071 (25) [back to overview]	Change From Baseline in the Hospital Anxiety and Depression (HAD) Anxiety Subscale at Week 8
NCT00734071 (25) [back to overview]	Clinical Global Impression Scale-Global Improvement at Week 8
NCT00734071 (25) [back to overview]	Percentage of Responders in HAM-A Total Score at Week 8
NCT00734071 (25) [back to overview]	Change From Baseline in 36-Item Short-Form Health Survey (SF-36) Bodily Pain Subscore at Each Week Assessed
NCT00734071 (25) [back to overview]	Change From Baseline in 36-Item Short-Form Health Survey (SF-36) General Health Subscore at Each Week Assessed
NCT00734071 (25) [back to overview]	Change From Baseline in 36-Item Short-Form Health Survey (SF-36) Mental Health Subscore at Each Week Assessed
NCT00734071 (25) [back to overview]	Change From Baseline in 36-Item Short-Form Health Survey (SF-36) Physical Functioning Subscore at Each Week Assessed
NCT00734071 (25) [back to overview]	Change From Baseline in 36-Item Short-Form Health Survey (SF-36) Role-Emotional Subscore at Each Week Assessed
NCT00734071 (25) [back to overview]	Change From Baseline in 36-Item Short-Form Health Survey (SF-36) Role-Physical Subscore at Each Week Assessed
NCT00734071 (25) [back to overview]	Change From Baseline in 36-Item Short-Form Health Survey (SF-36) Social Functioning Subscore at Other Weeks Assessed
NCT00734071 (25) [back to overview]	Change From Baseline in 36-Item Short-Form Health Survey (SF-36) Vitality Subscore at Each Week Assessed
NCT00734071 (25) [back to overview]	Change From Baseline in the Hamilton Anxiety Scale (HAM-A) Total Score at Week 8 in Participants With Baseline HAM-A ≥25
NCT00734071 (25) [back to overview]	Change From Baseline in Sheehan Disability Scale (SDS) Total Score at Other Weeks Assessed
NCT00734071 (25) [back to overview]	Percentage of Responders in HAM-A Total Score at Other Weeks Assessed
NCT00734071 (25) [back to overview]	Percentage of Participants in HAM-A Remission at Each Week Assessed
NCT00734071 (25) [back to overview]	Health Care Resource Utilization as Assessed by the Health Economic Assessment Questionnaire
NCT00734071 (25) [back to overview]	Clinical Global Impression Scale-Global Improvement at Other Weeks Assessed
NCT00734071 (25) [back to overview]	Change From Baseline in the Hospital Anxiety and Depression (HAD) Depression Subscale at Each Week Assessed
NCT00734071 (25) [back to overview]	Change From Baseline in the Hospital Anxiety and Depression (HAD) Anxiety Subscale at Other Weeks Assessed
NCT00734071 (25) [back to overview]	Change From Baseline in the Hamilton Anxiety Scale (HAM-A) Total Score at Other Weeks Assessed in Participants With Baseline HAM-A ≥25
NCT00734071 (25) [back to overview]	Change From Baseline in Hamilton Anxiety Scale (HAM-A) Total Score at Other Weeks Assessed
NCT00734071 (25) [back to overview]	Change From Baseline in Clinical Global Impression Scale-Severity of Illness at Each Week Assessed
NCT00735709 (26) [back to overview]	Change From Baseline in 36-Item Short-Form Health Survey (SF-36) Vitality Subscore at All Weeks Assessed
NCT00735709 (26) [back to overview]	Change From Baseline in Clinical Global Impression Scale-Severity of Illness at Each Week Assessed
NCT00735709 (26) [back to overview]	Change From Baseline in HAM-D24 Total Score at Other Weeks Assessed in Participants With a Baseline HAM-A Score ≥20
NCT00735709 (26) [back to overview]	Change From Baseline in Hamilton Anxiety Scale (HAM-A) Total Score at Each Week Assessed
NCT00735709 (26) [back to overview]	Change From Baseline in Hospital Anxiety and Depression (HAD) Scales at Each Week Assessed
NCT00735709 (26) [back to overview]	Change From Baseline in Montgomery Åsberg Depression Rating Scale (MADRS) Total Score at Each Week
NCT00735709 (26) [back to overview]	Change From Baseline in Sheehan Disability Scale (SDS) Total Score at Other Weeks Assessed
NCT00735709 (26) [back to overview]	Change From Baseline in the 24-item Hamilton Depression Scale Total Score at Other Weeks Assessed
NCT00735709 (26) [back to overview]	Clinical Global Impression Scale-Global Improvement at Other Weeks Assessed
NCT00735709 (26) [back to overview]	Change From Baseline in HAM-D24 Total Score at Week 8 in Participants With Baseline HAM-A Score ≥20
NCT00735709 (26) [back to overview]	Change From Baseline in 36-Item Short-Form Health Survey (SF-36) Social Functioning Subscore at Other Weeks Assessed
NCT00735709 (26) [back to overview]	Percentage of Responders in HAM-D24 Total Score at Week 8
NCT00735709 (26) [back to overview]	Change From Baseline in 36-Item Short-Form Health Survey (SF-36) Mental Health Subscore at All Weeks Assessed
NCT00735709 (26) [back to overview]	Change From Baseline in 36-Item Short-Form Health Survey (SF-36) Role-Emotional Subscore at All Weeks Assessed
NCT00735709 (26) [back to overview]	Healthcare Resource Utilization as Assessed by the Health Economic Assessment Questionnaire.
NCT00735709 (26) [back to overview]	Change From Baseline in the 24-item Hamilton Depression Scale Total Score At Week 8
NCT00735709 (26) [back to overview]	Percentage of Participants in MADRS Remission at Other Weeks Assessed
NCT00735709 (26) [back to overview]	Percentage of Responders in HAM-D24 Total Score at Other Weeks Assessed
NCT00735709 (26) [back to overview]	Change From Baseline in 36-Item Short-Form Health Survey (SF-36) General Health Subscore at All Weeks Assessed
NCT00735709 (26) [back to overview]	Change From Baseline in 36-Item Short-Form Health Survey (SF-36) Bodily Pain Subscore at All Weeks Assessed
NCT00735709 (26) [back to overview]	Percentage of Participants With a Sustained Response in HAM-D24 Total Score
NCT00735709 (26) [back to overview]	Change From Baseline in 36-Item Short-Form Health Survey (SF-36) Physical Functioning Subscore at All Weeks Assessed
NCT00735709 (26) [back to overview]	Percentage of Participants in MADRS Remission at Week 8
NCT00735709 (26) [back to overview]	Change From Baseline in 36-Item Short-Form Health Survey (SF-36) Role-Physical Subscore at All Weeks Assessed
NCT00735709 (26) [back to overview]	Clinical Global Impression Scale-Global Improvement at Week 8
NCT00735709 (26) [back to overview]	Change From Baseline in Sheehan Disability Scale (SDS) Total Score at Week 8
NCT00744627 (25) [back to overview]	Change From Baseline in 36-Item Short-Form Health Survey (SF-36) Social Functioning Subscore at Week 8
NCT00744627 (25) [back to overview]	Change From Baseline in Sheehan Disability Scale (SDS) Total Score at Week 8
NCT00744627 (25) [back to overview]	Change From Baseline in the Hamilton Anxiety Scale (HAM-A) Total Score at Week 8
NCT00744627 (25) [back to overview]	Change From Baseline in the Hamilton Anxiety Scale (HAM-A) Total Score at Week 8 in Participants With Baseline HAM-A ≥25
NCT00744627 (25) [back to overview]	Change From Baseline in the Hospital Anxiety and Depression (HAD) Anxiety Subscale at Week 8
NCT00744627 (25) [back to overview]	Clinical Global Impression Scale-Global Improvement at Week 8
NCT00744627 (25) [back to overview]	Change From Baseline in 36-Item Short-Form Health Survey (SF-36) Bodily Pain Subscore at Each Week Assessed
NCT00744627 (25) [back to overview]	Change From Baseline in 36-Item Short-Form Health Survey (SF-36) General Health Subscore at Each Week Assessed
NCT00744627 (25) [back to overview]	Change From Baseline in 36-Item Short-Form Health Survey (SF-36) Mental Health Subscore at Each Week Assessed
NCT00744627 (25) [back to overview]	Change From Baseline in 36-Item Short-Form Health Survey (SF-36) Physical Functioning Subscore at Each Week Assessed
NCT00744627 (25) [back to overview]	Change From Baseline in 36-Item Short-Form Health Survey (SF-36) Role-Emotional Subscore at Each Week Assessed
NCT00744627 (25) [back to overview]	Change From Baseline in 36-Item Short-Form Health Survey (SF-36) Social Functioning Subscore at Other Weeks Assessed
NCT00744627 (25) [back to overview]	Change From Baseline in 36-Item Short-Form Health Survey (SF-36) Vitality Subscore at Each Week Assessed
NCT00744627 (25) [back to overview]	Change From Baseline in Clinical Global Impression Scale-Severity of Illness at Each Week Assessed
NCT00744627 (25) [back to overview]	Change From Baseline in Hamilton Anxiety Scale (HAM-A) Total Score at Other Weeks Assessed
NCT00744627 (25) [back to overview]	Change From Baseline in Sheehan Disability Scale (SDS) Total Score at Other Weeks Assessed
NCT00744627 (25) [back to overview]	Change From Baseline in the Hamilton Anxiety Scale (HAM-A) Total Score at Other Weeks Assessed in Participants With Baseline HAM-A ≥25
NCT00744627 (25) [back to overview]	Percentage of Participants in HAM-A Remission at Each Week Assessed
NCT00744627 (25) [back to overview]	Percentage of Responders in HAM-A Total Score at Other Weeks Assessed
NCT00744627 (25) [back to overview]	Percentage of Responders in HAM-A Total Score at Week 8
NCT00744627 (25) [back to overview]	Change From Baseline in the Hospital Anxiety and Depression (HAD) Depression Subscale at Each Week Assessed
NCT00744627 (25) [back to overview]	Change From Baseline in the Hospital Anxiety and Depression (HAD) Anxiety Subscale at Other Weeks Assessed
NCT00744627 (25) [back to overview]	Change From Baseline in 36-Item Short-Form Health Survey (SF-36) Role-Physical Subscore at Each Week Assessed
NCT00744627 (25) [back to overview]	Clinical Global Impression Scale-Global Improvement at Other Weeks Assessed
NCT00744627 (25) [back to overview]	Health Care Resource Utilization as Assessed by the Health Economic Assessment Questionnaire
NCT00761306 (6) [back to overview]	Change From Baseline in HAM-D-24 Total Score After 52 Weeks of Treatment
NCT00761306 (6) [back to overview]	Number of Patients With Adverse Events (AEs)
NCT00761306 (6) [back to overview]	Proportion of Responders at Week 52 (Response Defined as a >=50% Decrease in MADRS Total Score)
NCT00761306 (6) [back to overview]	Proportion of Remitters at Week 52 (Remission Defined as a MADRS Total Score <=10)
NCT00761306 (6) [back to overview]	Percentage of Patients Who Withdrew Due to Intolerance to Treatment
NCT00761306 (6) [back to overview]	Change From Baseline in MADRS Total Score After 52 Weeks of Treatment
NCT00811252 (13) [back to overview]	Change From Baseline in HAM-A Total Score After 8 Weeks of Treatment
NCT00811252 (13) [back to overview]	Change From Baseline in HAM-D-24 Total Score After 1 Week of Treatment
NCT00811252 (13) [back to overview]	Change From Baseline in HAM-D-24 Total Score After 2 Weeks of Treatment
NCT00811252 (13) [back to overview]	Change From Baseline in HAM-D-24 Total Score After 4 Weeks of Treatment
NCT00811252 (13) [back to overview]	Change From Baseline in HAM-D-24 Total Score After 6 Weeks of Treatment
NCT00811252 (13) [back to overview]	Change From Baseline in HAM-D-24 Total Score After 8 Weeks of Treatment
NCT00811252 (13) [back to overview]	Change From Baseline in CGI-S Score After 8 Weeks of Treatment
NCT00811252 (13) [back to overview]	Risk of Suicidality Using C-SSRS Scores
NCT00811252 (13) [back to overview]	Proportion of Responders at Week 8 (Response Defined as a >=50% Reduction in the HAM-D-24 Total Score)
NCT00811252 (13) [back to overview]	Proportion of Remitters at Week 8 (Remission Defined as a MADRS Total Score <=10)
NCT00811252 (13) [back to overview]	Change in Clinical Status Using CGI-I Score at Week 8
NCT00811252 (13) [back to overview]	Change From Baseline in MADRS Total Score After 8 Weeks of Treatment
NCT00811252 (13) [back to overview]	Change From Baseline in GDS Total Score After 8 Weeks of Treatment
NCT00839423 (8) [back to overview]	Change From Baseline in MADRS Total Score After 1 Week of Treatment
NCT00839423 (8) [back to overview]	Change From Baseline in HAM-A Total Score After 6 Weeks of Treatment
NCT00839423 (8) [back to overview]	Change From Baseline in CGI-S Score After 6 Weeks of Treatment
NCT00839423 (8) [back to overview]	Proportion of Responders at Week 6 (Response Defined as a >=50% Decrease in the MADRS Total Score From Baseline)
NCT00839423 (8) [back to overview]	Proportion of Remitters at Week 6 (Remission is Defined as a MADRS Total Score <=10)
NCT00839423 (8) [back to overview]	Change in Clinical Status Using CGI-I Score at Week 6
NCT00839423 (8) [back to overview]	Change From Baseline in MADRS Total Score After 6 Weeks of Treatment
NCT00839423 (8) [back to overview]	Change From Baseline in HAM-D 24 Total Score After 6 Weeks of Treatment
NCT01140906 (8) [back to overview]	Change From Baseline in ASEX Total Score After 8 Weeks of Treatment
NCT01140906 (8) [back to overview]	Change From Baseline in MADRS Total Score After 8 Weeks of Treatment in Patients With Baseline HAM-A Total Score ≥20
NCT01140906 (8) [back to overview]	Change From Baseline in MADRS Total Score After 8 Weeks of Treatment.
NCT01140906 (8) [back to overview]	Change From Baseline in SDS Total Score After 8 Weeks of Treatment
NCT01140906 (8) [back to overview]	Change in Clinical Status Using CGI-I Score at Week 8
NCT01140906 (8) [back to overview]	Potential Discontinuation Symptoms After Abrupt Discontinuation of Treatment With Vortioxetine
NCT01140906 (8) [back to overview]	Proportion of Remitters at Week 8 (Remission Defined as a MADRS Total Score <=10)
NCT01140906 (8) [back to overview]	Proportion of Responders at Week 8 (Response Defined as a >=50% Decrease in the MADRS Total Score From Baseline)
NCT01152996 (10) [back to overview]	Change From Baseline in Sheehan Disability Scale (SDS) Total Score
NCT01152996 (10) [back to overview]	Number of Participants With Serious Treatment-Emergent Adverse Events
NCT01152996 (10) [back to overview]	Treatment-Emergent Adverse Events Leading to Study Discontinuation
NCT01152996 (10) [back to overview]	Change From Baseline in Clinical Global Impression Scale-Severity of Illness (CGI-S)
NCT01152996 (10) [back to overview]	Change From Baseline in Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score
NCT01152996 (10) [back to overview]	Change From Baseline in SDS Family Life/Home Responsibilities Subscale
NCT01152996 (10) [back to overview]	Change From Baseline in SDS Social Life Subscale
NCT01152996 (10) [back to overview]	Change From Baseline in the Hamilton Anxiety Scale (HAM-A) Total Score
NCT01152996 (10) [back to overview]	Number of Participants With Treatment-Emergent Adverse Events at a Frequency Threshold of ≥5%
NCT01152996 (10) [back to overview]	Change From Baseline in SDS Work/School Subscale
NCT01153009 (6) [back to overview]	Change From Baseline in Sheehan Disability Scale (SDS) Total Score at Week 8
NCT01153009 (6) [back to overview]	Change From Baseline in the Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score
NCT01153009 (6) [back to overview]	Mean Clinical Global Impression Scale - Improvement (CGI-I) Score at Week 8
NCT01153009 (6) [back to overview]	Percentage of Participants in MADRS Remission at Week 8
NCT01153009 (6) [back to overview]	Percentage of Participants With a MADRS Response at Week 8
NCT01153009 (6) [back to overview]	Change From Baseline in MADRS Total Score at Week 8 in Participants With Baseline Hamilton Anxiety Scale (HAM-A) Total Score ≥20
NCT01163266 (6) [back to overview]	Percentage of Participants in MADRS Remission at Week 8
NCT01163266 (6) [back to overview]	Percentage of Participants With a MADRS Response at Week 8
NCT01163266 (6) [back to overview]	Mean Clinical Global Impression Scale-Improvement (CGI-I) Score at Week 8
NCT01163266 (6) [back to overview]	Change From Baseline in Sheehan Disability Scale (SDS) Total Score at Week 8
NCT01163266 (6) [back to overview]	Change From Baseline in Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score
NCT01163266 (6) [back to overview]	Change From Baseline in MADRS Total Score at Week 8 in Participants With Baseline Hamilton Anxiety Scale (HAM-A) Total Score ≥20
NCT01179516 (6) [back to overview]	Percentage of Participants With a MADRS Response at Week 8
NCT01179516 (6) [back to overview]	Percentage of Participants in MADRS Remission at Week 8
NCT01179516 (6) [back to overview]	Mean Clinical Global Impression Scale - Improvement (CGI-I) Score at Week 8
NCT01179516 (6) [back to overview]	Change From Baseline in Sheehan Disability Scale (SDS) Total Score
NCT01179516 (6) [back to overview]	Change From Baseline in Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score
NCT01179516 (6) [back to overview]	Change From Baseline in MADRS Total Score at Week 8 in Participants With Baseline Hamilton Anxiety Scale (HAM-A) Total Score ≥ 20
NCT01255787 (5) [back to overview]	Percentage of Participants With a MADRS Response at Week 8
NCT01255787 (5) [back to overview]	Percentage of Participants in MADRS Remission at Week 8
NCT01255787 (5) [back to overview]	Mean Clinical Global Impression Scale - Improvement (CGI-I) Score at Week 8
NCT01255787 (5) [back to overview]	Change From Baseline in Sheehan Disability Scale (SDS) Total Score at Week 8
NCT01255787 (5) [back to overview]	Change From Baseline in Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score
NCT01299805 (12) [back to overview]	Maximum Concentration of 5-HT in Cerobrospinal Fluid
NCT01299805 (12) [back to overview]	Maximum Concentration of 5-HIAA in Plasma
NCT01299805 (12) [back to overview]	Maximum Concentration of 5-HIAA in Cerebrospinal Fluid
NCT01299805 (12) [back to overview]	Area Under the Effect Curve From Time Zero to 24 Hours Postdose of 5-hydroxytryptamine (5-HT) in Plasma
NCT01299805 (12) [back to overview]	Area Under the Effect Curve From Time Zero to 24 Hours Postdose of 5-hydroxyindoleacetic Acid (5-HIAA) in Plasma
NCT01299805 (12) [back to overview]	Area Under the Effect Curve From Time Zero to 24 Hours Postdose of 5-HT in Cerebrospinal Fluid
NCT01299805 (12) [back to overview]	Area Under the Effect Curve From Time Zero to 24 Hours Postdose of 5-HIAA in Cerebrospinal Fluid
NCT01299805 (12) [back to overview]	Maximum Concentration of 5-HT in Plasma
NCT01299805 (12) [back to overview]	Time to Maximum Concentration of 5-HT in Plasma
NCT01299805 (12) [back to overview]	Time to Maximum Concentration of 5-HT in Cerebrospinal Fluid
NCT01299805 (12) [back to overview]	Time to Maximum Concentration of 5-HIAA in Plasma
NCT01299805 (12) [back to overview]	Time to Maximum Concentration of 5-HIAA in Cerebrospinal Fluid
NCT01323478 (10) [back to overview]	Number of Patients With Adverse Events (AEs)
NCT01323478 (10) [back to overview]	Risk of Suicidality Using C-SSRS Scores
NCT01323478 (10) [back to overview]	Change From Baseline in CGI-S Score After 52 Weeks of Treatment
NCT01323478 (10) [back to overview]	Change From Baseline in HAM-A Total Score After 52 Weeks of Treatment
NCT01323478 (10) [back to overview]	Change From Baseline in MADRS Total Score After 52 Weeks of Treatment
NCT01323478 (10) [back to overview]	Percentage of Patients Who Withdrew Due to Intolerance to Treatment
NCT01323478 (10) [back to overview]	Proportion of Remitters at Week 52 (Remission Defined as a MADRS Total Score <=10)
NCT01323478 (10) [back to overview]	ASEX Total Score After 52 Weeks of Treatment
NCT01323478 (10) [back to overview]	Proportion of Responders at Week 52 (Response Defined as a >=50% Decrease in MADRS Total Score)
NCT01323478 (10) [back to overview]	SDS Total Score After 52 Weeks of Treatment
NCT01355081 (6) [back to overview]	Percentage of Patients With MADRS Response After 8 Weeks of Treatment
NCT01355081 (6) [back to overview]	Percentage of Patients With MADRS Remission After 8 Weeks of Treatment
NCT01355081 (6) [back to overview]	Clinical Global Impression Scale-Improvement (CGI-I) Score After 8 Weeks of Treatment
NCT01355081 (6) [back to overview]	Change From Baseline in the Hamilton Depression Scale (HAM-D17) Total Score After 8 Weeks of Treatment
NCT01355081 (6) [back to overview]	Change From Baseline in Sheehan Disability Scale (SDS) Total Score After 8 Weeks of Treatment
NCT01355081 (6) [back to overview]	Change From Baseline in Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score After 8 Weeks of Treatment
NCT01364649 (3) [back to overview]	Number of Participants With Shifts in the CSFQ-14 From Abnormal to Normal at Each Week Assessed
NCT01364649 (3) [back to overview]	Change From Baseline in the CSFQ-14 Total Score at All Other Time Points Assessed
NCT01364649 (3) [back to overview]	Change From Baseline in the Changes in Sexual Functioning Questionnaire Short-Form (CSFQ-14) Total Score at Week 8
NCT01422213 (18) [back to overview]	Risk of Suicidality Using C-SSRS Scores
NCT01422213 (18) [back to overview]	Proportion of Responders at Week 8 (Response Defined as a >=50% Decrease in the MADRS Total Score From Baseline
NCT01422213 (18) [back to overview]	Proportion of Remitters at Week 8 (Remission is Defined as a MADRS Total Score <=10)
NCT01422213 (18) [back to overview]	Clinical Status Using CGI-I Score at Week 8
NCT01422213 (18) [back to overview]	Change From Baseline to Week 1 Using the MADRS Total Score and the Composite Z-score
NCT01422213 (18) [back to overview]	Change From Baseline to Week 8 in CGI-S Score
NCT01422213 (18) [back to overview]	Change From Baseline to Week 8 in Congruent STROOP Time to Complete (Executive Function)
NCT01422213 (18) [back to overview]	Change From Baseline to Week 8 in DSST (Number of Correct Symbols)
NCT01422213 (18) [back to overview]	Change From Baseline to Week 8 Using the MADRS Total Score and the Composite Z-score
NCT01422213 (18) [back to overview]	Change From Baseline to Week 8 in DSST (Number of Correct Symbols) and RAVLT (Acquisition and Delayed Recall) Using the Composite Z-score Defined as the Weighted Sum of the Individual Patient Z-scores
NCT01422213 (18) [back to overview]	Change From Baseline to Week 8 in Incongruent STROOP Time to Complete (Executive Function)
NCT01422213 (18) [back to overview]	Change From Baseline to Week 8 in MADRS Total Score
NCT01422213 (18) [back to overview]	Change From Baseline to Week 8 in RAVLT (Acquisition)
NCT01422213 (18) [back to overview]	Change From Baseline to Week 8 in RAVLT (Delayed Recall)
NCT01422213 (18) [back to overview]	Change From Baseline to Week 8 in the CRT (Attention)
NCT01422213 (18) [back to overview]	Change From Baseline to Week 8 in the SRT (Speed of Processing)
NCT01422213 (18) [back to overview]	Change From Baseline to Week 8 in the TMT A (Speed of Processing)
NCT01422213 (18) [back to overview]	Change From Baseline to Week 8 in the TMT B (Executive Function)
NCT01488071 (14) [back to overview]	Change From Baseline in MADRS Total Score at Week 8
NCT01488071 (14) [back to overview]	Change From Baseline in MADRS Total Score at Week 12
NCT01488071 (14) [back to overview]	Change From Baseline in HAM-A Total Score at Week 8
NCT01488071 (14) [back to overview]	Change From Baseline in HAM-A Total Score at Week 12
NCT01488071 (14) [back to overview]	Change From Baseline in CGI-S Score at Week 8
NCT01488071 (14) [back to overview]	Change From Baseline in CGI-S Score at Week 12
NCT01488071 (14) [back to overview]	Change From Baseline in SDS Total Score at Week 8
NCT01488071 (14) [back to overview]	Change in Clinical Status Using CGI-I Score at Week 12
NCT01488071 (14) [back to overview]	Proportion of Patients Who Are in Remission at Week 12 (Remission is Defined as a MADRS Total Score <=10)
NCT01488071 (14) [back to overview]	Proportion of Patients Who Are in Remission at Week 8 (Remission is Defined as a MADRS Total Score <=10)
NCT01488071 (14) [back to overview]	Proportion of Patients Who Respond at Week 12 (Response Defined as a >=50% Decrease in the MADRS Total Score From Baseline)
NCT01488071 (14) [back to overview]	Proportion of Patients Who Respond at Week 8 (Response Defined as a >=50% Decrease in the MADRS Total Score From Baseline)
NCT01488071 (14) [back to overview]	Change in Clinical Status Using CGI-I Score at Week 8
NCT01488071 (14) [back to overview]	Change From Baseline in SDS Total Score at Week 12
NCT01491035 (7) [back to overview]	t½ of Vortioxetine
NCT01491035 (7) [back to overview]	Cmax of Vortioxetine
NCT01491035 (7) [back to overview]	Oral Clearance (CL/F) of Vortioxetine
NCT01491035 (7) [back to overview]	t½ of Lu AA34443
NCT01491035 (7) [back to overview]	Cmax of Lu AA34443
NCT01491035 (7) [back to overview]	AUC(0-24h) of Lu AA34443
NCT01491035 (7) [back to overview]	AUC(0-24h) of Vortioxetine
NCT01564862 (15) [back to overview]	Change From Baseline to Week 8 in the Trail Making Test B (TMT-B)
NCT01564862 (15) [back to overview]	Change in Time From Baseline to Week 8 in the Stroop Test
NCT01564862 (15) [back to overview]	Clinical Global Impressions-Improvement (CGI-I) Score at Week 8
NCT01564862 (15) [back to overview]	Change From Baseline to Week 8 in the Detection Task (DT)
NCT01564862 (15) [back to overview]	Change From Baseline to Week 8 in the Digit Symbol Substitution Test (DSST)
NCT01564862 (15) [back to overview]	Change From Baseline to Week 8 in the Groton Maze Learning Test (GMLT)
NCT01564862 (15) [back to overview]	Change From Baseline to Week 8 in the Identification Task (IT)
NCT01564862 (15) [back to overview]	Change From Baseline to Week 8 in the One-Back Task
NCT01564862 (15) [back to overview]	Change From Baseline to Week 8 in the Perceived Deficits Questionnaire (PDQ) Attention/Concentration and Planning/Organization Subscore
NCT01564862 (15) [back to overview]	Change From Baseline to Week 8 in the Clinical Global Impressions-Severity (CGI-S) Score
NCT01564862 (15) [back to overview]	Proportion of Cognitive Dysfunction Improvement Due to Improvement of Depression
NCT01564862 (15) [back to overview]	Percentage of Participants in MADRS Remission at Week 8
NCT01564862 (15) [back to overview]	Percentage of Participants With MADRS Response at Week 8
NCT01564862 (15) [back to overview]	Change From Baseline to Week 8 in the MADRS Total Score
NCT01564862 (15) [back to overview]	Change From Baseline to Week 8 in the Trail Making Test (TMT-A)
NCT01571453 (6) [back to overview]	Change From Baseline in MADRS Total Score at Week 8
NCT01571453 (6) [back to overview]	Change in CGI-S Score From Baseline to Week 8
NCT01571453 (6) [back to overview]	Change in HAM-A Total Score From Baseline to Week 8
NCT01571453 (6) [back to overview]	MADRS Response at Week 8 (Response Defined as a ≥50% Decrease in the MADRS Total Score From Baseline)
NCT01571453 (6) [back to overview]	Remission at Week 8 (Remission Defined as a MADRS Total Score ≤10)
NCT01571453 (6) [back to overview]	CGI-I Score at Week 8
NCT02170220 (11) [back to overview]	AUC(0-inf): Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for Vortioxetine Metabolite Lu AA34443
NCT02170220 (11) [back to overview]	AUC(0-inf)u: Area Under the Unbound Plasma Concentration-time Curve From Time 0 to Infinity for Vortioxetine
NCT02170220 (11) [back to overview]	AUC(0-tlqc): Area Under the Plasma Concentration-Time Curve From Time 0 to the Time of the Last Quantifiable Concentration for Vortioxetine
NCT02170220 (11) [back to overview]	AUC(0-tlqc): Area Under the Plasma Concentration-Time Curve From Time 0 to the Time of the Last Quantifiable Concentration for Vortioxetine Metabolite Lu AA34443
NCT02170220 (11) [back to overview]	AUC(0-tlqc)u: Area Under the Unbound Plasma Concentration-Time Curve From Time 0 to the Time of the Last Quantifiable Concentration for Vortioxetine
NCT02170220 (11) [back to overview]	Cmax: Maximum Observed Plasma Concentration for Vortioxetine
NCT02170220 (11) [back to overview]	Cmax: Maximum Observed Plasma Concentration for Vortioxetine Metabolite Lu AA34443
NCT02170220 (11) [back to overview]	Cmax: Maximum Observed Plasma Concentration for Vortioxetine Metabolite Lu AA39835
NCT02170220 (11) [back to overview]	Cmaxu: Maximum Observed Unbound Plasma Concentration for Vortioxetine
NCT02170220 (11) [back to overview]	AUC(0-tlqc): Area Under the Plasma Concentration-Time Curve From Time 0 to the Time of the Last Quantifiable Concentration for Vortioxetine Metabolite Lu AA39835
NCT02170220 (11) [back to overview]	AUC(0-inf): Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for Vortioxetine
NCT02234362 (14) [back to overview]	Change From Baseline in Vasomotor Symptoms (VMS) Severity During Nighttime at Week 8 (Visit 5)
NCT02234362 (14) [back to overview]	Change From Baseline in Beck Anxiety Inventory (BAI) Score at Week 8 (Visit 5)
NCT02234362 (14) [back to overview]	Change From Baseline in Clinical Global Impression-Fatigue (CGI-F) Scale Score at Week 8 (Visit 5)
NCT02234362 (14) [back to overview]	Change From Baseline in Clinical Global Impression-Severity (CGI-S) Scale Score at Week 8 (Visit 5)
NCT02234362 (14) [back to overview]	Change From Baseline in Cognitive and Physical Functioning Questionnaire (CPFQ) Score at Week 8 (Visit 5)
NCT02234362 (14) [back to overview]	Change From Baseline in Digit Symbol Substitution Test (DSST) Score at Week 8 (Visit 5)
NCT02234362 (14) [back to overview]	Change From Baseline in Greene Climacteric Scale (GCS) Score at Week 8 (Visit 5)
NCT02234362 (14) [back to overview]	Change From Baseline in Menopause Specific Quality of Life (MENQOL) Score at Week 8 (Visit 5)
NCT02234362 (14) [back to overview]	Change From Baseline in Montgomery-Asberg Depression Rating Scale Score (MADRS) at Week 8 (Visit 5)
NCT02234362 (14) [back to overview]	Change From Baseline in Pain Assessment (PEG) Score at Week 8 (Visit 5)
NCT02234362 (14) [back to overview]	Change From Baseline in Pittsburgh Sleep Quality Index (PSQI) Score at Week 8 (Visit 5)
NCT02234362 (14) [back to overview]	Change From Baseline in Vasomotor Symptoms (VMS) Frequency During Daytime at Week 8 (Visit 5)
NCT02234362 (14) [back to overview]	Change From Baseline in Vasomotor Symptoms (VMS) Frequency During Nighttime at Week 8 (Visit 5)
NCT02234362 (14) [back to overview]	Change From Baseline in Vasomotor Symptoms (VMS) Severity During Daytime at Week 8 (Visit 5)
NCT02327013 (42) [back to overview]	Change in BRIEF-A Subscales - Emotional Control
NCT02327013 (42) [back to overview]	Change in AISRS Inattention Sub-score
NCT02327013 (42) [back to overview]	Change in Adult ADHD Self-Report Scale (ASRS) Total Score
NCT02327013 (42) [back to overview]	Change in Adult ADHD Quality of Life Measure (AAQoL) Total Score
NCT02327013 (42) [back to overview]	Change in ADHD Investigator Symptom Rating Scale (AISRS) Total Score
NCT02327013 (42) [back to overview]	Change in AAQoL Subscales - Relationships Sub-score
NCT02327013 (42) [back to overview]	Change in AAQoL Subscales - Psychological Health Sub-score
NCT02327013 (42) [back to overview]	Change in AAQoL Subscales - Life Productivity Sub-score
NCT02327013 (42) [back to overview]	Change in AAQoL Subscales - Life Outlook Sub-score
NCT02327013 (42) [back to overview]	Change BRIEF-A Subscales - Initiate
NCT02327013 (42) [back to overview]	Change in Perceived Deficits Questionnaire - Depression (PDQ-D) Total Score
NCT02327013 (42) [back to overview]	Change AISRS Hyperactivity/Impulsivity Sub-score
NCT02327013 (42) [back to overview]	Response (Defined as a CGI-I Score of 1 or 2), Stage 1
NCT02327013 (42) [back to overview]	Productivity: Change in Work Limitations Questionnaire (WLQ) Productivity Loss Score
NCT02327013 (42) [back to overview]	Percentage of Patients Responding (Response Defined as 30% or Greater Reduction From Baseline in AISRS Total Score)
NCT02327013 (42) [back to overview]	Overall Functioning: Change in Sheehan Disability Scale (SDS) Total Score
NCT02327013 (42) [back to overview]	Inattention/Meta-cognition: Change in Behavior Rating Inventory of Executive Function - Adult Version (BRIEF-A) Using Metacognition Index
NCT02327013 (42) [back to overview]	Cognitive Function/Global Executive Function: Change in BRIEF-A Using the Global Executive Composite Score
NCT02327013 (42) [back to overview]	Clinical Global Impression - Global Improvement (CGI-I) Score
NCT02327013 (42) [back to overview]	Change in WLQ Using the Global Productivity Index
NCT02327013 (42) [back to overview]	Change in WLQ Domain Scores - Physical Demands
NCT02327013 (42) [back to overview]	Change in WLQ Domain Scores - Output Demands
NCT02327013 (42) [back to overview]	Change in WLQ Domain Scores - Mental-Interpersonal Work Demands
NCT02327013 (42) [back to overview]	Change in WLQ Domain Scores - Limitations Handling Time
NCT02327013 (42) [back to overview]	Change in SDS Item Scores - Work
NCT02327013 (42) [back to overview]	Change in SDS Item Scores - Social Life
NCT02327013 (42) [back to overview]	Change in SDS Item Scores - Number of Underproductive Days
NCT02327013 (42) [back to overview]	Change in SDS Item Scores - Number of Days Lost
NCT02327013 (42) [back to overview]	Change in SDS Item Scores - Family
NCT02327013 (42) [back to overview]	Change in PDQ-D Subscales - Attention and Concentration Sub-score
NCT02327013 (42) [back to overview]	Change in PDQ-D Sub-scales - Retrospective Memory Sub-score
NCT02327013 (42) [back to overview]	Change in PDQ-D Sub-scales - Prospective Memory Sub-score
NCT02327013 (42) [back to overview]	Change in PDQ-D Sub-scales - Planning and Organisation Sub-score
NCT02327013 (42) [back to overview]	Change in Clinical Global Impression - Severity of Illness (CGI-S) Score
NCT02327013 (42) [back to overview]	Change in BRIEF-A Using the Behavioural Regulation Index
NCT02327013 (42) [back to overview]	Change in BRIEF-A Subscales - Working Memory
NCT02327013 (42) [back to overview]	Change in BRIEF-A Subscales - Task Monitor
NCT02327013 (42) [back to overview]	Change in BRIEF-A Subscales - Shift
NCT02327013 (42) [back to overview]	Change in BRIEF-A Subscales - Self Monitor
NCT02327013 (42) [back to overview]	Change in BRIEF-A Subscales - Planning/Organize
NCT02327013 (42) [back to overview]	Change in BRIEF-A Subscales - Organization of Materials
NCT02327013 (42) [back to overview]	Change in BRIEF-A Subscales - Inhibit
NCT02371980 (5) [back to overview]	Clinical Global Impression Scale-Global Improvement Scale (CGI-I) Score
NCT02371980 (5) [back to overview]	Time From Randomization to Relapse of Major Depressive Disorder During the Entire 32-Week Double-Blind Treatment Period
NCT02371980 (5) [back to overview]	Time From Randomization to Relapse of Major Depressive Disorder During the First 28 Weeks of the 32-Week Double-Blind Treatment Period
NCT02371980 (5) [back to overview]	Change From Baseline in Clinical Global Impression Scale-Severity (CGI-S) Score at Each Week Assessed
NCT02371980 (5) [back to overview]	Change From Baseline in Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score
NCT02389816 (9) [back to overview]	Clinical Global Impressions-Improvement (CGI-I) Score at Week 8 (LOCF)
NCT02389816 (9) [back to overview]	Change From Baseline in Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score to Week 8
NCT02389816 (9) [back to overview]	Change From Baseline in Sheehan Disability Scale (SDS) Total Score to Week 8 (LOCF)
NCT02389816 (9) [back to overview]	MADRS Remission at Week 8 (LOCF)
NCT02389816 (9) [back to overview]	MADRS Response at Week 8 (Last Observation Carried Forward (LOCF))
NCT02389816 (9) [back to overview]	Change From Baseline in Perceived Deficits Questionnaire (PDQ-5) Total Score to Week 8 (LOCF)
NCT02389816 (9) [back to overview]	Change From Baseline in Clinical Global Impressions-Severity (CGI-S) Score to Week 8 (LOCF)
NCT02389816 (9) [back to overview]	Change From Baseline in Digit Symbol Substitution Test (DSST) Total Score to Week 8 (LOCF)
NCT02389816 (9) [back to overview]	Change From Baseline in Hamilton Depression Scale (HAM-D17) Total Score to Week 8 (LOCF)
NCT02528409 (9) [back to overview]	Yale-Brown Obsessive Compulsive Scale Modified for Binge Eating
NCT02528409 (9) [back to overview]	Change in Number of Binge Eating Episodes
NCT02528409 (9) [back to overview]	BMI
NCT02528409 (9) [back to overview]	Clinical Global Impression Improvement Scale (CGI)
NCT02528409 (9) [back to overview]	Hamilton Anxiety Rating Scale
NCT02528409 (9) [back to overview]	Hamilton Depression Rating Scale
NCT02528409 (9) [back to overview]	Number of Participants With 4-week Cessation From Binge Eating
NCT02528409 (9) [back to overview]	Quality of Life Inventory
NCT02528409 (9) [back to overview]	Three-Factor Eating Questionnaire
NCT02637895 (4) [back to overview]	Change Clinician Administered PTSD Scale Score
NCT02637895 (4) [back to overview]	Change in Depressive Symptoms in PTSD
NCT02637895 (4) [back to overview]	Number of Participants That Achieve Treatment Response Via CGI-I
NCT02637895 (4) [back to overview]	Number of Participants That Achieve Treatment Response Via Clinician Administered PTSD Scale (CAPS)-5
NCT02709655 (21) [back to overview]	Change From Baseline in PQ-LES-Q Overall Evaluation Score (Item 15) at Weeks 4 and 8 of Phase B
NCT02709655 (21) [back to overview]	Clinical Global Impression - Global Improvement (CGI-I) Score
NCT02709655 (21) [back to overview]	Parent Global Assessment (PGA) Score
NCT02709655 (21) [back to overview]	Percentage of Participants With CDRS-R Remission
NCT02709655 (21) [back to overview]	Percentage of Participants With CGI-S Remission
NCT02709655 (21) [back to overview]	Percentage of Participants With CDRS-R Response
NCT02709655 (21) [back to overview]	Change From Baseline in Children Depression Rating Scale - Revised (CDRS-R) Total Score at Week 8 of Phase B
NCT02709655 (21) [back to overview]	Change From Baseline in CDRS-R Subscores (Mood, Somatic, Subjective, and Behaviour) at Weeks 2, 4, 6, and 8 of Phase B
NCT02709655 (21) [back to overview]	Change From Baseline in CDRS-R Total Score at Weeks 2, 4, and 6 of Phase B
NCT02709655 (21) [back to overview]	Change From Baseline in Children's Global Assessment Scale (CGAS) Score at Weeks 4 and 8 of Phase B
NCT02709655 (21) [back to overview]	Change From Baseline in Clinical Global Impression - Severity of Illness (CGI-S) Score at Weeks 1, 2, 3, 4, 6, and 8 of Phase B
NCT02709655 (21) [back to overview]	Change From Baseline in General Behaviour Inventory (GBI) Depression Subscale Score, Using the 10-Item Depression Subscale Assessed by Parent (PGBI-10D) and Child (CGBI-10D) at Weeks 2, 4, 6, and 8 of Phase B
NCT02709655 (21) [back to overview]	Change From Baseline in Paediatric Quality of Life Enjoyment and Satisfaction Questionnaire (PQ-LES-Q) Total Score (Items 1 to 14) at Weeks 4 and 8 of Phase B
NCT02709655 (21) [back to overview]	Change From Baseline in Pediatric Quality of Life Inventory (PedsQL) Visual Analogue Scales (VAS): Afraid or Scared (Anxiety) Score at Weeks 4 and 8 of Phase B
NCT02709655 (21) [back to overview]	Change From Baseline in PedsQL Emotional Distress Summary Average Score at Weeks 4 and 8 of Phase B
NCT02709655 (21) [back to overview]	Change From Baseline in PedsQL VAS Total Average Score at Weeks 4 and 8 of Phase B
NCT02709655 (21) [back to overview]	Change From Baseline in PedsQL VAS: Angry Score at Weeks 4 and 8 of Phase B
NCT02709655 (21) [back to overview]	Change From Baseline in PedsQL VAS: Pain or Hurt Score at Weeks 4 and 8 of Phase B
NCT02709655 (21) [back to overview]	Change From Baseline in PedsQL VAS: Sad or Blue (Sadness) Score at Weeks 4 and 8 of Phase B
NCT02709655 (21) [back to overview]	Change From Baseline in PedsQL VAS: Tired (Fatigue) Score at Weeks 4 and 8 of Phase B
NCT02709655 (21) [back to overview]	Change From Baseline in PedsQL VAS: Worry Score at Weeks 4 and 8 of Phase B
NCT02709746 (28) [back to overview]	Change in Paediatric Quality of Life Enjoyment and Satisfaction Questionnaire (PQ-LES-Q) Total Scores
NCT02709746 (28) [back to overview]	Change in PedsQL VAS: Tired (Fatigue) Score
NCT02709746 (28) [back to overview]	Change in PedsQL VAS: Worry Score
NCT02709746 (28) [back to overview]	Change General Behaviour Inventory (GBI) Depression Subscale Score Assessed by the Child
NCT02709746 (28) [back to overview]	Change in CDRS-R Behaviour Score
NCT02709746 (28) [back to overview]	Change in CDRS-R Somatic Score
NCT02709746 (28) [back to overview]	Change in PQ-LES-Q Overall Score
NCT02709746 (28) [back to overview]	Change in Symbol Digit Modalities Test (SDMT)
NCT02709746 (28) [back to overview]	Clinical Global Impression - Global Improvement (CGI-I) Score
NCT02709746 (28) [back to overview]	Parent Global Assessment-Global Improvement (PGA) Score
NCT02709746 (28) [back to overview]	Change in CDRS-R Subjective Score
NCT02709746 (28) [back to overview]	Change in CDRS-R Total Score During Treatment (at Week 4)
NCT02709746 (28) [back to overview]	Change in CDRS-R Total Score During Treatment (at Week 2)
NCT02709746 (28) [back to overview]	Change in CDRS-R Total Score During Treatment (at Week 6)
NCT02709746 (28) [back to overview]	CDRS-R Remission
NCT02709746 (28) [back to overview]	CDRS-R Response
NCT02709746 (28) [back to overview]	Change in Children Depression Rating Scale - Revised (CDRS-R) Total Score After Treatment
NCT02709746 (28) [back to overview]	Change in Children's Global Assessment Scale (CGAS) Score
NCT02709746 (28) [back to overview]	Change in Clinical Global Impression Severity of Illness (CGI-S) Score
NCT02709746 (28) [back to overview]	Change in CDRS-R Mood Score
NCT02709746 (28) [back to overview]	Change in General Behaviour Inventory (GBI) Depression Sub Scale Score Assessed by the Parents
NCT02709746 (28) [back to overview]	Change in PedsQL Emotional Distress Summary Average Score
NCT02709746 (28) [back to overview]	CGI-S Remission
NCT02709746 (28) [back to overview]	Change in Pediatric Quality of Life Inventory (PedsQL) Visual Analogue Scales (VAS): Afraid or Scared (Anxiety) Score
NCT02709746 (28) [back to overview]	Change in PedsQL VAS Total Average Score
NCT02709746 (28) [back to overview]	Change in PedsQL VAS: Angry Score
NCT02709746 (28) [back to overview]	Change in PedsQL VAS: Pain or Hurt Score
NCT02709746 (28) [back to overview]	Change in PedsQL VAS: Sad or Blue (Sadness) Score
NCT02749721 (10) [back to overview]	Correlations Between BNA Latency Scores and Clinical, Cognitive, and Functionality Assessments Using Baseline Scores
NCT02749721 (10) [back to overview]	Changes in Quick Inventory of Depressive Symptomatology - Self-Report (QIDS-16-SR) From Baseline to 8 Week Endpoint
NCT02749721 (10) [back to overview]	Changes in Hamilton Depression Rating Scale (HDRS) 28 From Baseline to 8 Week Endpoint
NCT02749721 (10) [back to overview]	Changes in Hamilton Depression Rating Scale (HDRS) 17 From Baseline to 8 Week Endpoint
NCT02749721 (10) [back to overview]	Changes in Clinical Global Impression Scale (CGI-S) From Baseline to 8 Week Endpoint
NCT02749721 (10) [back to overview]	Change in Montgomery and Asberg Depression Rating Scale (MADRS)
NCT02749721 (10) [back to overview]	Change From Baseline to Endpoint in Digital Symbol Substitution Test.
NCT02749721 (10) [back to overview]	BNA Scores Latencies
NCT02749721 (10) [back to overview]	Correlations Between BNA Amplitude Scores and Clinical, Cognitive, and Functionality Assessments Using Baseline Scores
NCT02749721 (10) [back to overview]	BNA Scores Amplitudes
NCT02871297 (12) [back to overview]	Clinical Global Impression - Global Improvement (CGI-I) Score
NCT02871297 (12) [back to overview]	Adolescents (12-18 Years): Change From Baseline in Behaviour Rating Inventory of Executive Function - Self-report (BRIEF-SR) Using the GEC Score at Week 26
NCT02871297 (12) [back to overview]	Number of Participants With Response to the Palatability Questionnaire
NCT02871297 (12) [back to overview]	Number of Participants With Response to the Acceptability Questionnaire
NCT02871297 (12) [back to overview]	Children (7-11 Years): Change From Baseline in BRIEF-P Using the MI Score at Week 26
NCT02871297 (12) [back to overview]	Children (7-11 Years): Change From Baseline in Behaviour Rating Inventory of Executive Function - Preschool (BRIEF-P) Using the Global Executive Composite (GEC) Score at Week 26
NCT02871297 (12) [back to overview]	Change From Baseline in Pediatric Quality of Life Inventory Present Functioning Visual Analogue Scale (PedsQL VAS) Total Score at Week 26
NCT02871297 (12) [back to overview]	Change From Baseline in Clinical Global Impression - Severity of Illness (CGI-S) Score at Week 26
NCT02871297 (12) [back to overview]	Change From Baseline in Children's Global Assessment Scale (CGAS) Score at Week 26
NCT02871297 (12) [back to overview]	Change From Baseline in Children Depression Rating Scale - Revised (CDRS-R) Total Score at Week 26
NCT02871297 (12) [back to overview]	Number of Participants With Treatment-Emergent Adverse Events (TEAEs)
NCT02871297 (12) [back to overview]	Adolescents (12-18 Years): Change From Baseline in BRIEF-SR Using the MI Score at Week 26
NCT02932904 (9) [back to overview]	Change From Baseline in the Changes in Sexual Functioning Questionnaire (CSFQ-14) Total Score Difference for Vortioxetine Versus Paroxetine at Week 5 in Full Analysis Set (FAS)
NCT02932904 (9) [back to overview]	Change From Baseline in the CSFQ-14 Total Score Difference for Vortioxetine Versus Paroxetine at Week 5 in Modified Full Analysis Set 1 (mFAS1)
NCT02932904 (9) [back to overview]	Change From Baseline in the CSFQ-14 Total Score Difference for Vortioxetine Versus Paroxetine at Week 5 in Modified Full Analysis Set 2 (mFAS2)
NCT02932904 (9) [back to overview]	Change From Baseline in the CSFQ-14 Total Score Difference for Vortioxetine Versus Paroxetine at Weeks 1, 2, 3 and 4
NCT02932904 (9) [back to overview]	Change From Baseline in CSFQ-14 Total Score Difference for Vortioxetine Versus Placebo at Weeks 1, 2, 3, 4 and 5
NCT02932904 (9) [back to overview]	Percentage of Participants Meeting Criteria for Sexual Dysfunction at Weeks 1, 2, 3, 4 and 5
NCT02932904 (9) [back to overview]	Change From Baseline in CSFQ-14 3 Phases of the Sexual Response Cycle (Desire, Arousal, and Orgasm/Completion) at Weeks 1, 2, 3, 4 and 5
NCT02932904 (9) [back to overview]	Change From Baseline in CSFQ-14 Subscales 5 Dimensions at Weeks 1, 2, 3, 4 and 5
NCT02932904 (9) [back to overview]	Change From Baseline in CSFQ-14 Total Score Difference for Paroxetine Versus Placebo at Weeks 1, 2, 3, 4 and 5
NCT02969876 (3) [back to overview]	Quick Inventory of Depressive Symptomatology - Clinician Version (QIDS-C)
NCT02969876 (3) [back to overview]	Rey Auditory Verbal Learning Test
NCT02969876 (3) [back to overview]	Digital Symbol Substitution Test
NCT02972632 (8) [back to overview]	Change From Baseline in Total Goal Attainment Scale Score at Weeks 6 and 12
NCT02972632 (8) [back to overview]	Change From Baseline in Quality of Life Enjoyment and Satisfaction Scale (Q-LES-Q) Total Score at Week 12
NCT02972632 (8) [back to overview]	Change From Baseline in Perceived Deficits Questionnaire-Depression (PDQ-D) at Weeks 6 and 12
NCT02972632 (8) [back to overview]	Change From Baseline in Patient Health Questionnaire (PHQ-9) Score at Weeks 6 and 12
NCT02972632 (8) [back to overview]	Change From Baseline in Clinical Global Impression Scale Severity (CGI-S) at Week 12
NCT02972632 (8) [back to overview]	Change From Baseline in 5-Item World Health Organization Well-being Index (WHO-5) Score at Week 12
NCT02972632 (8) [back to overview]	Percentage of Participants Who Achieved Goal Attainment Scale (GAS) Score of ≥50 at Week 12
NCT02972632 (8) [back to overview]	Clinical Global Impression Scale-Improvement (CGI-I) Score at Week 12
NCT03053362 (7) [back to overview]	Cognition Measured Using the THINC-it Tool
NCT03053362 (7) [back to overview]	Changes in the World Health Organization Wellbeing Index (5-Item)
NCT03053362 (7) [back to overview]	Changes in Mood as Measured by the Montgomery Åsberg Depression Rating Scale (MADRS)
NCT03053362 (7) [back to overview]	Changes in Global Functional Impairment Using the Sheehan Disability Scale Total Score
NCT03053362 (7) [back to overview]	Changes in Cognitive Function Assessed by the Trail Making Test - Part B (TMT-B)
NCT03053362 (7) [back to overview]	Changes in Cognitive Function Assessed by the Digit Symbol Substitution Task (DSST)
NCT03053362 (7) [back to overview]	Changes in Changes in Anhedonia From Baseline to Week 8
NCT03272711 (3) [back to overview]	Change in Total Fluid Cognitive Score
NCT03272711 (3) [back to overview]	Change in Total Fluid Cognitive Score
NCT03272711 (3) [back to overview]	Participant Function
NCT03437564 (12) [back to overview]	AUC∞: Area Under the Plasma Concentration-Time Curve From Time 0 to Infinity of Unchanged Lu AA21004
NCT03437564 (12) [back to overview]	AUClast: Area Under the Plasma Concentration-Time Curve From Time 0 to the Last Quantifiable Time Point of Unchanged Lu AA21004
NCT03437564 (12) [back to overview]	Cmax: Maximum Plasma Concentration (Observed Value) of Unchanged Lu AA21004
NCT03437564 (12) [back to overview]	MRTlast, ev: Mean Residence Time From Time 0 to the Time of the Last Quantifiable Concentration of Unchanged Lu AA21004
NCT03437564 (12) [back to overview]	λz: Apparent Elimination Rate Constant of Unchanged Lu AA21004
NCT03437564 (12) [back to overview]	Number of Participants With TEAE Related to Clinical Laboratory Tests (Alanine Aminotransferase Increased)
NCT03437564 (12) [back to overview]	Tmax: Time to Reach Cmax (Observed Value) of Unchanged Lu AA21004
NCT03437564 (12) [back to overview]	MRT∞, ev: Mean Residence Time 0 to Infinity of Unchanged Lu AA21004
NCT03437564 (12) [back to overview]	Number of Participants With TEAE Related to Vital Sign
NCT03437564 (12) [back to overview]	Number of Participants With TEAE Related to 12-lead Electrocardiograms
NCT03437564 (12) [back to overview]	Number of Participants Who Experienced at Least One Treatment-Emergent Adverse Event (TEAE)
NCT03437564 (12) [back to overview]	T1/2z: Apparent Elimination Half-Life of Unchanged Lu AA21004

Change From Double-blind Baseline in HAM-A Total Score After 24 Weeks of Double-blind Treatment

The Hamilton Anxiety Rating Scale (HAM-A) consists of 14 items that assess anxious mood, tension, fear, insomnia, intellectual (cognitive) symptoms, depressed mood, behaviour at interview, somatic (sensory), cardiovascular, respiratory, gastrointestinal, genitourinary, autonomic, and somatic (muscular) symptoms. Each symptom is rated from 0 (absent) to 4 (maximum severity). Total score from 0 to 56. The higher the score, the more severe. (NCT00596817)
Timeframe: Double-blind Baseline and Week 24 of the double-blind period

Intervention	units on a scale (Mean)
Placebo	0.89
Vortioxetine: 5 or 10 mg	-0.23

Intervention	units on a scale (Mean)
Placebo	2.52
Vortioxetine 2.5 mg	2.32
Vortioxetine 5 mg	2.32
Vortioxetine 10 mg	2.35
Duloxetine 60 mg	2.31

Intervention	units on a scale (Mean)
Placebo	-0.41
Vortioxetine 2.5 mg	-0.53
Vortioxetine 5 mg	-0.66
Vortioxetine 10 mg	-0.62
Duloxetine 60 mg	-0.38

Intervention	units on a scale (Mean)
Placebo	-1.64
Vortioxetine 2.5 mg	-1.83
Vortioxetine 5 mg	-1.81
Vortioxetine 10 mg	-1.83
Duloxetine 60 mg	-1.82

Intervention	units on a scale (Mean)
Placebo	-9.57
Vortioxetine 2.5 mg	-9.87
Vortioxetine 5 mg	-10.7
Vortioxetine 10 mg	-10.6
Duloxetine 60 mg	-11.0

Intervention	units on a scale (Mean)
Placebo	-14.8
Vortioxetine 2.5 mg	-16.2
Vortioxetine 5 mg	-16.5
Vortioxetine 10 mg	-16.3
Duloxetine 60 mg	-16.8

Intervention	units on a scale (Mean)
Placebo	-13.3
Vortioxetine 2.5 mg	-14.4
Vortioxetine 5 mg	-15.0
Vortioxetine 10 mg	-14.9
Duloxetine 60 mg	-15.7

Intervention	units on a scale (Mean)
Placebo	-14.7
Vortioxetine 2.5 mg	-14.3
Vortioxetine 5 mg	-15.8
Vortioxetine 10 mg	-15.8
Duloxetine 60 mg	-17.3

Intervention	percentage of patients (Number)
Placebo	46.9
Vortioxetine 2.5 mg	54.2
Vortioxetine 5 mg	56.1
Vortioxetine 10 mg	57.6
Duloxetine 60 mg	57.1

Intervention	percentage of patients (Number)
Placebo	33.8
Vortioxetine 2.5 mg	32.9
Vortioxetine 5 mg	36.1
Vortioxetine 10 mg	35.8
Duloxetine 60 mg	34.9

Intervention	units on a scale (Mean)
Placebo	-6.11
Vortioxetine 2.5 mg	-7.10
Vortioxetine 5 mg	-6.52
Vortioxetine 10 mg	-7.81
Duloxetine 60 mg	-7.91

Intervention	scores on a scale (Least Squares Mean)
	Week 1 (n=142, 143, 149, 147)	Week 2 (n=149, 146, 153, 149)	Week 4 (149, 146, 153, 149)	Week 6 (149, 146, 153, 149)	Week 8 (n=149, 146, 153, 149)
Duloxetine 60 mg	3.31	2.99	2.73	2.50	2.39
Placebo	3.54	3.21	2.97	2.83	2.79
Vortioxetine 2.5 mg	3.42	3.17	2.93	2.82	2.73
Vortioxetine 5 mg	3.46	3.10	2.87	2.74	2.63

Intervention	participants (Number)
	Baseline: Any resource use	Baseline: Any hospitalization-related services	Baseline: Hospitalization related to depression	Baseline: Any sick leave	Baseline: Sick leave related to depression	Week 8: Any resource use	Week 8: Any hospitalization-related service	Week 8: Hospitalization related to depression	Week 8: Any sick leave	Week 8: Sick leave related to depression
Duloxetine 60 mg	42	3	0	14	11	27	2	1	5	2
Placebo	40	4	2	18	13	21	1	0	5	2
Vortioxetine 2.5 mg	51	1	1	11	9	19	0	0	5	4
Vortioxetine 5 mg	42	0	0	11	10	20	1	0	9	3

Intervention	percentage of participants (Number)
	Week 1 (n=142, 143, 150, 147)	Week 2 (n=149, 146, 153, 149)	Week 4 (n=149, 146, 153, 149)	Week 6 (n=149, 146, 153, 149)	Week 8 (n=149, 146, 153, 149)
Duloxetine 60 mg	10.2	22.1	34.9	47.0	51.0
Placebo	9.2	15.4	26.2	32.9	32.2
Vortioxetine 2.5 mg	8.4	17.1	30.8	37.7	41.1
Vortioxetine 5 mg	8.7	17.6	24.2	37.3	37.9

Intervention	scores on a scale (Least Squares Mean)
Placebo	-6.83
Vortioxetine 2.5 mg	-6.46
Vortioxetine 5 mg	-6.59
Duloxetine 60 mg	-8.91

Intervention	scores on a scale (Least Squares Mean)
Placebo	-10.50
Vortioxetine 2.5 mg	-12.04
Vortioxetine 5 mg	-11.08
Duloxetine 60 mg	-13.47

Intervention	percentage of participants (Number)
Placebo	22.8
Vortioxetine 2.5 mg	28.8
Vortioxetine 5 mg	23.5
Duloxetine 60 mg	37.6

Intervention	percentage of participants (Number)
Placebo	12.1
Vortioxetine 2.5 mg	15.8
Vortioxetine 5 mg	17.0
Duloxetine 60 mg	21.5

Intervention	scores on a scale (Least Squares Mean)
	Week 1 (n=141, 142, 149, 146)	Week 4 (148, 145, 152, 149)	Week 8 (n=148, 145, 152, 149)
Duloxetine 60 mg	-2.88	-4.89	-5.70
Placebo	-2.51	-4.02	-4.25
Vortioxetine 2.5 mg	-2.43	-3.65	-3.98
Vortioxetine 5 mg	-2.74	-3.69	-4.04

Intervention	percentage of participants (Number)
	Week 1 (n=281, 286)	Week 2 (n=286, 291)	Week 3 (n=286, 292)	Week 4 (n=286, 292)	Week 5 (n=286, 292)	Week 6 (n=286, 292)
Placebo	7.8	23.8	31.8	39.2	44.4	46.2
Vortioxetine	7.0	21.0	32.9	37.0	43.8	46.2

Intervention	scores on a scale (Least Squares Mean)
	Week 1 (n=281, 286)	Week 2 (n= 286, 291)	Week 3 (n= 286, 292)	Week 4 (n= 286, 292)	Week 5 (n=286, 292)
Placebo	-6.03	-9.30	-11.05	-12.33	-13.11
Vortioxetine	-5.96	-9.05	-11.73	-12.66	-13.98

vortioxetine

Description

Cross-References

Synonyms (62)

Research Excerpts

Overview

Effects

Actions

Treatment

Toxicity

Pharmacokinetics

Compound-Compound Interactions

Bioavailability

Dosage Studied

Roles (4)

Drug Classes (2)

Protein Targets (9)

Potency Measurements

Inhibition Measurements

Biological Processes (114)

Molecular Functions (27)

Ceullar Components (25)

Bioassays (46)

Research

Studies (395)

Market Indicators

Research Demand Index: 94.64

Study Types

Clinical Trials (103)

Trial Overview

Trial Outcomes

Change From Double-blind Baseline in HAM-A Total Score After 24 Weeks of Double-blind Treatment

Relapse Within First 24 Weeks of the Double-blind Period Based on a MADRS Total Score >=22 or an Unsatisfactory Treatment Effect (Lack of Efficacy) as Judged by the Investigator

Relapse During the Entire Double-blind Period Based on a MADRS Total Score >=22 or an Unsatisfactory Treatment Effect (Lack of Efficacy) as Judged by the Investigator

Proportion of Responders at Week 24 of the Double-blind Period (Response Defined as a >=50% Reduction in MADRS Total Score From Open-label Baseline)

Change From Double-blind Baseline in HAM-D-17 Total Score After 24 Weeks of Double-blind Treatment

Change From Double-blind Baseline in MADRS Total Score After 24 Weeks of Double-blind Treatment

Change From Double-blind Baseline in SDS Total Score at Week 24 of the Double-blind Period

Proportion of Remitters at Week 24 of the Double-blind Period (Remission Defined as a MADRS Total Score <=10)

Change From Double-blind Baseline in CGI-S Score After 24 Weeks of Double-blind Treatment

Change in Clinical Status Using CGI-I Score at Week 8

Change From Baseline in ASEX Total Score After 8 Weeks of Treatment

Change From Baseline in CGI-S Score After 8 Weeks of Treatment

Change From Baseline in HAM-A Total Score After 8 Weeks of Treatment

Change From Baseline in MADRS Total Score After 8 Weeks of Treatment

Change From Baseline in HAM-D-24 Total Score After 8 Weeks of Treatment

Change From Baseline in HAM-D-24 Total Score After 8 Weeks of Treatment in Patients With Baseline HAM-A Total Score >=20

Proportion of Responders at Week 8 (Response Defined as a >=50% Decrease in the MADRS Total Score From Baseline)

Proportion of Remitters at Week 8 (Remission Defined as a MADRS Total Score <=10)

Change From Baseline in SDS Total Score After 8 Weeks of Treatment

Clinical Global Impression Scale-Global Improvement Scale

Healthcare Resource Utilization as Assessed by the Health Economic Assessment Questionnaire

Percentage of Responders in HAM-D 24 Total Score by Study Visit

Change From Baseline in the Hamilton Anxiety Scale (HAM-A) Total Score

Change From Baseline in Sheehan Disability Scale (SDS) Total Score at Week 8

Change From Baseline in the 24-item Hamilton Depression Scale Total Score at Week 8

Percentage of Participants in MADRS Remission at Week 8

Percentage of Participants With a Sustained Response in HAM-D24

Change From Baseline in Montgomery-Åsberg Depression Rating Scale - Self-assessment (MADRS-S)

Change From Baseline in the 24-item Hamilton Depression Scale Total Score at Other Weeks Assessed

Change From Baseline in the Clinical Global Impression Scale-Severity of Illness Scale

Change From Baseline in the Montgomery Åsberg Depression Rating Scale (MADRS) Total Score

Percentage of Responders in HAM-D24 Total Score by Study Visit

Health Care Resource Utilization as Assessed by the Health Economic Assessment Questionnaire

Clinical Global Impression Scale-Global Improvement Scale

Change From Baseline in the 24-item Hamilton Depression Scale Total Score at Other Weeks Assessed

Change From Baseline in Montgomery-Åsberg Depression Rating Scale - Self-assessment (MADRS-S)

Change From Baseline in Montgomery Åsberg Depression Rating Scale (MADRS) Total Score

Change From Baseline in Hamilton Anxiety Scale (HAM-A)

Change From Baseline in Clinical Global Impression Scale-Severity of Illness

Change From Baseline in 36-item Short-form Health Survey (SF-36) at Week 6

Change From Baseline in Sheehan Disability Scale (SDS) Total Score at Week 6

Percentage of Participants With a Sustained Response in HAM-D24

Percentage of Participants in MADRS Remission at Week 6

Change From Baseline in the 24-item Hamilton Depression Scale Total Score at Week 6

Change From Baseline in CGI-S Score After 52 Weeks of Treatment

Change From Baseline in HAM-A Total Score After 52 Weeks of Treatment

Change From Baseline in HAM-D-24 Total Score After 52 Weeks of Treatment

Change From Baseline in MADRS Total Score After 52 Weeks of Treatment

Change From Baseline in SDS Total Score After 52 Weeks of Treatment

Intervention	scores on a scale (Least Squares Mean)
	Week 1 (n=279, 286)	Week 4 (n=284, 292)	Week 6 (n=284, 292)
Placebo	-2.81	-4.18	-4.56
Vortioxetine	-2.73	-4.05	-4.97

Intervention	scores on a scale (Least Squares Mean)
	Physical functioning	Role - physical	Bodily pain	General health	Vitality	Social functioning	Role - emotional	Mental health
Placebo	5.47	11.73	10.77	7.65	18.00	21.34	19.43	18.98
Vortioxetine	6.87	14.41	10.39	7.37	17.34	22.01	20.76	20.00

Intervention	participants (Number)
	Patients With AEs	Patients With SAEs	Patients With AEs Leading to Withdrawal
Vortioxetine 2.5, 5, or 10 mg/Day	391	18	42

Intervention	participants (Number)
	Heart rate ≤50 bpm and change ≤-15bpm	Heart rate ≥120 bpm and change ≥15 bpm	RR interval <500 msec and change ≤-200 msec	RR interval >1200 msec and change ≥200 msec	PR interval <120 msec	PR interval ≥250 msec	QT interval <280 msec	QT interval >500 msec	QTcB <340 msec	QTcB >500 msec	QTcB Change <-60 msec	QTcB Change >60 msec	QTcF <340 msec	QTcF >500 msec	QTcF Change <-60 msec	QTcF Change >60 msec
Vortioxetine	9	0	0	13	31	2	0	2	0	3	6	4	0	2	3	2

Intervention	participants (Number)
	Alanine aminotransferase (ALT) ≥ 3 X ULN	Aspartate aminotransferase (AST) ≥ 3 X ULN	Bilirubin ≥ 34.2 μmol/L	Cholesterol ≥ 7.8 mmol/L	Creatine kinase ≥ 2 X ULN	Creatinine ≥ 175 μmol/L	Glucose ≤ 2.8 mmol/L	Glucose ≥ 13.9 mmol/L	High density lipoprotein cholesterol < 0.9 mmol/L	Low density lipoprotein cholesterol ≥ 5.0 mmol/L	Potassium ≤ 3.0 mmol/L	Potassium ≥ 5.5 mmol/L	Sodium ≤ 125 mmol/L	Sodium ≥ 155 mmol/L	Triglycerides ≥ 3.40 mmol/L	Urate ≤ 0.7 X LLN	Urate ≥ 1.3 XULN	Eosinophils ≥ 0.6 10^9/L	Erythrocytes ≤ 0.9 X LLN	Erythrocytes ≥ 1.1 X ULN	Hematocrit ≤ 0.9 X LLN	Hemoglobin ≤ 0.9 X LLN	Leukocytes ≤ 2.8 X 10^9/L	Leukocytes ≥ 16 X 10^9/L	Lymphocytes ≤ 0.6 X 10^9/L	Lymphocytes ≥ 7 X 10^9/L	Neutrophils ≤ 1.4 X 10^9/L	Neutrophils ≥ 15 X 10^9/L
Vortioxetine	3	6	1	49	80	1	9	7	102	69	0	45	1	1	168	4	12	24	9	1	16	41	10	3	5	0	26	2

Intervention	participants (Number)
	SSBP ≤90 mmHg and decrease of ≥20 mmHg	SSBP ≥180 mmHg and increase of ≥20 mmHg	SDBP ≤50 mmHg and decrease of ≥15 mmHg	SDBP ≥105 mmHg and increase of ≥15 mmHg	Supine pulse rate ≤50 bpm and decrease of ≥15 bpm	Supine pulse rate ≥120 bpm and increase of ≥15 bpm	Weight Change of ≥7% weight
Vortioxetine	7	4	1	8	7	2	155

Intervention	participants (Number)
	Appearance at Baseline: Normal	Appearance at Baseline: Abnormal	Appearance at Week 52: Normal	Appearance at Week 52: Abnormal	Extremities at Baseline: Normal	Extremities at Baseline: Abnormal	Extremities at Week 52: Normal	Extremities at Week 52: Abnormal	Skin at Baseline: Normal	Skin at Baseline: Abnormal	Skin at Week 52: Normal	Skin at Week 52: Abnormal	Head-Neck at Baseline: Normal	Head-Neck at Baseline: Abnormal	Head-Neck at Week 52: Normal	Head-Neck at Week 52: Abnormal	Eyes-Ears-Nose-Throat at Baseline: Normal	Eyes-Ears-Nose-Throat at Baseline: Abnormal	Eyes-Ears-Nose-Throat at Week 52: Normal	Eyes-Ears-Nose-Throat at Week 52: Abnormal	Lungs-Chest at Baseline: Normal	Lungs-Chest at Baseline: Abnormal	Lungs-Chest at Week 52: Normal	Lungs-Chest at Week 52: Abnormal	Heart/Cardiovascular at Baseline: Normal	Heart/Cardiovascular at Baseline: Abnormal	Heart/Cardiovascular at Week 52: Normal	Heart/Cardiovascular at Week 52: Abnormal	Abdomen at Baseline: Normal	Abdomen at Baseline: Abnormal	Abdomen at Baseline: Not done	Abdomen at Week 52: Normal	Abdomen at Week 52: Abnormal	Abdomen at Week 52: Not done	Musculoskeletal at Baseline: Normal	Musculoskeletal at Baseline: Abnormal	Musculoskeletal at Week 52: Normal	Musculoskeletal at Week 52: Abnormal
Vortioxetine	758	76	484	40	806	28	511	13	730	104	465	59	822	12	518	6	772	62	485	39	827	7	523	1	816	18	512	12	818	12	4	515	8	1	790	44	493	31

Intervention	scores on a scale (Mean)
	Week 1 (n=805)	Week 2 (n=822)	Week 4 (n=805)	Week 8 (n=752)	Week 12 (n=715)	Week 16 (n=671)	Week 20 (n=639)	Week 24 (n=613)	Week 28 (n=599)	Week 36 (n=568)	Week 44 (n=540)	Week 52 (n=522)	Final Visit (n=829)
Vortioxetine	-1.1	-3.1	-4.7	-6.5	-7.0	-7.7	-8.4	-8.3	-8.9	-9.3	-9.6	-10.0	-7.9

Intervention	participants (Number)
	Any adverse event	Related adverse event	Not related adverse event	Mild adverse event	Moderate adverse event	Severe adverse event	Adverse event leading to early termination	Serious adverse event	Serious related adverse event	Serious not related adverse event	Serious adverse event leading to early termination	Deaths
Vortioxetine	589	413	176	187	320	82	50	29	5	33	11	0

Intervention	scores on a scale (Mean)
	Week 4 (n=818)	Week 24 (n=642)	Week 52 (n= 527)	Final Visit (n=818)
Vortioxetine	-0.53	-0.98	-1.33	-1.00